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SUMMARY 
The mechanical properties of the respiratory system such as resistance, elastance and 
mechanical work of breathing are rarely measured directly but are inferred from the effect of 
respiratory disease on maximal lung volumes and flows. Although such tests have proved 
very useful, they have shortcomings, e.g. changes in lung volumes are poor at detecting 
progression in interstitial lung disease and correlate only weakly with changes in functional 
capacity achieved post-bronchodilator in patients with airways obstruction. In addition, 
measurement of maximal flows and volumes requires active patient cooperation which may 
not be possible if patients are anxious, breathless, cognitively impaired, have reduced 
conscious level or are at the extremes of age. 
The direct measurement of mechanical properties are of interest as they have an obvious 
physical interpretation but their usefulness has as yet not been systematically tested. 
Resistance aside, their measurement is rarely performed as it is invasive, requiring either a 
sedated patient on controlled ventilation to abolish spontaneous respiratory muscle activity or 
measurement of oesophageal and gastric pressures. 
The aim of this thesis was to explore the feasibility and potential clinical value of non-
invasive measurements of respiratory mechanics and work of breathing. The work is 
presented in three sections:-
• Firstly, conventional methods for measuring resistance, elastance and mechanical work of 
breathing were reviewed and the methods for the non-invasive approaches to be used were 
described in detail. 
• The results from the non-invasive methods were then validated by comparison with 
conventional techniques in both ventilated patients and in subjects in the pulmonary 
function laboratory where oesophageal and gastric manometry were performed. 
• Finally the non-invasive methods were evaluated in three clinical scenarios: 
bronchodilator reversibility testing, assessment of progression in interstitial lung disease 
and monitoring recovery from exacerbation of chronic obstructive pulmonary disease. 
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Although not widely applied, the non-invasive measurement of resistance has been available 
since the 1940s through such methods as body plethysmography, airway interruption and 
forced oscillometry. The same is not true of resistive work of breathing which currently 
requires the simultaneous measurement of transpulmonary pressure (by application of 
oesophageal manometry) and flow. In the fIrst validation study, transpulmonary resistance 
and resistive work of breathing calculated from oesophageal manometry during histamine 
challenge tests on asthmatic subjects were compared with forced oscillometry variables. The 
most signifIcant fInding was that transpulmonary resistance was not best predicted by 
oscillometry resistance but by reactance, which is the oscillometry component calculated from 
a comparison of pressure and flow which are 90° out of phase. It was also shown that 
resistive work of breathing could be estimated by a function of reactance and flow. 
By contrast, the conventional measurement of elastance and elastic work of breathing remains 
invasive, requiring sedation and controlled ventilation or oesophageal manometry. Non-
invasive techniques based upon patient relaxation or positive pressure breathing were 
proposed and evaluated in sporadic studies throughout the 20th century. None achieved 
widespread application because of the combination of poor subject compliance and unwieldy 
apparatus. In this thesis, two methods for measuring elastance and thereby elastic work of 
breathing were evaluated by comparison with conventional measurements. The fIrst was a 
direct translation of the positive pressure method proposed by Heaf and Prime in 1956 where 
the subject was exposed to a pulse of continuous positive airways pressure lasting several 
breaths. The second was developed in the 1990s applying the technique of least squares 
multiple linear regression to estimate mechanical variables by examining the effect on volume 
and flow of small changes in positive inspiratory pressure on adjacent breaths. Although both 
methods could predict elastance, the simpler method based on a pulse of continuous positive 
airways pressure proved the more accurate. 
The non-invasive methods were then evaluated in three clinically relevant scenarios. 
• Firstly, forced oscillometry variables were compared with conventional pulmonary 
function tests and exercise testing in the assessment of bronchodilator reversibility of 
airways obstruction (predominantly chronic obstructive pulmonary disease). 
Bronchodilators produced measurable changes in plethysmography, oscillometry and 
exercise test variables. Changes in resting pulmonary function tests were unable to 
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predict changes in endurance exercise time but several variables (including inspiratory 
capacity, plethysmographic resistance and oscillometry reactance) had modest 
associations with change in end-exercise ventilation. Reactance was clearly superior in 
this regard to oscillometry derived work of breathing and resistance. Of interest, the 
absence of an improvement in exercise capacity post-bronchodilator was associated with 
increased ventilatory equivalents, suggesting that bronchodilator was having an adverse 
effect on the efficiency of ventilation. 
• The second study looked at the ability of elastance and elastic work of breathing to detect 
progression in interstitial lung disease over a twelve month period using both survival and 
a surrogate score derived from vital capacity, diffusing capacity, endurance exercise time, 
symptoms and health related quality of life. Changes in endurance exercise test variables 
(especially ventilatory equivalents for oxygen) and health related quality of life proved the 
most discriminating and were superior to standard measurements such as vital capacity 
and diffusing capacity. Elastance and elastic work of breathing did not significantly 
predict survival although they were associated with worse progression scores. 
• The third study assessed the ability of forced oscillometry variables to monitor 
physiological recovery over six weeks following an exacerbation of chronic obstructive 
pulmonary disease compared with spirometry, gas exchange, symptoms and health related 
quality of life. Once again, reactance proved superior to oscillometry resistance and work 
of breathing conferred no added advantage. Of all outcome measures used, oscillometry 
variables had the widest association with improvements in dyspnoea and health related 
quality of life. 
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PART 1: INTRODUCTION AND METHODS 
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1.1 The Contemporary Measurement of Respiratory 
Mechanics 
Introduction 
The effect of disease on mechanical properties of the respiratory system such as resistance, 
elastance and mechanical work of breathing is rarely measured directly during routine 
pulmonary function tests but usually inferred from the effect of the pathophysiology on 
maximal volumes and flows 1• For example, the increased elastic recoil or stiffness seen in 
pulmonary fibrosis is detected by its effect on static lung volumes such as vital capacity (VC) 
or total lung capacity (TLC). Similarly the increased resistance seen in asthma or chronic 
obstructive pulmonary disease is deduced from the value of forced expiratory flow in 1 
second (FEV 1) and its ratio to VC or from the peak expiratory flow (PEF). These 
conventional pulmonary function tests are very useful but do have areas of deficiency. 
Examples include detecting progression in interstitial lung disease which is insensitive when 
using lung volumes2 or predicting improvement in functional capacity in chronic obstructive 
pulmonary disease (COPD) from changes in resting pulmonary function3. In addition, 
measurement of maximal flows and volumes requires active patient cooperation which may 
not be possible if patients are anxious, breathless, cognitively impaired, have reduced 
conscious level or are at the extremes of age. 
Direct measurements of mechanical properties such as resistance, elastance and work of 
breathing are attractive in that the physical interpretation of the result is more obvious than 
inferring changes from volumes and flows. Whilst several techniques are available for 
quantifying resistance \ the measurement of elastance and mechanical work of breathing 
remain invasive and therefore rarely performed. The aim of the work presented in this thesis 
is to develop, validate and evaluate non-invasive methods for assessment of resistance, 
elastance and mechanical work of breathing. 
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Chronology of Measurement of Respiratory Mechanics 
Since 500BC when Alcmaeon of Croton postulated that goats breathe through their ears, the 
understanding of respiratory mechanics has come a long way. Over the following two and a 
half millennia many individuals contributed to our qualitative understanding of the 
mechanism of breathing and a useful summary has been provided by Otis5• Singling out a 
few individuals, Galen (130-200AD) described the action of the respiratory muscles and 
Leonardo da Vinci (1452-1519) drew the analogy between the respiratory system and a pair 
of bellows. Andreas Vesalius (1514 - 1564) introduced experimentation to this area by 
resecting the thoracic wall of a dog, but leaving the pleura intact so that lung movement could 
be observed. By the late 17th century, John Mayow (1640-1679) was able to give a 
reasonably accurate account of the process and produced a model based on a pair of bellows 
with a glass window to illustrate the process. 
Modem understanding of respiratory mechanics underwent a step change in the early part of 
the 20th century with the work of Fritz Rohrer (1888-1926). He was a descendant of Bernoulli 
and his skills lay both in mathematics and quantitative experimentation. His body of work is 
very relevant to the subjects of this thesis and remains frequently cited6• His conceptual 
breakthrough was to apply Newtonian mechanics to respiratory physiology, i.e. to state that 
expansion of the lungs requires forces to be exerted to overcome resistance, elastance and 
inertia. Thereby he analysed and formulated the complex mechanical process of breathing in 
terms of simple variables such as pressure and volume. His papers encompassed the theory 
and quantification of such subjects as flow resistance in the airways, pressure-volume 
relaxation curves and estimation of mechanical respiratory work. 
Rohrer's ideas were further developed by his pupils, Neergard and Wirz, but then fell from 
attention until rediscovery by two American groups of physiologists (Fenn, Bayliss and 
Robertson) approximately twenty years later. Since then the subject has received continuous 
attention with many fundamental contributions originating in the decades immediately 
following the Second World War. One of the principal contributors, Mead7, has suggested 
that the three major mechanical concepts demonstrated and to a great extent explained since 
the 1950s have been pulmonary hysteresis (i.e. the loop of transpulmonary pressure and lung 
volume), frequency dependence of respiratory mechanics and expiratory flow limitation. 
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Advancement in respiratory mechanics could not have occurred without the development of 
techniques for measuring pressure, volume, flow and resistance and a concise chronology of 
this is given in Table 1.1.1. 
Table 1.1.1. Chronology of measurement techniques in respiratory mechanics5• 
1643 
1826 
1842 
1915-1925 
1925 
1927 
1930s 
1949 
1956 
1956 
Development 
Torricelli developed the mercury barometer 
Carson was the first to describe measurement of intrapleural 
pressure and hence elastic recoil in cadaveric animals 
Hutchinson developed the spirometer for measuring dynamic lung 
volumes 
Rohrer's major publications 
Fleisch introduced the pneumotachograph for measuring flow 
Neergard & Wirz develop the interrupter technique for measuring 
flow resistance 
Development of electrical strain gauges for measuring pressure 
Buytendijk popularised estimation of intrapleural pressure using the 
oesophageal balloon 
Dubois developed the body plethysmograph for measuring static 
lung volumes and airway resistance 
Dubois proposed the forced oscillometry technique for measuring 
respiratory resistance 
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Contemporary Measurement Techniques 
Resistance and Elastance 
Def"mition 
The concepts of resistance and elastance of the respiratory system or its component parts 
(airways and tissues) are most simply defmed from the following equation ofmotion8:-
where P rs is the driving pressure 
Ers is the elastance of the respiratory system 
V is the volume and Vo the relaxed volume 
Rrs is the resistance of the respiratory system 
V is flow 
Irs is the inertance 
V is acceleration. 
At breathing frequencies Irs is negligible9,1o and the equation simplifies to:-
eqn 1.1.1 
eqn 1.1.2 
Thus, resistance and elastance can be interpreted as fixed lumped elements defining the 
coefficients of proportionality between resistive pressure drop and flow and elastic pressure 
drop and volume respectively. 
This linear, single compartment model is only accurate in normal subjects and then over a 
small range of values. In practice, elastic and resistive properties of the respiratory system are 
time and frequency dependent, have nonlinear relationships with flow and volume and are 
interdependent11 • This behaviour reflects such physical phenomena as viscoelasticity due to 
stress adaptation of the tissues12, plastoelasticity indicating hysteresis of the pressure-volume 
relationship13 and time constant inequalities causing gas redistribution14• Consequently, 
values of Rrs and Ers defined at any time point by equation 1.1.2 can vary widely over the 
breathing cycle. 
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Measurement of Resistance 
Of the three variables discussed in this thesis, measurement of resistance is by far the most 
developed. There are four widely accepted methods for this, namely:-
1. Oesophageal manometry to measure intrapleural pressure and transpulmonary 
resistance, RL, which is thought to represent the sum of airway and lung tissue 
resistance15,16. 
2. Body plethysmography to measure airway resistance, Raw17. 
3. Airway interruption to measure interrupter resistance, Rint. which is thought also to 
give airway resistance18• 
4. The forced oscillation technique which gives respiratory impedance, Zrs, from which 
the resistance, Rrs, and reactance, Xrs, can be calculated 19,20. Rrs is thought to 
represent the resistance of airways, lung and chest wall. 
Oesophageal manometry is necessarily invasive. Usually, a single result is calculated for each 
breath by determining the width of the pressure-volume loop at iso-volume, dividing by the 
difference between inspiratory and expiratory flow and averaging over the breath4,15. 
Alternatively, the same result can be achieved by applying the least squares multiple linear 
regression (LSMLR) technique to equation 1.1.221. Theoretically, RL could be calculated 
continuously to give a value of resistance at each volume point during the breath but in 
practice the signal to noise ratio is low especially in normal subjects and this approach is not 
practical. 
Body plethysmography is not invasive but does require bulky equipment and the panting 
manoeuvre required in a sealed box can be difficult and claustrophobic for a patient in a 
degree of respiratory distress. Each measurement gives a single value of Raw at the lung 
volume used (usually functional residual capacity) although the measurements can be 
repeated at different lung volumes. 
Interrupter resistance is measured by occluding airflow for 100 ms. This is usually performed 
only once per breath although techniques for multiple occlusion have been described. The 
value for Rint therefore reflects a spot value of resistance at the point in the breath where the 
occlusion occurs. With increasing airway obstruction, there is slow equilibration of alveolar 
and mouth pressure which leads to an underestimate of resistance. 
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Forced oscillometry is arguably the most versatile of the techniques. Like interrupter 
resistance, it requires only tidal breathing but, if within-breath analysis is performed, it is able 
to provide a quasi-continuous value of resistance throughout the breathing cycle. It also 
suffers from the problem of underestimating resistance with increasing levels of airways 
obstruction which in this case is due to the shunting effect of extra thoracic airways. 
Typical Values of Resistance 
The normal value of resistance depends upon the technique used and also the gender and body 
habitus of the subject. Shorter subjects with lower lung volumes and females will tend to 
have higher values of resistance. The average normal value would be in the vicinity of 0.15 to 
0.2 kPa.s.L-1 but could be a factor of 10 larger in patients with severe COPD or asthmatics 
during a bronchoprovocation test4,21,22. A comparison of the four techniques in the same 
subjects4 showed similar basal median values but, after resistance was increased by 
bronchoprovocation, Rrs and Rint increased less than RL and Raw. 
Measurement of Elastance 
In comparison with resistance, the measurement of elastance is far from a routine 
measurement. The following approaches are the techniques conventionally used in 
ventilated and spontaneously breathing patients. Both assume a constant value for elastance 
over the tidal volume. 
1. Controlled ventilation 
Airway opening pressure (P ao) and thoracic volume (V) are measured during 
controlled ventilation (i.e. no respiratory effort) with constant flow inflation23. The 
ratio of the change in pressure to the change in volume between the start and end of 
inspiration approximates to dynamic elastance (Ers,dyn) (see Figure 1.1.1). Static 
elastance (Ers,st) is obtained if end-inspiratory and expiratory occlusions (of 5 seconds) 
are used. The immediate decay in pressure seen after the end-inspiratory pause is 
attributable to the phenomena of viscoelasticity12 and time constant inhomogeneity14 
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which will be discussed in more detail shortly. End-expiratory occlusion is used to 
determine the level of static intrinsic positive end-expiratory pressure (PEEPi,st). 
Figure 1.1.1. Ers,dyn measured by controlled ventilation with no pauses. 
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Several other approaches have been described to measure mechanical properties 
during controlled ventilation such as passive expiratory relaxation24, multiple 
expiratory occlusion25, supersyringe methods26,27 and volume recruitmenr8. These 
differ in the way that resistance is calculated but elastance measurement is essentially 
the same as the end-inspiratory occlusion method, namely the ratio of change in 
pressure to volume. The only significant variant to this approach29,3o has employed 
multiple linear regression to fit the linear equation of motion (eqn 1.1.2) to the 
pressure trace obtained during controlled ventilation. 
2. Spontaneous Breathing 
Dynamic lung elastance (EL,dyn) can be determined relatively simply from 
measurements of oesophageal pressure (P oes) and V and is given by the gradient of the 
line joining points of zero flow on the P oes - V curve15,31. Similarly to the case of 
resistance, a value can also be obtained by applying the LSMLR technique to equation 
1.1.221 • Measurement of static lung elastance (EL,st) also involves measurement of P oes 
but V is usually determined by a spirometer or body plethysmograph and there is the 
additional requirement for interruption or breath-holding32-34• Static chest wall 
elastance (Ecw,st) is conventionally estimated from a prediction equation35,36 
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E = 1 . kP CWst ill a. 
, 0.4 x predictedVC 
eqn 1.1.3 
Ers, either dynamic or static, is then given by the sum of these two components:-
eqn 1.1.4 
It can be seen that this method can only give an approximate value for Ers as Ecw is a 
predicted value and the method cannot be applied in cases where the chest wall is 
abnormal such as kyphoscoliosis. 
Typical Values of Elastance 
Over the tidal volume range, Ecw and EL are thought to be of similar size. The widely quoted 
prediction formula for static respiratory elastance (Ers,st) from AgostoneS,36 where 
E = 1 . kP L- l st In a. , 
rs, 0.2 x predictedVC 
eqn 1.1.5 
was derived from data obtained by relaxation methods. In one study of normal adults37, 
values for EL,dyn were found to lie in the range 0.30 to 1.12 kPa.L-l. In a further study3l, 
values of EL,st for young adults were found to be 0.56 to 1.25 kPa.L-l. Theoretically, values 
for EL,st should be marginally lower than EL,dyn but in normals there is likely to be little 
difference. By comparison, Ers,st values in anaesthetised normal subjects38 were found to be 
1.45 to 2.39 kPa.L-l. Values for Ers,dyn would be higher, the exact value depending on such 
variables as tidal volume and respiratory frequency (and thereby the flow rates achievedi9. 
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Work of Breathing 
Definition 
Work is the product of force and distance moved in the direction of the force and is measured 
in Joules (1). It can alternatively be expressed as the product of pressure and resulting change 
in volume which is more relevant to the fluid, three-dimensional situation pertaining in the 
respiratory system. 
F or the purposes of this thesis, work of breathing is the mechanical work done by the 
respiratory muscles40-42. At its simplest, it can be divided into three components:-
- WORK due to AIRWAY RESISTANCE - work expended against friction in driving 
gas through the airways 
- ELASTIC WORK - energy stored in the chest wall and lungs in an elastic manner 
during inspiration. During expiration, this energy is used to drive the expulsion of air 
from the lungs. 
- INERTIAL/GRAVITATIONAL WORK - airway gas and lung and chest wall tissues 
have finite mass and so work must be done when they are accelerated or moved 
against gravity 9. 
In practice there are several further elements contributing to work of breathing namely:-
- WORK due to TISSUE RESISTANCE- this represents the additional resistive work 
arising from the non-elastic or resistive behaviour of the lungs and chest wall. 
- VISCOELASTIC WORK - due to stress adaptation. If an elastic tissue is stretched 
and held at a new length, the force in the tissue is maximal at first but then falls to a 
lower, constant value, probably reflecting rearrangements at a molecular level 12 • 
- PLASTOELASTIC WORK - this is a reflection of elastic hysteresis. Static 
inspiratory and expiratory pressure-volume plots form loops, the width of which 
increases with tidal volume. This is principally an effect of surfactantI3. 
- WORK DUE TO TIME CONSTANT INEQUALITIES - in diseased lungs, there is 
heterogeneity of filling of different areas because of variation in mechanical 
properties. This can be visualised as difference in time constants for different lung 
units. If inflation is held, the phenomenon of "pendelluft" will be seen where gas 
redistributes from fast to slow filling units14,39,43,44. 
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- WORK DONE TO COMPRESS AND RAREFY AIR - in moving air in and out of 
the lungs work must necessarily be performed on its compression and rarefaction 45. 
WORK TO ALTER CHEST WALL SHAPE - with increased ventilation, the chest 
wall shape differs from its passive configuration which leads to additional work46• 
- WORK AGAINST INTRINSIC PEEP - when expiratory time is insufficient, alveolar 
pressure remains positive at the end of expiration (intrinsic PEEP). This pressure has 
to be overcome before inspiration can commence and this initial pressure load must be 
continued throughout inspiration which leads to additional work47,48. 
The relative contribution of each of these components varies between subjects, with breathing 
pattern and in respiratory disease. F or example, intrinsic PEEP and time constant 
inhomogeneities are absent in healthy lungs, alteration of chest wall shape is only significant 
with increased ventilation and work done rarefying air becomes significant at high lung 
volumes, high respiratory rates and at high altitude. 
A final concept to be introduced here is that of NEGATIVE WORK which describes the 
situation seen during expiration where contracting inspiratory muscles are forced to extend by 
greater opposing elastic forces. Physically this work represents that component of the elastic 
energy stored in the thorax during inspiration which is subsequently not converted to useful 
work overcoming resistance during expiration. It is instead converted to heat by the braking 
action of the inspiratory muscles. 
Measurement of Work of Breathing 
The conventional measurement of work of breathing is an invasive process. The precise 
methodology available depends upon the context ofthe subject. 
1. Ventilated Subjects 
If the subject is paralysed and on controlled ventilation, the mechanical work of 
breathing performed by the ventilator (Wtot) can be measured from the area within the 
loop formed by P ao and V during inspiration38• This is shown in Figure 1.1.2. 
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Figure 1.1.2. A typical plot of thoracic volume versus airway opening pressure 
during the inspiration phase of controlled ventilation. 
The area subtended by the pressure-volume curve to the volume axis gives the 
mechanical work performed by the ventilator. If airway opening pressure is measured 
at the proximal rather than distal end of the trachea, the work includes that done 
against the endotracheal tube. 
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It is possible to partition the work of breathing further as shown in Figure 1.1.3 to 
estimate resistive work (Wres), elastic work (Welas) and work done against intrinsic 
PEEP (WPEEP). 
These areas are given by the following equations:-
1 2 
We/as =-Ersd""VT 2 . ~ .. 
where V T is tidal volume and PEEPi,dyn is dynamic intrinsic PEEP. 
eqn 1.1.6 
eqn 1.1.7 
eqn 1.1.8 
The advantages of this method are that it is easy to perform in ventilated subjects and 
the elastic properties of the chest wall can be determined because of the absence of 
respiratory muscle activity. However, the work of breathing measured is that 
performed by the ventilator and this will not be the same as the work that would be 
performed if the subject were unsedated and breathing spontaneously because:-
- Work of breathing depends upon the ventilatory flow waveform. This is 
particularly true of Wres, an effect which is augmented by the nonlinear 
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resistance characteristics of the endotracheal tube 49-53. PEEPi,dyn is sensitive to 
any factor which increases tidal volume, reduces expiratory time or lowers 
thoracic recoil54. Ers,dyn and Welas are also affected by changes in breathing 
frequency, flow and inspiratory waveform but are less sensitive than 
W 39,49,52,53,55 res • 
To exclude the effect of the endotracheal tube, tracheal pressure must be 
measured5o. 
- Anaesthesia alters mechanical properties and therefore work of breathing. It 
increases elastance and resistance, probably due to reduced functional residual 
capacity56. 
- During passive inflation, there is little change of chest wall shape 57. The 
distortion caused to the chest wall during spontaneous breathing increases 
elastic work. This component increases with minute ventilation46 and will not 
be measured by this technique. 
Figure 1.1.3. A plot of thoracic volume versus ainvay opening pressure during 
controlled ventilation divided into areas corresponding to resistive work, elastic 
work and work done against intrinsic PEEP. 
V T is tidal volume. The dashed line joins points of zero flow at the beginning and end 
of inspiration. 
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Several variations of this method have been employed to overcome the above 
problems. In one approach, the work of breathing during spontaneous breathing was 
estimated by setting the ventilator to mimic a spontaneous pattern ofbreathing47,58. In 
a second approach, the relative contributions of the ventilator and patient In 
overcoming the work of breathing were estimated59. This required a pressure volume 
loop to be measured during controlled ventilation in the absence of muscular effort. 
Then the patient was allowed to make breathing efforts and was placed on a setting 
(such as assist control ventilation) which enabled prescription of breathing frequency 
and tidal volume. The pressure volume loop was re-measured and the difference in 
area between the relaxed and active loops presumed to give the patient's contribution 
to work of breathing. 
2. Spontaneously Breathing Subjects 
In this context, the measurement of work of breathing becomes more complex. It is 
helpful to visualise the process using the Campbell diagram, shown in Figure 1.1.46°. 
To generate the Campbell diagram, transpulmonary pressure is measured during 
spontaneous breathing. Transpulmonary pressure can be obtained from the difference 
between pressure in the lower oesophagus (P oes) and mouth or airway opening 
pressure (P ao). A plot of P oes-P ao against volume generates a loop whose area gives 
Wres. If the points of this loop corresponding to zero flow are joined by a straight line, 
then the gradient of the line gives the dynamic compliance (compliance is the 
reciprocal of elastance) of the lung and the loop area is divided into inspiratory and 
expiratory Wres. 
Next the static pressure volume relationship of the chest wall is determined. This can 
be measured accurately by (Poes) measurements during controlled ventilation61 but this 
approach is usually not an option unless the patient is already on a ventilator. An 
alternative technique is to measure (P oes) at different lung volumes whilst the subject 
rel~es against an occluded airway with an open glottis. This measurement is difficult 
to perform reliably35,62. Many investigators resort to the use of predicted Ecw 
(equation 1.1.3). If a line with a gradient equal to the chest wall compliance is then 
placed on the Campbell diagram passing through the end-expiratory point where flow 
is zero, then WeIas is given by the triangular area between the compliance lines of the 
lung and chest wall. 
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Figure 1.1.4. The Campbell diagram. 
The loop shows transpulmonary pressure during spontaneous breathing and its area 
gives Wres. CL,dyn is the line joining points of zero flow and its gradient gives dynamic 
lung compliance. (Compliance is the reciprocal of elastance). Ccw is a line with 
gradient equal to the static chest wall compliance (determined elsewhere) and placed 
on the graph to intersect with CL,dyn at FRC, the functional residual capacity. The 
triangular area ABC gives elastic work of breathing. 
CCW 
Volume 
FRC 
Transpulmonary pressure 
If PEEPj,dyn is present, then the effect of this on the Campbell diagram is shown in 
Figure 1.1.5 and WPEEP can be calculated from this diagram or from equation 1.1.7. 
The optimum way to determine PEEPj,dyn in a spontaneously breathing subject has not 
yet been determined63• The simplest way to measure it is by the fall in intrapleural 
pressure at the end of expiration before inspiratory flow commences. However, this 
approach is only valid if expiratory muscles are relaxed. If not, then several means of 
correcting the value using gastric pressure measurements have been proposed64-67. 
Use of the Campbell diagram can be further complicated (e.g. by significant 
expiratory muscle activity or chest wall distortion during increased ventilation) and a 
more detailed analysis is given by Roussos and Campbell41 . 
The Campbell Diagram method has the advantage that it does not require paralysis and 
ventilation but it is again invasive, requiring oesophageal and perhaps gastric pressure 
measurement. A significant problem is the need to use predicted values for Ecw,st 
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which limits its applicability to subjects with a normal chest wall at a normal FRC. In 
addition, work due to resistance of the chest wall tissues is completely neglected. 
Finally a problem common to all techniques using measurement of volume or flow at 
the mouth is error introduced due to gas compressibility as the volume change actually 
produced by the respiratory muscles is that occurring in the lungs4s• 
Figure 1.1.5. The effect of PEEPj,dyn on the Campbell diagram. 
The compliance lines no longer intersect at the point of zero flow at end-expiration. 
Instead, they are separated at this point by a pressure difference equal to PEEPi,dyn 
(distance AB). The volume of this line above FRC (L\ V) represents dynamic 
hyperinflation. WPEEP is given by the rectangular area ABCD. 
CCW 
Volume 
~V 
Transpulmonary pressure 
Typical Values 
There are no published reference values or prediction equations for work of breathing but 
there are studies measuring it in several different clinical conditions. Comparing values 
between studies is difficult for several reasons:-
- variation in the subjects' condition, e.g. stable or exacerbated chronic obstructive 
pulmonary disease. 
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variation in the subjects' context e.g. paralysed and ventilated, ventilated but not 
paralysed or spontaneously breathing 
- variation in the details of measurement or analysis. If measured during controlled 
ventilation, what were the ventilator settings (which may not have been standardised 
during the study) and was tracheal pressure measured to eliminate the resistance of the 
endotracheal tube? If the Campbell diagram was used, how was chest wall elastance 
dealt with (e.g. a predicted value or construction of static oesophageal pressure 
volume curves)? In some studies the chest wall was ignored and work was measured 
using both the inspiratory and expiratory areas of the oesophageal pressure volume 
loop. 
- variation in the units used, e.g. work per breath (J.breath-1), work per unit respired 
volume (J.L-1) or work per unit time (J.min-1). 
Table 1.1.2 illustrates work of breathing values available for adults from the literature. Unless 
otherwise specified the values are means for the groups calculated using the techniques 
described earlier. 
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Table 1.1.2. Work of breathing values 
Wtot Wres W~ WPEEP JL-1 ~J .-1 JL-1 J.L- J.L-I • .mm 
Normals 
Controlled ventilation (CMV)47 0.61 0.23 0.38 
Campbell diagram 
Fessler68 0.69 6.37 
Jenningl 9 6.06 1.14 4.92 
(J.min-1) (J.rni.Ii 1 ) 
Schonhojer70 - note (1) 0.48 
Montravers 71 - note (1) 0.36 3 
COPD 
CMV / exacerbation47 1.37 0.57 0.58 0.42 
Campbell diagram 
Exacerbation 1-3 days 
OnCPAp72 2.26 57.1 
OnNIV72 1.61 35.3 
Giraull3 1.89 17.06 
E b· . 74 1.61 17.37 0.76 0.89 xacer atlOn - weamng 
Exacerbation at 1 week 5 1.13 8.14 
Stable COPD 
Normocapnic76 0.73 7.6 
Hypercapnic 76 1.03 6.3 
Schonhojer70 - note (1) 0.85 
LVRS77 -pre - note (2) 1.42 
-post 1.03 
Asthma 78 - pre challenge 0.56 6.2 0.11 0.45 
- peak challenge 2.45 32.1 0.67 1.78 
Cystic fibrosis 79 12.6 5.1 7.6 (J.min-1) 
(J.min-1) 
Obesity8o 1.3 0.24 1.06 
Heart Failure81 1.3 18 0.45 0.75 
Restrictive Lung Disease82 1.98 22.9 
Motor Neurone Disease83 0.7 5.7 
Sedation (IV midazolam) 71 1.04 6 
Ascites84 1.15 0.15 1.0 
Tracheostomy85 - pre 0.92 0.48 0.44 
- post 0.65 0.27 0.38 
Notes 
1. These values were determined from the integral of the oesophageal pressure - volume 
loop and chest wall elastance was disregarded. 
2. Lung volume reduction surgery 
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Why Measure Work of Breathing? 
Whilst the physical significance of resistance and elastance is generally obvious, the concept 
of work of breathing is more complicated. Work of breathing gives in one value a global 
indication of the state of the mechanical properties of the respiratory system, which can be 
partitioned into resistive and elastic components. The units in which it is expressed determine 
its precise physical significance86• If summed over a minute and normalised by minute 
ventilation (J.L-1), it closely reflects the mechanical properties of elastance and resistance. If 
expressed per unit time (J.min-\ it represents rate of doing work or power and tracks changes 
in minute ventilation. 
Work of breathing even when expressed in J.min-1 is unlikely to give information about the 
likelihood of developing respiratory muscle fatigue which is much better predicted by a 
pressure time product87• Work of breathing is not the same as oxygen cost of breathing, 
which is the oxygen and hence energy consumption of the respiratory muscles. The ratio of 
work of breathing to oxygen cost gives the mechanical efficiency of breathing and many 
factors affect this ratio. Work of breathing does not include isometric work which has an 
energy cost but no volume change despite the generation of pressure. Similarly two breaths 
which have the same volume and pressure changes but different duration will incur different 
energy costs although the same mechanical work is performed. The timing and nature of the 
load on the respiratory muscles also affects efficiency with expiratory and resistive loads 
requiring greater energy costs for the same mechanical work compared with inspiratory and 
elastic loads88,89. Also working at a higher lung volume impairs efficiency9o. 
Despite the invasive process involved, interest in the measurement of work of breathing has 
been sufficient for it to have been reported in several hundred studies. Unsurprisingly, the 
frequency of this increased with the introduction of a dedicated monitor for performing the 
measurement91 • Owing to the accessibility of the measurement during anaesthesia, the largest 
single group of studies has used work of breathing as an outcome measure for assessing 
ventilation strategies92-97 • 
Other uses in respiratory failure requmng ventilatory support have been to assess the 
mechanical work imposed by the ventilator circuitry (different ventilators98, heat and moisture 
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exchangers99, nebuliser fittings lOO, PEEP valves 1 01 , breath triggering settingsl02, endotracheal 
tubes and laryngeal masksl03) and to predict when to extubate a patient. An objective 
approach to the weaning of patients from ventilators has been sought for many years but still 
proves elusivelO4. Threshold values have been proposed below which it is deemed safe to 
extubate regardless of other factors such as tachypnoea but these have been derived from 
retrospective analysesI05-107. Use of work of breathing values in the decision to extubate has 
been studiedl08,109 but not in an appropriately randomised and controlled manner. Whilst 
work of breathing has shown a degree of promise in these studies, it is not likely to be 
sufficient on its own because, as described earlier, it is relatively weakly associated with 
oxygen cost of breathing. 
The impact of treatment strategies on work of breathing is an obvious application for this 
measurement and this has been most clearly illustrated in subjects with COPD. The 
application of PEEP or CP AP in ventilated subjects with COPD is complex and work of 
breathing has been helpful in both demonstrating benefit and providing insight into the 
mechanism by which it has its effectllO,lll. More recently CP AP and positive pressure 
ventilation (NIV) have been applied non-invasively using face masks and their effects studied 
in both acutely unwell72 and stable subjects with COPD76 It proved possible to demonstrate 
that both CP AP and NIV reduced work of breathing but only NIV improved ventilation. 
Work of breathing has been used to assess the impact of a number of other treatments in 
COPD including helium-oxygen mixtures1l2, bronchodilatorsl13, blood transfusions in 
anaemic patients70, PEEP during exercise1l4,1l5 and the effect of epidural anaesthesiall6, 117. 
One of the few groups studied serially has been patients following lung volume reduction 
surgery to document longitudinal postoperative trends77• Beyond COPD, the study 
populations whose work of breathing has been measured form an eclectic collection, the range 
of which is summarised in Table 1.1.2. 
In conclusion work of breathing has been used with some success as a short-term outcome 
variable for the effect of an intervention which is likely to alter respiratory mechanics. A 
potential application not yet investigated is that of serial measurements to assess longitudinal 
change in respiratory disease, the obvious problem with this being the invasive nature of the 
measurement process. 
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Thesis Aims 
The work covered in this thesis is the further development and testing of techniques for the 
non-invasive measurement of mechanical properties such as resistance, elastance and work of 
breathing. Proposal and development of the new methods together with the equipment used 
to measure them are described in Chapter 1.2. 
The validation work is covered in Section 2. In the fIrst part, a novel means of utilising 
forced oscillometry variables is used to measure resistance and resistive work of breathing. In 
the second part, elastance and elastic work of breathing are measured using changes induced 
by positive airway pressure delivered from modem non-invasive ventilators. In both cases 
validation is by comparison with the conventional invasive measurements described in this 
introduction. 
In Section 3 the new techniques are evaluated in contexts where there are defIciencies with 
current pulmonary function tests. In bronchodilator reversibility testing and documenting 
recovery from exacerbation of COPD, the usefulness of resistance and resistive work of 
breathing are assessed. In longitudinal measurements in interstitial lung disease, elastance 
and elastic work of breathing are more relevant. Comparison in these studies is with the 
pulmonary function tests conventionally used in the area. 
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1.2 Non-invasive Methods for Measuring Respiratory 
Mechanics 
Introduction 
This chapter describes the theory and application of the non-invasive methods proposed for 
measuring respiratory mechanics. As measurements of resistance and elastance were required 
to determine the respective components of work of breathing, these are not described 
separately but have been included in the discussion of work of breathing. In developing these 
methods, it was the intention that they should be as widely applicable as possible. Ideally, a 
passive test was required, capable of being performed in patients unable to cooperate with 
active manoeuvres, and the result should be continuous and real-time, analogous to the 
measurement of pulse oximetry, or at least measurable on a breath by breath basis. The test 
should be quick to perform and feasible for patients in respiratory failure, both off and on 
ventilation. The equipment should be portable to allow measurement in immobile patients 
and it should allow partitioning of the value into resistive work, elastic work and work done 
against intrinsic PEEP. As will be seen, some but not all of these requirements have been 
met. 
There were no pre-existing systems for performing these measurements "on the shelf'. 
Hence, the development of these methods involved:-
devising the method of measurement 
assembly of the equipment for performing the measurement which in some cases 
required the commissioning of its construction 
writing software to convert the measured data into mechanical parameters. 
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Resistive Work of Breathing 
Theory for Non-invasive Measurement 
From the Campbell diagram, Wres is given by the area within the loop formed by 
transpulmonary pressure and volume. Mathematically, this can be expressed as 
eqn 1.2.1 
This measurement is invasive because of the requirement to measure P oes. At any moment in 
time, P oes is related to V by the following expression 
eqn 1.2.2 
where RL varies throughout the breathing cycle and is a complex function of V and V. It 
represents resistive contributions from airways and lung tissue. Substituting from eqn 1.2.2 
into 1.2.1, the expression for resistive work becomes 
eqn 1.2.3. 
This expression no longer contains P oes but RL instead (which is normally derived itself from 
P oes). If RL is replaced by a value of resistance from one of the alternative methods which 
does not require measurement ofPoes, then a non-invasive method of estimating Wres becomes 
possible. 
Of the four techniques for measuring resistance described in Chapter 1.1, forced oscillometry 
was the most attractive for fulfilling this role. It is a passive measurement requiring only tidal 
breathing and can be performed by unconscious or uncooperative patients or children. The 
measurement is quick to perform (useful data are available from recordings of less than one 
minute's duration) and it can give a quasi-continuous, within-breath value of resistance 
available in real-time if required. Two problems were envisaged with this approach. Firstly, 
oscillometry resistance, Rrs, is thought to represent resistance of the total respiratory system 
including the resistive contribution from the chest walL For normal subjects it would 
therefore exceed RL by a small amount. Secondly, a well-recognised feature of forced 
oscillometry when delivered by mouthpiece or facial mask is the upper airway wall shunt 1 18 • 
As the degree of distal airways obstruction increases, more of the forcing signal is dissipated 
in the upper airway wall which leads to Rrs increasingly underestimating true respiratory 
system resistance. Solutions to this problem have included attempts to correct Rrs by separate 
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estimation of upper airway wall shunt resistance with a Valsalva manoeuvre and using it as a 
correction factor118• Alternatively, a head plethysmograph technique has been used to apply 
the forcing signal to the exterior of the neck and head as well as the airway by using a box 
sealed at the neck119. The former is a difficult voluntary manoeuvre and inaccurate, the latter 
is too cumbersome. A further suggestion to navigate this problem is to use other oscillometry 
parameters which are less sensitive to the upper airway shunt, such as admittance (the 
reciprocal of impedance)12o. This approach is the more attractive and will be developed 
further in later chapters. 
Forced Oscillation Technique: the Method 
The forced oscillation technique (FOT) was first described by Dubois in 195619,2°. It requires 
the excitation of the respiratory system at a frequency higher than the breathing rate and 
impedance is deduced from the system's response. To achieve this, the subject performs tidal 
breathing on a mouthpiece or through a face mask. The air which the subject breathes 
contains a sound wave (a forcing signal) which can be single or multi-frequency. Pressure 
and flow are measured at the mouth. The composite waveforms obtained are then separated 
into breathing waveforms and the forcing signal (see Figure 1.2.1). The forcing signals for 
pressure and flow are combined, usually in the frequency domain using Fourier transform 
theory, to give impedance (Zrs) and phase (9) as a function of frequency. These quantities 
can be converted into resistance (Rrs) and reactance (Xrs). 
Typical results for a normal subject are shown in Figure 1.2.2. The simplest physical 
interpretation of these results is obtained by assuming that the respiratory system obeys a 
linear, three component model of resistance (R), elastance (E) and inertance (1)121 as m 
equation 1.1.1:-
Then 
and X rs = 21tft - E/27!/ 
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eqn 1.2.4 
eqn 1.2.5 
eqn 1.2.6 
where f is the forcing frequency. So in a normal subject Rrs is equivalent to resistance of the 
respiratory system and is independent of frequency whereas Xrs is a combination of elastance 
and inertance and is frequency dependent. 
Figure 1.2.1. Composite flow waveform measured at the mouth during the forced 
oscillation technique. 
This is then separated into breathing waveform and forcing signal using a moving average 
technique. 
Breathing waveform 
Composite waveform 
Time 
Forcing signal 
In the presence of respiratory disease, Rrs increases in value and acquires frequency 
dependence whilst Xrs decreases (see Figure 1.2.3). The degree of change seen depends upon 
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the type and severity of the respiratory disease but the pattern. is generally the sameI22-126. 
Debate continues as to the underlying physical process responsible for this behaviour (e.g. 
lung inhomogeneityl27, upper airway shunt11S, compliance of intrathoracic airwaysl2S) and 
hence the correct mathematical model with which to interpret these changes. 
Figure 1.2.2. Typical FOT results for a normal subject presented in the frequency 
domain. 
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Figure 1.2.3. Typical FOT results for a subject with respiratory disease presented in the 
frequency domain. 
Relative to a normal subject, these show increased Rrs with negative frequency dependence 
and decreased Xrs. 
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The conventional presentation of FOT results is in the frequency domain and involves the 
averaging of results over a number of breaths2o. The data can alternatively be measured and 
analysed to give a continuous value for Zrs over time as shown in Figure 1.2.4129-133• This is 
more successfully achieved using a single excitation frequency rather than a range. The Zrs 
trace usually shows minima at points of zero flow whilst maxima occur at peak flow. This 
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variation during the respiratory cycle is due to a combination of factors, such as the relative 
contributions of laminar and turbulent flow (the latter makes 4s flow dependent), change in 
airway calibre as lung volume increases or decreases and variation in glottic aperture Size132. 
Figure 1.2.4. Typical within-breath FOT values for Rrs from a subject with mild 
airways obstruction. 
Flow below the zero axis is expiratory. Note that the minima in Rrs correspond with points of 
zero flow. 
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Forced Oscillation Technique: Equipment 
For the purposes of this study, it was decided to apply the technique using a single excitation 
frequency to enable the calculation of within-breath values of Zrs and using as Iowa 
frequency as possible (i.e. in the range 5-8 Hz) to minimise the degradation of Rrs values by 
upper airway wall shunt. Commercial devices (e.g. Jaeger Toennies Masterscreen lOS, D-
97204 Hoechberg, Germany; SensorMedics R.O.S. Oscilink, Yorba Linda, CA 92887-4645 
USA) use mUltiple frequencies and produce an analysis in the frequency domain although 
they can be modified to give limited temporal data as a non-standard option. Several groups 
have therefore developed their own devices for within-breath Zrs measurement134,135. The 
machine used in these studies is a copy of that described by Birch 135, which was built in the 
Royal London Hospital and measures within-breath Zrs using a single excitation frequency of 
5 Hz. It is a portable device (on a trolley) with good reach for the transducer head enabling 
use by immobile bed bound patients. In addition there is direct access to the raw 
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measurements allowing great flexibility for data processing. A picture of the device in use is 
shown in Figure 1.2.5 and the layout shown schematically in Figure 1.2.6. 
Figure 1.2.5. The forced oscillometry equipment used in these studies. 
The most recent statement of the technical requirements for forced oscillometry devices was 
written in 20032°. The recommendations are summarised in Appendix 1 together with the 
performance of the device used in this study. 
The biological filter used throughout the studies with FOT was pulmonary function filter 
model RTP2800/01 (Henleys Medical Supplies Ltd., Welwyn Garden City, Hertfordshire, 
UK). The 5 Hz impedance of this in combination with the PVC mouthpiece was measured in 
each subject using the FOT device and found to have mean (±SD) Rrs of 0.041 (±0.002) 
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kPa.s.L-1 and mean (±SD) Xrs of 0.0128 (± 0.0008) kPa.s.L-1• These values were then used to 
correct in software the measured impedance of the study subjects as recommended2o• 
Figure 1.2.6. Schematic layout of the forced oscillometry device. 
Sensortechnics single-ended gauge 
pressure transducer (pXLO025DN) 
2.5 kPa fsd --------+~ 
PVC large bore / short 
length mouthpiece 
(PKMorgan) / 
Pulmonary function filter 
(R TP2800/0 1) - Henley 
Medical Supplies 
Sensortechnics differential pressure 
transducer (PXL02X5DN) 
0.25 kPafsd 
Hans Rudolph 3700A 
heated screen 
pneumotachograph 
160 Lmin-I fsd 
Intersurgical smoothbore 
corrugated tube (5018) 
Length 1.8 m Diameter 22 rom 
Loudspeaker 
+ 
, 3rom diameter tubing 
v 
• Air 15 Lmin-I 
I Biasjlow 
Exhaust tube - corrugated 
Length 2 m Diameter 22 mm 
Provides low impedance at 
breathingfrequency but high 
impedance at forcingfrequency 
Calibration of the FOT device was checked before use on every day on which measurements 
were taken. Pressure calibration was checked at three points (±1000 Pa, 0 Pa) using an 
electronic pressure meter (Comark C9551, Comark, Stevenage, UK). Flow calibration was 
checked at three points (±0.25 L.s-1, 0 L.s-1) using a rotameter (Platon Instrumentation, 
Bramley, UK). As confirmation, volume calibration was also checked using a 3-litre 
calibration syringe (MultiFlow, Pulmonary Data Service Instrumentation, NIST accredited 
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calibration, Louisville, Colorado, USA) and the values accepted if within 50 ml accuracy. 
Three standard resistors were used to check resistance calibration, namely 0.2, 0.38 and 2.0 
kPa.s.L -1 (see Appendix 1). Impedance of a normal biological control (MKJ: mean (SD) Rrs = 
0.293(0.025) kPa.s.L-1, mean (SD) Xrs = -0.036(0.009) kPa.s.L-1) and the resistance of 
mouthpiece and filter combination were measured on all days that the equipment was used. 
Measurements were performed seated with the neck slightly extended. The subjects wore 
noseclips, supported their cheeks with their hands and were instructed to breathe normally. 
When the subject was comfortable on the mouthpiece and the volume trace was stable (a 
minimum of30 seconds), the oscillometry measurement was made. The measurement period 
was 1 minute and at least two measurements were recorded with the subject off the 
mouthpiece between measurements. Obvious artefacts due to swallowing, glottis closure, 
leaks were visible via the flow signal and, if extensive, the measurement was repeated. 
P ao and V were passed from the FOT device into two channels of an analogue to digital 
(AID) data acquisition system (MP100A, BIOPAC Systems Inc., Goleta, CA, USA). The 
signals were then digitised with 16-bit resolution at a sampling rate of 200 Hz and displayed 
and stored on an IBM-compatible PC using software specific to the above acquisition system 
(AcqKnowledge 3.7, BIOPAC Systems Inc.). This frequency is much larger than twice the 
maximum frequency of importance (i.e. 10Hz) which is that strictly required by the Shannon 
Sampling TheoremfNyquist Criterion to define a sinusoidal signal of 5 Hz. To calculate 
within-breath Zrs, it is necessary to perform a Fourier transform within each 5 Hz cycle. The 
high sampling rate gives 40 data points within each 5 Hz cycle which gives reasonable within 
breath resolution of Zrs. 
Forced Oscillation Technique: Software Algorithm 
P ao and V data were analysed in software using the MA TLAB numeric computing 
environment (MATLAB v6, The MathWorks Inc., Natick, MA, USA), which is designed 
specifically for vector and matrix manipulation and signal processing. The sequence of 
events in the software algorithm used for the FOT results is summarised in Figure 1.2.7 and 
the details amplified in the text when necessary. 
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Figure 1.2.7. Outline of the algorithm used to analyse the FOT results. 
The subscriptsfo and br refer to the forcing and breathing waveforms respectively. tl and tE 
are arrays containing the start times of inspiration and expiration for the breaths in the 
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The process of separating the breathing and forcing wavefonns employed a moving average 
filter129, which used the principle that the average over one cycle of a sine wave is zero. If the 
composite wavefonn is averaged over 0.2 s (one complete 5 Hz cycle) spanning a particular 
time point, the contribution from the 5 Hz forcing signal is zero and the result is the breathing 
wavefonn at that point. This can then in turn be subtracted from the original composite 
wavefonn to deliver the forcing signal at that point. This process can be repeated at each time 
point along the composite flow wavefonn and is in essence a filter. With an even number of 
data points in one cycle of the forcing signal, this filtering process causes a phase shift 
equivalent to half of the sampling interval (i.e. 2.5 ms) which can be corrected by linear 
interpolation of adjacent data points. 
The algorithm for generating impedance values from the forcing signals was developed and 
refined in the 1970s and 1980s and is not simply the process of dividing the pressure signal by 
the flow, although such analysis in the time domain can be done for single frequency 
results 136-138. A more convenient way to generate impedance results is to use a method based 
upon Fourier transfonns and power spectra first proposed in 1975118. The Fourier transfonn 
(FT) is a method for determining the frequency content of a time-varying signal, i.e. data 
expressed as a function of time are converted to a function of frequency. The results of FTs 
are complex numbers {i.e. they have a real (A) and imaginary (B) part and are usually 
expressed in the fonn, A + jB , where j = ~). Power spectra are generated by multiplying 
an FT result by the complex conjugate of a second FT. Auto-spectra are power spectra where 
the two FTs are the same and cross-spectra are power spectra where they are different. The 
importance of auto-spectra is that they are real numbers and give the power of a time varying 
signal as a function of frequency. By contrast, cross-spectra are generally complex and yield 
the phase infonnation between two time varying signals. Whilst impedance can simply be 
calculated by the ratio of the FTs for pressure and flow, power spectra are used instead 
because this minimises the errors involved in the process139,140. 
Both the magnitude (IZrsl) and phase (9) of impedance can be calculated from power spectra 
using the following approach. Let Sp be the FT of Pfo and Sf be the FT of "fO. Then we can 
represent these FTs in the fonn oftheir real and imaginary parts 
eqn 1.2.7 
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and eqn 1.2.8 
From equations 1.2.7 and 1.2.8 
G S S• = A2 +B2 pp=pp p p eqn 1.2.9 
and 
where * indicates complex conjugate, Gpp is the auto-spectra of Pfo and Gfp is the cross-
spectra of Pfo and "fo. A system with input x and output y can be linked by the following 
expression 
H=Y 
x 
eqn 1.2.11 
where H is the system frequency response function141. If x is Pfo and y is "fO' then 
H = _1_ = _A~f_+_J_B-,-f 
Zrs Ap + jBp eqn 1.2.12. 
After rearranging, 
1 
eqn 1.2.13. 
Therefore from eqns 1.2.9 and 1.2.10 
eqn 1.2.14 
and _I(Im(G fpJ) f) = -tan 
Re(GfpJ 
eqn 1.2.15 
where 1m signifies the imaginary part and Re the real part. 
In practice, the required auto and cross-spectra were calculated from P fo and "fo using the 
Welch method (MATLAB v6) which incorporates a Hanning window to reduce leakage II s. 
These power spectra were combined as described in equations 1.2.14 and 1.2.15 above to give 
!Zrs! and e. Rrs and X rs were calculated from the following expressions 
and 
Rrs = !Zrs!cosf) 
Rrs = !Zrs!sinf) . 
54 
eqn 1.2.16 
eqn 1.2.17 
A further parameter which can be calculated from the power spectra is the coherence118• This 
is a measure of quality control which quantifies the degree of nonlinearity and extraneous 
noise in the system. It is calculated from the equation 
y2 = IGJPI2 
GppGfJ 
eqn 1.2.18 
where "/ is the coherence. It is analogous to a correlation coefficient in the frequency 
domain and similarly ranges from 0 to 1 with the usual interpretation of these figures. It can 
be important in multifrequency FOT to define which frequency components are of adequate 
quality142,143 but it is not essential when using a single forcing frequency as an alternative way 
of assessing quality control is to use the coefficient of variatio~o. 
The above description details how to obtain IZrsl and e from the forcing signal. To acquire 
these as continuous within-breath quantities requires additional refinements. If at any given 
time point, power spectra are calculated from Pfo and "fo over one period or cycle of the 
forcing signal centred about that time point, then an impedance value can be attached to that 
time. If the analysis is then moved on to a later time point, a further value of Zrs can be 
calculated and thus a time varying function generated. In one approach, the author129 
calculated a value of Zrs from the data at each time point. In this situation the analysis 
achieves an apparent resolution of 1/(sampling frequency) although, with significant 
overlapping of the power spectrum windows, there is intrinsic averaging of adjacent Zrs 
values. A second approach132,144 is to calculate values of Zrs at intervals of one period of the 
forcing frequency. The resolution is then reduced to 1/(forcing frequency) but each data point 
is independent. Here the former approach has been used. So, for example, with the 5 Hz 
forcing signal and sampling rate of 200 Hz, there were 40 data points per cycle of the forcing 
signal. Power spectra were therefore computed using 40 point windows centred on each time 
point to give a value of Zrs for each pressure and flow sampling point. With the even number 
of data points in one cycle of the forcing frequency, calculation of Zrs produced a 2.5 ms 
phase shift which was corrected before combining Zrs or derived values with "br. 
The within-breath Zrs values were low pass filtered to remove biological noise using a 
Butterworth 8-pole filter with a cut-off frequency of 2 Hzl44. This process employed the 
fiZtfiZt function in Matlab which does not introduce any phase distortion. Finally the 
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impedance of the biological filter was subtracted from the measured total impedance to leave 
the subject impedance. 
The detection of end-inspiratory and expiratory points required location of the points where 
flow changes sign. The difficulty with this was noise on the flow signal, particularly at points 
in the breathing waveform where there was prolonged low flow such as end-expiration. To 
solve this problem, noise was temporarily removed from the flow signal using a low pass 
Butterworth 8-pole filter with a cut-off frequency of 10Hz. The smoothed flow was then 
searched for points at which flow reversed in order of decreasing time as flow reversals were 
more rapid phenomena when viewed in this direction. When a zero point was found, two 
actions were taken. Firstly, the exact point of zero flow closest to this time point was found 
by recourse to the unfiltered flow signal. Secondly, conditions were imposed which the next 
point of zero flow had to meet before it would be accepted. It had to be the opposite flow 
transition i.e. if the current point was inspiration to expiration then it had to be expiration to 
inspiration. It also had to lie at least 0.5 s distant from the current point. With this approach, 
a successful algorithm for the automatic detection of zero flow points was developed. 
Volume was generated by integrating Vbf • This introduced the problem of volume drift 
whereby the volume seen over time shows a negative or positive trend regardless of the 
zeroing accuracy of the pneumotachograph. The method used to correct for this is described 
in Appendix 3. 
The variables calculated by the above algorithm are listed in Figure 1.2.7. Their subsequent 
use to estimate resistive work of breathing is described in Chapter 2.1. 
Elastic Work of Breathing 
Theory for Non-invasive Measurement 
If elastance can be assumed to be constant over the tidal volume, then elastic work of 
breathing is given by the following equation 
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1 2 
We/as = 2 ErsVT eqn 1.2.18 
where from now En. denotes the dynamic elastance of the respiratory system. This equation 
gives the elastic work performed during a particular breath. It should be summed over the 
breaths in one minute to give it in J.min-1 and then divided by minute ventilation to give it in 
J.L-l. It can therefore be seen that a non-invasive technique for estimating Ers is the basis of 
estimating Welas• 
In ventilated patients making no respiratory effort, measurement of En. is straightforward by 
measurement ofPao and V (see Chapter 1.1). However, this is not the scenario pertaining in 
the pulmonary function laboratory with spontaneously breathing subjects where the activity of 
respiratory muscles alters airway opening pressures. The conventional approach in such 
subjects is to measure lung elastance using oesophageal manometry (see Chapter 1.1) but this 
is invasive, gives no indication of chest wall elastance and cannot be widely or routinely 
applied. 
There have been several attempts to develop a non-invasive technique to measure elastance, 
both dynamic and static. The relaxation technique proposed by Rohrer in 19166 and repeated 
elsewhere145-147 was probably the earliest. This required the subject to attain a certain lung 
volume (measured by spirometry) and then relax with an open glottis against a closed shutter 
in the breathing circuit. Pressure was measured at the mouth. This process gave one point on 
the pressure-volume curve for the respiratory system and was used to build up the entire curve 
by repeating the process at several different lung volumes. Training was required in order to 
perform this manoeuvre reliably and even then only 1 in 3 subjects succeeded because of 
failure either to maintain an open glottis or to relax completelf5. In 1956 Heaf and Prime 
proposed an approach based on positive pressure breathing33,148-151. The subjects breathed 
spontaneously whilst positive pressure was introduced at the mouth which induced an 
increase in end-expiratory lung volume. The ratio of pressure to volume changes gave 
dynamic elastance. The weighted spirometer approach proposed in 1965 by Cherniack was 
simply a different means of applying positive airway pressure 1 52-155. A fmal variant proposed 
in 1960 was to place the subject in a body plethysmograph and induce volume changes by 
exposure to negative pressure at the body surface150,156-159. A common problem with these 
techniques in the 1950s to 60s was the bulky apparatus required. 
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More recent approaches for measuring elastance non-invasively have drawn on techniques 
used in ventilated subjects. In the early 1980s, several studies explored a technique using 
constant flow inflation where elastance is given by the slope of the linear pressure-volume 
curve160-163. Some studies have attempted to use occlusion or interrupter techniques (see 
Chapter 1.1) which required complete subject relaxation at end-inspiration in order that 
change in volume and pressure can be measuredl64,165 or completely passive expiration to 
derive a time constant166. Again such manoeuvres were found to require training and were 
not applicable to all-comers. An occlusion technique was also successfully applied during 
spontaneous breathing with the proportional assist mode of ventilation in intubated patients167. 
An interesting and attractive approach was the use of pressure support ventilation to abolish 
respiratory muscle activity and then the application of LSMLR to fit an eqmtion of motion to 
the data168,169. Finally forced oscillometry itself can theoretically be used to estimate 
elastance but the technique has proved of limited practical use in this area so far170-172• The 
problem with forced oscillometry is that elastance changes markedly with frequency and 
inertance also becomes an increasingly significant component as frequency rises. For these 
reasons, the forcing frequency used must be as close to that of spontaneous breathing as 
possible. At such frequencies, the oscillometry measurements must be performed with the 
subject apnoeic as it is impossible to separate the breathing and forcing waveforms by moving 
average techniques. 
None of the techniques discussed above have achieved any mainstream acceptance for 
measuring elastance in the pulmonary function laboratory although several have shown 
promIse. Two of the approaches described were chosen for further evaluation in this study, 
namely:-
1. Positive pressure breathing or Continuous Positive Airways Pressure (CP AP) 
method 
With the widespread availability of devices to deliver continuous positive airways 
pressure (CP AP) and ventilation non-invasively, the earlier problems with bulky 
apparatus have largely disappeared and it has now become straightforward to apply a 
technique based on positive pressure breathing. Since this is performed without pause 
during spontaneous breathing, it measures dynamic elastance. The accuracy of such 
an approach is affected by several assumptions. Firstly, volume change induced by 
positive pressure breathing is assessed at end-expiration and the method assumes 
relaxation or similar activity of the respiratory muscles at this time-point both with and 
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without CP AP. This situation is certainly not satisfied if high positive pressures are 
used (>2 kPa) when expiratory muscles are recruited but has been found to be the case 
with more modest pressures «2 kPa)35. Secondly, elastance is only measured over the 
volume region covered by the change in end-expiratory lung volume induced and it is 
assumed to be constant over this region. In normal subjects this is correct for volume 
changes up to 80% of vital capacity36. In this study, CP AP of magnitude 0.8 to 1.2 
kPa induced a change in thoracic volume of a similar magnitude to the tidal volume as 
shown in Figure 1.2.8. Elastance was estimated from the ratio of change in mouth 
pressure to change in thoracic volume measured at end-expiration before and after the 
introduction of CP AP. 
Figure 1.2.8. Effect of introduction of CP AP on mouth pressure and thoracic volume. 
The measurements here were from a normal subject in the pulmonary function laboratory. 
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2. Non-invasive Ventilation (NIV) method 
The second method used is an approach which has only recently been proposed and 
employs the technique of pressure support ventilation delivered non-invasively. The 
subject breathes with a small amount of inspiratory pressure support delivered by a 
mouthpiece. After a few breaths, the inspiratory pressure is increased for one breath 
(typically by 0.4 kPa) (see Figure 1.2.9). Ers is then estimated from the difference in 
P ao, V and V between high and preceding low pressure breaths presuming that 
respiratory muscle effort has not altered between the two breaths. 
Figure 1.2.9. The NIV method for estimating Ers. 
Inspiratory pressure support has been increased for the third breath, leading to an increase in 
both P ao and V. These measurements were taken from a ventilated subject on pressure 
support ventilation. 
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To give a value for Ers, the respiratory system is assumed to follow a simple linear, 
two-component model, namely:-
where 
P muse is the pressure generated by the respiratory muscles 
PEEP is the combination of external and intrinsic PEEP. 
eqn 1.2.19 
It is assumed that Pmuse and PEEP are unchanged between consecutive breaths, then 
comparing high and preceding low pressure breaths, called 1 and 2 respectively, 
eqn 1.2.20 
where Mlao = Pao2 - Pao1 etc (see Figure 1.2.10). A set of equations (one for each 
sampling point) is generated by the difference between the two breaths. This 
represents an overdefrned problem that can be solved to give an estimate of Ers using 
LSMLR. 
This method is derived from work done by Iotti30 in which pressure support ventilation 
was used to abolish respiratory effort in ventilated patients and an equation of motion 
fitted using LSMLR. Two studies have published data using this method of 
differences in level of pressure support. In the first published in abstract form onlyl73, 
the method was compared with results from oesophageal manometry in 12 intubated 
patients. This study found it to be a method with remarkably low bias and limits of 
agreement for compliance (-0.00069 ± 0.001 L.kPa-l). In the second studyl72, non-
invasive ventilation was delivered by facemask to 15 volunteers who were either 
normal (n=8) or had COPD (n=7). It was found to overestimate elastance with 
significant scatter in both groups (mean ± SD: 3.62 ± 0.97 kPa.L-1 in normals and 4.86 
± 2.75 kPa.L-1 in COPD) when compared with the rather unconventional choice of 
forced oscillometry as the gold standard (mean ± SD: 2.24 ± 0.51 kPa.L-l in normals 
and 4.07 ± 1.56 kPa.L-l in COPD). 
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Figure 1.2.10. Illustration of the process of aligning and subtracting corresponding 
points on high pressure and low pressure breaths. 
Pao and V are shown for the first 0.5 s of inspiration 
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Elastic Work of Breathing: Equipment 
The same equipment was used to perform the measurements for both the CP AP and NIV 
methods and is shown in Figure 1.2.11. The pneumotachograph and transducer for measuring 
mouth pressure were the ones used in the forced oscillometry measurements and were 
described earlier. The major change to the breathing circuit shown earlier is the replacement 
of the exhaust pathway for the bias flow by an exhaust valve. 
In the CP AP method, the subjects were seated in a relaxed position against the chair back and 
were asked to breathe on a mouthpiece with nose clipped. They were told that they would be 
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breathing with raised pressure for approximately 20 s but were advised to breathe normally 
throughout. They were also asked to keep as tight a lip seal on the mouthpiece as they could 
comfortably maintain. After a period of 30 s of breathing with a stable volume baseline, 
CP AP was introduced manually up to a level of 0.8-1.2 kPa over a period of three to five 
seconds. This was maintained for a further five to six breaths and then gradually removed at 
the same rate. 
Figure 1.2.11. Equipment used to make the measurements of E rs• 
Sensortechnics single-ended gauge 
pressure transducer (PXLO025DN) 
2.5 kPafsd 
PVC large bore / short 
length mouthpiece 
(PKMorgan) / 
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(RTP2800/0 1 ) - Henley 
Medical Supplies 
v 
Sensortechnics differential 
pressure transducer (PXL02X5DN) 
0.25 kPafsd 
Hans Rudolph 3700A 
heated screen 
pneurnnotachograph 
160 L.min -I fsd 
Intersurgicalsmoothbore 
corrugated tube (5018) 
Length 1.8 m Diameter 22 mm 
Respironics 
BiPAP ST30 
ventilator 
I 
Respironics 
plateau valve 
+ 
In the NIV method, the subjects were again seated in as relaxed a position as possible and 
breathed into a mouthpiece with nose clipped. They were advised that they would feel a blast 
of air at each inspiration but simply to ignore it and breathe normally. They were warned that 
the pressure through the tubing would change from time to time but they should put the same 
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effort into every breath regardless of ventilator activity. Again they were asked to keep a tight 
lip seal on the mouthpiece. The ventilator was set to spontaneous mode with an inspiratory 
pressure of 0.6 kPa and no expiratory pressure. After 30 s, the inspiratory pressure setting 
was increased (manually during the expiratory phase) by 0.3-0.4 kPa. This was repeated 8 to 
12 times in total in two recording periods each lasting approximately two minutes and 
separated by an interval of two minutes. 
These measurements when performed on intubated subjects involved an essentially identical 
procedure and the equipment used is shown in Figure 1.3.1. The measurements ofPao and V 
were performed whilst on pressure support ventilation with an inspiratory pressure of 1.0-1.2 
kPa and external positive end-expiratory pressure (PEEP) of 0.5-0.7 kPa The increments of 
pressure for both techniques were the same as in the laboratory. 
Details of the calibration procedure, biological filtration and data acquisition system were 
given earlier in this Chapter. For these measurements, the analogue signals were digitised at a 
sampling rate of 500 Hz. 
Elastic Work of Breathing: Software Algorithms 
These calculations again used only P ao and V data and were performed with MA TLAB. The 
algorithms are shown in Figure 1.2.12. The first part of the algorithm was the same as for the 
implementation of the forced oscillometry method and was described earlier (Figure 1.2.7). 
The two algorithms diverged after volume drift was corrected. In the CP AP method, the only 
requirement thereafter was to determine the end-expiratory values of P ao and V. These results 
were then exported to EXCEL (Microsoft Corp., USA) and inspected manually for each 
manoeuvre to determine that a satisfactory step in end-expiratory V could be identified. To 
improve accuracy, the average of three end-expiratory P ao and V values were taken pre and 
post each step in pressure. Values during the transition in P ao were not used. In addition a 
single elastance value was calculated from each recording by averaging the P ao and V changes 
from the step up and step down in P ao. 
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Figure 1.2.12. Outline of the algorithm used to analyse the CP AP and NIV results. 
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The NIV algorithm was more complex. To align high and low pressure breaths for 
subtraction, a point on the breath needed to be identified to provide a reference for alignment. 
One option used in earlier studiesl72 was the point of zero flow. However, this was not found 
to be the optimum approach because, until the ventilator was triggered, the flow and pressure 
in high and low pressure breaths were the same (excluding biological variation). Triggering 
with the BiP AP ST30 (Respironics Inc., Murraysville, Pennsylvania, USA) is preset and flow-
controlled and typically occurs 0.1-0.2 s into a breath. After triggering, flow and pressure in 
the high pressure breaths rose at a faster rate than in the low pressure breaths. The typical 
appearance of flow in early inspiration was therefore as shown in Figure 1.2.13. As a 
consequence, if the point of zero flow (Z) was used to align breaths, the first 50 to 100 points 
(sampling rate of 500 Hz) in the LSMLR analysis added nothing but noise to the analysis. It 
was more logical to attempt to align the breaths at the point at which they diverged (i.e. 
ventilator triggering) and start the LSMLR analysis from there. Several points were 
considered as candidates for automatic detection of inter-breath reference positions (Figure 
1.2.13), e.g. minima in Pao (MP), maxima in dY/dt (OF) or dPao/dt (GP) but the point of 
inflexion of flow (IF) combined the qualities of being a logical starting point and was 
consistently demonstrated in the traces from most subjects. 
A point of inflexion simply represents a point where a curve changes direction sharply. At 
such a point, the rate of change of the gradient ( d2y / de ) is a maximum. At any maximum, 
the derivative of the quantity is zero. Hence, at the points of inflexion in flow 
d 3v 
-3- = 0 . eqn 1.2.21 
dt 
The steps used by the algorithm were as follows. Firstly, the point of maximum gradient in 
flow following the zero flow point at the start of inspiration was located. This was generally 
beyond the ventilator triggering point (see Figure 1.2.13). Then the algorithm looked 
backwards in time to find the closest point satisfying the condition in equation 1.2.21. All 
these operations were sensitive to noise in the Y waveform and were therefore performed on 
data that had been temporarily smoothed using a low pass filter (Butterwoth 8-pole cut off 
frequency 10Hz). Typical results are shown in Figure 1.2.14. 
Having identified points of reference with which to align the high pressure breaths with 
preceding low pressure breaths, differences were calculated. A set of n equations (equation 
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1.2.20) were established for each low pressure breath by comparing it with the next high 
pressure breath. n is the sampling rate divided by the time interval over which the breaths 
were compared (typically 250). Since there were only two unknown variables (Ers and Res) 
and only two equations are required to solve for two unknowns, this represented an 
overdefined problem which was solved by statistical means (LSMLR). 
Figure 1.2.13. Pao and V in early inspiration. 
Several candidate points for the start of the LSMLR analysis are shown, namely Z - point of 
zero flow, MP - point of minimum in P ao ' IF - inflexion point in V , GP - maximum gradient 
in Pao and GF - maximum gradient in V. The data wasted by using point Z as the starting 
point of the LSMLR analysis is indicated. 
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LSMLR is well described174 and has been widely applied to respiratory problems, mostly in 
children 175 but also in adults29• It produces the optimum values for several unknown 
parameters by minimising the sum of the squared residuals between the predicted and 
measured values of the dependent variable. The calculations required can be expressed 
concisely if matrix arithmetic is used. Recalling the equation which we are required to solve, 
namely:-
eqn.l.2.20 
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this has become a set of n simultaneous equation for each low pressure breath. Let Y 
represent the n x 1 vector of Mlao values, X represent the n x 2 matrix of ~ V and ~ V values 
and b the 2 x 1 vector comprising the unknowns Ers and Rrs• Then 
Y=Xb+& eqn 1.2.22 
where & is the error. The optimum values for Ers and Rrs are given by the equation 
eqn 1.2.23 
where T indicates matrix transpose, -1 matrix inverse and b that this is a least squares estimate 
rather than an exact solution. The calculations involved are laborious but thankfully done by 
computer. 
Figure 1.2.14. Automatic detection of reference points used to align breaths for 
subtraction. 
Pao and V are shown for five breaths, the last of which is a high pressure breath. 0 and 0 are 
points of zero flow at the beginning and end of inspiration and expiration respectively. X on 
the flow curve is point IF. (Measurements from a normal subject in the pulmonary function 
laboratory). 
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In applying LSMLR to the NIV data, there were two further issues which needed to be 
addressed. Firstly, over what time interval should a comparison be made between the high 
and low pressure breaths? On the one hand, this was defined by the range of validity of the 
assumptions used to generate the mechanical model. A major model assumption was that the 
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muscular effort was identical in the portion of the breath compared. This was generally seen 
to break down in the later stages of inspiration as the shape of the flow and pressure curves 
began to diverge between breaths but the location of this point in each breath was variable. 
On the other hand, sufficient data points needed to be included in the analysis so as to provide 
an accurate estimate of Ers and Rrs. At the start of inspiration, Rrs~V is much larger than 
Ers~ V and unsurprisingly it was seen that Rrs reached a stable value before Ers. Empirically it 
was found that the inclusion of 0.5 s of data for comparison between breaths was an 
acceptable compromise between these two competing issues. This gave a set of250 equations 
from which to calculate the values ofErs and Rrs. 
Secondly, quality control criteria need to be applied to the data to exclude results with a poor 
fit. The most commonly quoted parameter is R2, the coefficient of determination, although 
several other measures of aptness of fit have been used, e.g. root mean square residual, 
normalised residual and standard error of coefficients. It was not possible to make use of R2 
with LSMLR as implemented here because the prediction equation was constrained to go 
through the origin, which made the value ofR2 uninterpretable174• The approach adopted was 
to exclude obvious outliers and then assess quality of the data by looking at the scatter of the 
results. Breaths were identified as outliers if they obviously violated the model assumptions, 
in particular the requirement that muscular effort should remain unchanged between high and 
low pressure breaths. The exact conditions applied were that at the end of the comparison 
interval (i.e. 0.5 s) the low pressure breath should have a lower pressure and flow that the high 
pressure breath and that its volume should be more than 0.025L smaller. This volume 
difference was chosen to exclude erroneously high values of elastance generated by a 
reduction in muscular effort. 
Work against Intrinsic PEEP 
Theory for Non-invasive Measurement 
From Chapter 1.1, the work done against intrinsic PEEP is given by 
WpEEP = PEE~,dynVT 
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eqn 1.2.24 
It requires therefore measurement of the value of PEEPj,dyn which is conventionally performed 
as follows:-
1. Controlled Ventilation 
This is the simplest scenario in which to measure PEEPj,dyn as it can be determined 
directly from measurements of P ao and V provided the subject makes no respiratory 
effort. PEEPj,dyn is given by the size of the change in P ao at the end of expiration 
required to initiate inspiratory flowl76 . 
2. Spontaneous Breathing 
This requires the measurement of P oes and gastric pressure (P gas). PEEPj,dyn is 
measured as the abrupt drop in Poes (M>oes) occurring before flow becomes inspiratory. 
P gas is needed to compensate for expiratory muscle activity which increases alveolar 
pressure. A number of methods of correction have been proposed such as subtracting 
the expiratory rise in Pgas65 (M>gas,l) or subtracting the decrease in Pgas at the beginning 
of inspiration64,65. The latter can be either the complete fall (M>gas,2) or the fall from 
the expiratory peak in P gas to the value at zero flow (M> gas,3). These methods have 
recently been compared with each other and with the Campbell diagram as gold 
standard 177,178. 
An acceptable non-invasive method for measuring work against intrinsic PEEP was not found 
in this study. This section serves to document the approaches considered. 
1. Respiratory waveform variation (RWV) 
This is a phenomenon seen in the pulse oximetry waveform in subjects with severe 
airways obstruction (Figure 1.2.15)179-182. It is thought to be due to differences in 
arterial blood pressure between inspiration and expiration, i.e. pulsus paradoxus, which 
in turn is strongly related to the degree of airways obstructionI83,184. Since dynamic 
hyperinflation and PEEPj are associated with airways obstruction, it has been 
postulated that RWV could be a surrogate measure of PEEPj. In the single study 
where this has been evaluated, the correlations between R WV and pulsus paradoxus 
and RWV and PEEPj had ~ values of 0.88 and 0.96 respectivelyl82. 
2. Pulse transit time (PTT) 
This is a parameter currently of interest in the field of obstructive sleep apnoea 
hypopnoea syndrome which bears a strong relationship to arterial blood pressure and is 
measured non-invasively. It is the time taken for the arterial pulse pressure wave to 
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travel from the heart to the point of measurement, such as the pulse oximeter probe on 
the subject's finger. It is usually measured by the time delay between the start of the R 
wave on the electrocardiogram (ECG) and a fixed point on the oximetry waveform 
(e.g. 50% of the peak height of the pulse). Changes in PTT are strongly related to 
changes in blood pressure (and hence would detect pulsus paradoxus)185 (?=0.72) and 
oesophageal pressure186 (?=0.88) during breathing. By analogy with the reasoning for 
RWV, it is therefore also possible that PTT could be a surrogate measure of PEEPj. 
This hypothesis has not previously been tested. 
Figure 1.2.15. Illustration of the phenomenon of respiratory waveform variation 
(RWV). 
Note the pronounced swing in the pulse oximetry waveform between inspiration and 
expiration. The magnitude of R WV is indicated. (Measurements taken from a subject with 
an acute exacerbation of COP D). 
Oximetry 
waveform 
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Conclusions 
In this chapter techniques have been proposed which allow the non-invasive estimation of the 
components of work of breathing. Detailed descriptions have been given of the equipment 
used to implement these techniques and the mathematical steps involved in calculating and 
interpreting the results. 
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1.3 Conventional Physiological Methods 
Introduction 
The conventional physiological techniques used in these studies are described in this chapter. 
Measurements in Ventilated Patients on the Intensive Care Unit 
P ao and V measurements were made on ventilated patients to validate the elastance 
techniques. The breathing circuit used is shown in Figure 1.3 .1. The time delay between the 
P ao signal measured by the two different pressure transducers was determined as described in 
Appendix 4 and corrected in software. The design of the FOT machine ensured that there was 
no time delay between P ao measured by the Sensortechnics transducer and V . 
To calculate Ers conventionally, the intubated subjects had a period of volume controlled 
ventilation following sedation with remifentanil (Glaxo Wellcome UK Ltd., Uxbridge, 
Middlesex, UK) or propofol (AstraZeneca, London, UK). The absence of muscular effort was 
assessed from the ventilator pressure waveform during a 5-10 second period of apnoea. 
Inspired oxygen concentration and PEEP were unchanged between pressure support and 
controlled ventilation. Measurements were taken of P ao and V over a period of two to five 
minutes. Ers was calculated for each breath by determining the points of zero flow at the 
beginning of inspiration (point 2) and expiration (point 1) with no end-inspiratory pause and 
calculating 
eqn 1.3.1 
(see also Chapter 1.1). The final value was the average over all the breaths. Values were 
excluded from breaths where there was obvious spontaneous effort causing a dip in P ao. 
During the period of controlled ventilation, PEEPi,st was also determined using the end-
expiratory occlusion technique (see Chapter 1.2) via the preset function on the Galileo 
ventilator (Hamilton-Medical, 7403 Rhazuns, Switzerland). 
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Figure 1.3.1. Breathing circuit used when measuring P ao and V on ventilated patients. 
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Measurements in the Pulmonary Function Laboratory 
Oesophageal and Gastric Manometry 
P oes and P gas were required to calculate gold standard values of Wres, RL, EL,dyn and PEEPi,dyn, 
this technique being well described15,16,21,187. Latex balloons attached to PVC catheters 
(Ackrad Laboratories Inc., Cranford, NJ, USA) were used (Figure 1.3.2). The working range 
of the balloon catheter (i.e. the range over which changes in internal volume of the balloon 
did not influence pressure within the balloon catheter system, this remaining <0.05 kPa) was 
determined using the method described by Coates188• Figure 1.3.3 shows the pressure-volume 
relationship indicating that a volume of 0.5 ml was appropriate for inflating the balloon. 
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Figure 1.3.2. Dimensions of the oesophageal balloon catheter. 
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Figure 1.3.3. Working volume of the oesophageal balloon catheter. 
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The balloon catheters were inserted in a conventional manner188 using topical analgesia for 
the upper airway (2 ml of nebulised 4% lidocaine). Each balloon was initially inflated to 3-4 
ml to remove any folding of the balloon walls. The volume in the oesophageal balloon was 
then reduced to its working volume of 0.5 ml whereas the volume in the gastric balloon was 
reduced to 2 m1189• The adequacy of the balloon position for measuring Poes was assessed 
using the occlusion test190• Occlusion was achieved using a 3 way tap (Hans Rudolph 2100B, 
Hans Rudolph Inc., Kansas City, Missouri, USA) with the tap not completely closed to 
prevent glottis closure. Balloon position was considered to be acceptable when 0.95 < 
MlaoiMloes < 1.05 during the occlusion test. To measure Poes and Pgas, an array of four pressure 
transducers (Honeywell 26PC series, Bracknell, Berkshire, UK) was custom-built (DCPB 
Electronics, South Glasgow University Hospital NHS Trust). This interfaced directly with the 
BIOPAC system (Figure 1.3.4). The pressure transducers were single ended gauge sensors, 
two with range ±7 kPa and two with range ±35 kPa. Only the former were used for 
measurement of P oes and P gas. Further technical specifications of the balloon catheters and 
the pressure transducers (including linearity, frequency response and volume coefficient of 
displacement) are given in Appendix 4. 
Figure 1.3.4. Pressure transducer array with an oesophageal balloon catheter. 
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Three point calibration covering the working pressure range was performed on each day that 
the transducer array was used. The signals were low pass filtered at 100 Hz and the analogue 
signal sampled at either 200 or 500 Hz depending on the experiment being performed. 
Transpulmonary pressure was determined by subtracting P ao (measured by the FOT 
transducer) from P oes after correcting for transducer phase delay in software. 
Values were calculated for RL during inspiration (RL,insp) and expiration (RL,exp) for each breath 
by two techniques. Firstly, LSMLR was applied to the following model:-
P oes - Pao = Po + E L.dyn V + R L,insp V;nsp + R L,exp Vexp eqn 1.3.1 
where Po is a constant and 
V. and V represent flow during inspiration and expiration respectively and were 
msp exp 
otherwise set to zero21 • 
Secondly, least-squares regression was used to calculate RL,insp and RL,exp after elastic pressure 
changes were removed by a computational method analogous to the electrical subtraction 
technique of Mead and Whittenberger15• V was obtained by integrating V (obtained from the 
FOT pneumotachograph). The issues of volume drift and BTPS conversion are covered in 
Appendices 2 and 3. 
Wres was calculated from the area enclosed by the loop formed by a plot of P oes-P ao and V. It 
was divided further into inspiratory and expiratory components (Wres,insp and Wres,exp 
respectively) by assuming constant lung compliance over the tidal volume and joining the 
points of zero flow. The calculation of EL,dyn from P oes data is described in Chapter 1.1. 
Similarly, the calculation of PEEPi,dyn was covered in Chapter 1.2. Typical data collection 
periods were for one minute performed at least in duplicate. 
Lung Volumes and Gas Transfer 
With the exceptions of the asthmatic subjects undergoing histamine challenge tests and the 
subjects in the study on exacerbation of COPD, all spirometry and lung volumes were 
measured using a constant volume body plethysmograph (SensorMedics V6200 Autobox). 
The variables measured were slow or relaxed vital capacity (VC), forced vital capacity (FVC), 
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forced expiratory volume in one second (FEV 1), FEV I!FVC or FEV INC ratio, residual 
volume (RV), total lung capacity (TLC), inspiratory capacity (lC), airway resistance (Raw), 
specific airways conductance (sGaw) and peak expiratory flow (PEF)191. In the histamine 
challenge test, spirometry was performed by the subjects using a wedge bellows spirometer 
(Vitalograph, Maids Moreton, Buckingham, UK). The subjects in the study on exacerbation of 
COPD had spirometry performed using a laptop-based spirometer (KoKo Spirometer, Ferraris 
Respiratory, Louisville, USA). The diffusing capacity for carbon monoxide (T Leo) was 
measured using the single breath technique (SensorMedics Vmax29 SystemTM)192. These 
values were corrected for haemoglobin concentration. 
Body plethysmography and gas transfer measurements were performed by trained pulmonary 
function technicians. Quality control and procedures of testing followed the guidelines of the 
European Respiratory Society endorsed by the British Thoracic Society and the Association 
of Respiratory Technology and Physiology191-193. Results of at least three satisfactory 
manoeuvres were analysed and the reported values were the highest value for FEV 1, VC and 
FVC and the mean results for each of the remaining indices. IC was measured during the 
slow VC manoeuvre which was repeated until two IC values were within 10% of each other 
and the average of these two values was used. Predicted normal values were calculated using 
the European Community for Steel and Coal (ECSC) equations191,192. The predicted value for 
IC was obtained by subtracting the value for FRC from that for TLC. 
Capillary Blood Sampling and Transcutaneous Oxygen/Carbon Dioxide Measurement 
Capillary sampling of arterialised capillary blood was performed to obtain values for arterial 
partial pressure of oxygen (Pa0 2) and carbon dioxide (PaC02) 194. A nictotinate vasodilator 
cream (Transvasin, SSL International pIc, Knutsford, UK) was applied to the earlobe and the 
subject sat at rest for 20 minutes. The earlobe was then punctured using a 21 G gauge needle, 
blood was collected into a heparinised 140 JlL capillary tube (Multicap, Bayer Diagnostics, 
Sudbury, UK) and analysed immediately on an arterial blood gas analyser (Chiron 
Diagnostics Rapidlab 865, Halstead, UK). The Alveolar-arterial oxygen gradient (PcA-aP2) in 
kPa was calculated from the equation195:-
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eqn 1.3.2 
where R was obtained from the values at contemporaneous cardiopulmonary exercise testing. 
Transcutaneous oxygen and carbon dioxide partial pressure (Ptc02 and PtcC02) were measured 
during exercise using a heated sensor attached to the chest wall which combined a modified 
Clark polarographic oxygen electrode and a modified Severinghaus solid state pH electrode 
for the measurement of carbon dioxide (E5280 Solid State, Tina, Radiometer AlS, 
Copenhagen, Denmark). The system (E5280, Radiometer, Copenhagen, Denmark) was 
calibrated in vitro at two points (the first calibration gas contained 5% carbon dioxide and 
20.9% oxygen and the second 10% carbon dioxide in nitrogen) and in vivo after the output of 
the heated transcutaneous electrode was stable at 45°C (10-20 minutes) using an earlobe 
specimen of arterialised capillary blood. This technique has previously been validated in 
Glasgow Royal Infirmary (GRI)196,197. 
Cardiopulmonary Exercise Testing 
Cardiopulmonary exercise testing195,198 was performed using an electromagnetically braked 
cycle ergometer (Corival, Medgraphics Corp., St Paul, MN, USA) with breath-by-breath gas 
exchange variables and ventilation measured using a software-based system (MGC-CPX 
System, Medgraphics Corp., St Paul, MN, USA). Gas analysers were calibrated with certified 
gas mixtures, and the pneumotachograph system was calibrated using a three litre syringe 
before each exercise test. Pulse oximetry (Nellcor NPB-295, Pleasanton, California, U.S.A.) 
was used to measure heart rate (RR) and oxygen saturation (Sp02)' The subjects were 
initially monitored for 2 minutes whilst seated on the cycle ergometer with a nose clip in 
place and breathing through the pneumotachograph. They were then instructed to cycle with 
no load for a further three minutes. Thereafter either an incremental or endurance exercise 
protocol was followed. In the incremental protocol, the workload was increased every 
minute by a constant amount ranging from 5 to 25 W. The size of the step was estimated so 
as to give rise to a loaded cycling time of 8 to12 minutes. Cycling continued until symptoms 
prevented further exercise or the pedalling rate could not be maintained above 40 revolutions 
per minute and the primary symptom limiting exercise was recorded. In the endurance 
protocol, the subject cycled at a constant work rate which was calculated to be a fixed 
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percentage (70 or 80%) of the maximum work rate achieved in a previous incremental test. 
Again, cycling continued until symptoms prevented further exercise or the pedalling rate 
could not be maintained above 40 revolutions per second. The modified Borg scaleI99 was 
used to rate the intensity of breathlessness (Borgdysp) and leg fatigue (BorgIeg) perceived 
before, every minute during and at the end of exercise. In the endurance tests of the 
bronchodilator reversibility study (Chapter 3.1), IC was measured each minute during loaded 
cycling by asking the subject to make a maximum inspiratory effort. From this, inspiratory 
reserve volume (IRV) and change in end-expiratory lung volume (LlliEL V) were calculated 
using the equations 
lRV=lC-VT 
AEELV = let -lCo 
eqn 1.3.3 
eqn 1.3.4 
where V T is tidal volume, ICo is inspiratory capacity during rest at the start of the exercise test 
and ICt is inspiratory capacity at time t during the test. In the endurance tests of the interstitial 
lung disease longitudinal assessment study (Chapter 3.2), Ptc02 and PtcC02 values were 
recorded each minute. 
The following variables were calculated breath-by-breath from expired gas analysis and 
ventilation measurements198:-
V02 - Oxygen uptake (L.min-I) 
VC02 - carbon dioxide output (L.min-I) 
VE - minute ventilation (L.min-I) 
V T - tidal volume (L) 
VEN02 - ventilatory equivalent for O2 
VENC02 - ventilatory equivalent for CO2 
RR - respiratory rate (min-I) 
R - respiratory exchange ratio 
VoNT - dead space to tidal volume ratio 
Other output variables from exercise testing included:-
Tlim - the duration ofloaded cycling in the endurance test 
WR - the cycle work rate (W) 
HR - heart rate (min-I) 
HRR - heart rate reserve (min-I) 
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BR - breathing reserve (min-I) 
AT - anaerobic threshold 
O2 pulse - oxygen pulse (mI.beafI) 
M>tc02,peak, M>tcC02,peak - change in Ptc02 and PtcC02 between resting state and 
peak exercise (kPa) 
PCA-tc)02 - Alveolar-arterial pressure gradient (kPa) calculated using Ptc0 2 and 
PtcC02 
,rest - subscript indicating measurement at rest 
,iso - subscript indicating measurement at isotime 
,peak - subscript indicating peak measurement 
,end - subscript indicating end-exercise measurement. 
Breath-by-breath values were averaged over eight breaths. The peak value was the maximum 
of these over the last eight breaths during loaded cycling in the incremental cycle test. The 
end value was the average over the last eight breaths during loaded cycling in the endurance 
cycle test. The isotime point was defined separately for each patient as the minimum of the 
two endurance exercise times rounded to the whole minute below. The dead space of the 
mouthpiece, pneumotachograph and valve box were known and corrected for in software. 
Following convention, VE and VT were converted to BTPS whereas V02 and VC02 were 
standardised to standard temperature and pressure dry (STPD). The equation used for 
predicted peak V02 was from JonesI95. The predicted value for HR was 220-Age (years) and 
for maximum voluntary ventilation (MVV) was FEV 1 multiplied by 40198. Derived values 
as described in Jones195 and Wasserman198. 
Quality of Life and Symptom Questionnaires 
A number of questionnaires for measuring symptoms and health-related quality of life 
(HRQOL) were used in these studies. The symptom scales were completed by the 
investigator interviewing the subject whereas the HRQOL questionnaires were self-
completed. 
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St George's Respiratory Questionnaire 
The St George's Respiratory Questionnaire (SGRQ) is a disease specific instrument for 
measuring HRQOL which has been developed for and extensively used in patients with 
airways obstruction200,201 and bronchiectasis202• It provides a Total score and three component 
scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that 
cause or are limited by breathlessness), and Impacts (social and psychological effects of the 
disease). Each score can range from 0 to 100 where 0 indicates best and 100 indicates worst 
health. An EXCEL worksheet was used to calculate the SGRQ component scores using the 
method described in the User Manual and missing values were dealt with in the recommended 
way. Mean (95% confidence intervals) SGRQ scores in normal individuals with no history of 
respiratory disease are Symptoms - 12 (9-15), Activity 9 (7-12), Impacts 2 (1-3) and Total 6 
(5-7i03• Scores in individuals with airways obstruction weakly correlate with the FEV1• In 
a study where the baseline FEV 1 score was 45% predicted, the Total SGRQ score was 52201 . 
A change in the Total score of four units is thought to indicate a clinically significant change 
in the patient201 ,204. 
Short Form 36 
The Short Form-36 (SF-36) is a brief instrument for measuring generic HRQOL205• The 
questionnaire consists of 36 questions that cover eight health scales: physical functioning, 
physical role, pain index, general health, vitality, social functioning, emotional role and 
mental health. These eight scores can be further condensed into two items, physical and 
mental component scores (PCS, Mcsi06• The scores of the eight health scales could range 
from 0 (the worst possible condition) to 100 (the best possible condition) and values for the 
general US population from 1998 are shown in Table 1.3.t2°6• PCS and MCS values are 
transformed to a norm-based system using values for the healthy population such that the 
mean score is 50 and the standard deviation 10. Again a lower score indicates worse health. 
The questionnaires were scored using an EXCEL spreadsheet incorporating the scoring 
algorithms described in the SF-36 manuals206,207. 
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Table 1.3.1. SF -36 health scale scores from the US general population in 1998. 
SF-36 Scale Mean Score (SD) 
Physical functioning 82.97 (23.84) 
Physical role 77.93 (35.35) 
Bodily pain 70.23 (23.35) 
General health 70.10 (21.36) 
Vitality 57.00 (21.13) 
Social functioning 83.56 (23.03) 
Emotional role 83.10 (31.64) 
Mental health 75.22 (17.61) 
The London Chest Activity of Daily Living Scale 
The London Chest Activity of Daily Living Scale (LCADL) is a 15-item questionnaire 
designed to measure dyspnoea during activities of daily living in patients with COPD208,2o9. It 
consists of four components: Self-care, Domestic, Physical and Leisure. For each of the 15 
items, patients score from 0: "I wouldn't do anyway", to 5 "Someone else does this for me (or 
helps)", with higher scores representing maximal disability. 
Borg Scale 
The modified Borg scale is used to rate the perceived intensity of breathlessness and leg 
fatigue and can be used during rest or exercise199• In this scale, simple verbal expressions are 
linked to numbers from 0 to 10, 0 being no appreciable breathlessness or leg fatigue and 10 
being the maximum. The modified version is a ratio scale, i.e. a doubling of the numeric 
value indicates a doubling of the perceived breathlessness or leg effort. 
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Oxygen Cost Diagram 
The Oxygen Cost Diagram (OCD) is a visual analogue scale based on a 10 cm line where 
daily activities (such as "brisk walking uphill", "medium walking on the level", "bed 
making", "standing") are ranked along the line in proportion to their associated oxygen 
cosr lO. The line is marked at the point above which a task would have to be stopped because 
of breathlessness and increasing distance along the line from 0 to 1 represents increasing 
exercise capacity. 
Baseline and Transitional Dyspnoea Index 
The Baseline Dyspnoea Index (BDI) grades dyspnoea by combining the scores in three 
different categories; functional impairment, magnitude of task, and magnitude of efforrll. 
Dyspnoea is graded from 0 (severe) to 4 (unimpaired) for each category. The ratings for the 
three categories are added to form the baseline score, ranging from 0 to 12. The Transitional 
Dyspnoea Index (TDI) compares the patient's current dyspnoea with the baseline state with 
seven grades for each of the three categories. Scores range from -3 (major deterioration) to 0 
(unchanged) to +3 (major improvement). The ratings on each of the three scores are added to 
form a total score ranging from -9 to +9. 
Medical Research Council Dyspnoea Scale 
The Medical Research Council (MRC) dyspnoea scale212 is a questionnaire that consists of 
five statements about perceived breathlessness ranging from grade 1 ("I only get breathless 
with strenuous exercise") to grade 5 ("I am too breathless to leave the house"). 
Dyspnoea Scale from the Clinical, Radiographic and Physiologic Scoring System 
The dyspnoea scale from the Clinical, Radiographic and Physiologic Scoring System for 
pulmonary fibrosis213 (CRP dyspnoea scale) is a scale with 11 statements about dyspnoea 
ranging from ''None (or same as peers) even after 30 min of vigorous activity such as 
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running" to "At rest". The subject is asked to choose one statement which applies to them 
and the scale is scored from 0 ("None") to 20 ("At Rest") respectively in steps of2. 
Visual Analogue Scales for Symptoms 
The symptom scores are visual analogue scales (V AS) adapted from the study by Davies214• 
They ask about three symptoms: Quality of sleep, Wheeze and Mobility. The scale ranges 
from -100 ("much worse than usual") through 0 ("usual") to +100 ("much better than usual") 
and the subjects were asked to rate how they had felt with respect to each symptom over the 
previous 24 hours. The visual analogue scale for breathlessness is a similar scale ranging 
from -100 ("very, very much worse") through 0 ("before treatment") to +100 ("very, very 
much better") and the subjects were asked to rate their breathlessness at the present moment 
compared with that at presentation. 
Paggiaro Symptom Scores 
The symptom scores from the study by Paggiaro215 rate cough, breathlessness and sputum 
volume and colour. Several statements are attached to each symptom and the subjects were 
asked to choose the most appropriate answer. 
Ethical Approval 
Ethical approval for these studies was obtained from the Local Research & Ethics Committee 
of GRI (Glasgow, UK). 
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Part 2: Validation of non-invasive techniques for 
measuring work of breathing 
This section describes two studies performed to validate the techniques described in Chapter 
1.2. In Chapter 2.1, the performance of forced oscillometry variables for measuring W res are 
assessed. In Chapter 2.2, two techniques for non-invasive estimation of Ers are evaluated. 
Work validating the non-invasive measurement of intrinsic PEEP is not presented because 
very limited data were ultimately available for this purpose. R WV was absent in the 
intubated subjects on controlled ventilation and so no data were available from these subjects. 
PEEPi,dyn measurements were available from twelve patients with airways obstruction in the 
pulmonary function laboratory. However the median level of PEEPi,dyn was only 0.148 kPa 
with a range of 0.013 to 0.556 kPa. In these subjects there was no association between RWV 
measurements and PEEPi,dyn. There was a significant correlation between PEEPi,dyn and 
.M>TTave (r=0.73). Despite the absence of proper validation, the phenomena of respiratory 
waveform variation and pulse transit time were analysed further in the evaluation studies in 
Section 3 as these two variables are surrogate markers of respiratory effort (due to their 
relationship with P oes) and hence might still give useful information in this respect. 
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2.1 The use of forced oscillometry to estimate 
transpulmonary resistance and resistive work of breathing 
Introduction 
Forced oscillometry is a method of measuring Rrs which is passive, requiring only tidal 
breathing from the subject, and can give a continuous value of Rrs, delineating within-breath 
changes with sub-second resolution. It has two main limitations. Firstly, as distal airways 
obstruction increases, there is worsening agreement of Rrs with RL measured by oesophageal 
manometry4. Under these conditions, Rrs is an underestimate because of the increasing 
contribution of the upper airway wall, which acts as an impedance in parallel (or shunt) with 
the lower airway. Secondly, it is less useful for diagnosis as any pathology produces a similar 
pattern of abnormality in oscillometry results although differing in degree20. Despite these 
drawbacks, oscillometry performs similarly to standard tests in areas dependent on assessing 
airways obstruction such as bronchodilator reversibiliry216 and bronchial challenge testing217. 
There has been interest of late in using less conventional oscillometry parameters to overcome 
the limitations of the technique or to extract added value from the measurements. A recent 
proposal was the use of changes in admittance (the reciprocal of impedance)120 during 
bronchoprovocation. Theoretically the effect of upper airway wall shunt should be removed 
during calculation of the change in admittance and the results from standard oscillometry 
equipment compared with the head plethysmograph, although not identical, did support this 
claim. However, admittance could only be used to predict changes in resistance rather than 
absolute value. A further suggestion was the use of expiratory reactance (Xrs,exp) to 
demonstrate the presence of expiratory flow limitation218. This study showed that in COPD 
subjects a within-breath Xrs,exp value below a threshold « -0.7 kPa.s.L-1) could detect 
expiratory flow limitation proven by oesophageal manometry with 100% sensitivity. It had 
also been noted in earlier work that Xrs decreased (becomes more negative) as airways 
obstruction increased and in several studies this variable appeared to correlate more strongly 
with FEV 1 and Raw than did Rrs219-221. 
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Aims 
1. To assess the ability of Rrs measured by within-breath oscillometry at a single 
excitation frequency of 5 Hz to estimate RL. 
2. To explore the potential for using other within-breath oscillometry parameters such as 
Xrs or Zrs as a surrogate measure of RL. 
3. To assess the ability of forced oscillometry measurements to predict resistive work of 
breathing (Wres) using whichever variable proved optimal. 
Methods 
Study Design 
Oscillometry and oesophageal manometry were performed simultaneously on eleven 
asthmatic patients at several points during a histamine challenge test. The data generated 
from the fIrst fIve asthmatics were used to investigate the relationship between RL and the 
oscillometry variables. A linear model to predict the absolute value ofRL was generated from 
the data using the single most strongly correlated oscillometry variable. Then data from the 
remaining six asthmatics were used to assess the fIt of the predictive modeL Finally, single 
point measurements were performed in both normal subjects and others with a range of 
respiratory conditions (COPD, interstitial lung disease (lLD), chest wall disease and 
respiratory muscle myopathy) to see whether this behaviour was also seen outside the context 
of asthma. 
Subjects 
The normal and asthmatic subjects were drawn from the staff of the Departments of 
Respiratory Medicine and Anaesthesia at GRI. The fust fIve asthmatic subjects had median 
(range) age 39 (28 - 47) years, median (range) FEV! of 92 (78 - 106) % predicted and median 
(range) FEVt/FVC ratio of 70 (62 - 76) % and the second six median (range) age of33 (28-
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36) years, median (range) FEVl of 94 (69 - 112) % predicted and median (range) FEVlIFVC 
of 72 (69 - 82) %. All were non-smoking males who satisfied the BTS definition of 
asthma222• The remaining subjects were volunteers from the respiratory outpatient clinics 
(see Table 2.1.1). The subjects with COPD satisfied the BTS definition for this condition223• 
All the subjects with ILD had CT scan evidence of diffuse parenchymal lung disease and five 
were biopsy proven. The subjects with chest wall disease and myopathy used chronic 
nocturnal non-invasive ventilation for these conditions. 
Table 2.1.1. Characteristics of the non-asthmatic subjects studied. 
Number Age FEVt FVC FEVllFVC 
Normal 7 (5 male) 27 (20-30) 97 (89-107) 98 (92 -108) 83 (79-88) 
COPD 9 (8 male) 68 (53-73) 54 (31-107) 104 (70-160) 39 (25-52) 
Myopathyt 2 (no males) 62 (60-64) 63 (46-79) 68 (43-93) 81 (72-90) 
ILD§ 9 (4 male) 61 (50-75) 84 (50-122) 105 (50-130) 77 (59-80) 
Chest wall 8 (3 male) 68 (49-78) 
disease' 
32 (27-40) 40 (31-66) 58 (39-92) 
All values are median (range) 
tMitochondrial myopathy (1), diaphragmatic palsy (1) 
§Idiopathic pulmonary fibrosis (3), connective tissue disease (3), sarcoidosis (1), silicosis (1), 
hypersensitivity pneumonitis (1) 
'Kyphoscoliosis (4), thoracoplasty (3), pneumonectomy (1) 
Histamine Challenge Test 
This followed the method outlined by Sterk224. Baseline spirometry, oesophageal manometry 
and forced oscillometry were performed. After diluent (0.9% sterile sodium chloride), 
histamine (Tayside Pharmaceuticals, Dundee, UK) was delivered in doubling concentrations 
using a jet nebuliser (Micro-Neb Nebuliser, Lifecare Hospital Supplies, Market Harborough, 
UK) driven by an airflow of 8 L.min-l (Aquilon Nebuliser System, AFP Medical, Rugby, UK) 
through a face mask (Duo Mask Adult, Lifecare Hospital Supplies) and inhaled for two 
minutes of tidal breathing with the nose clipped. The starting concentration of histamine 
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varied between 0.0625 mg.ml-1 and 0.5 mg.ml-1• Between doses of histamine, two 
simultaneous recordings, each of one minute's duration, were made of oesophageal 
manometry and forced oscillometry. The test was stopped when FEV 1 dropped to less than 
60% of baseline or at a maximum concentration of histamine of 16 mg.mr1• 
Oesophageal Manometry 
This technique is described in Chapter 1.3. Values were calculated for RL during inspiration 
(RL,insp) and expiration (RL,exp) for each breath. For the asthmatic subjects, LSMLR was used 
to calculate RL,insp and RL,exp. The fit achieved by the LSMLR model to transpulmonary 
pressure values was reasonable. The median (inter-quartile range) R2 value generated by the 
LSMLR analysis was 0.94 (0.89-0.97). For the non-asthmatic subjects least-squares 
regression was applied after elastic pressure changes were removed by the Mead-
Whittenberger technique. The latter method was used in non-asthmatic subjects as 
occasionally in this group LSMLR produced non-physiological values of elastance and 
resistance. WOBres was calculated from the area enclosed by the loop formed by a plot of 
Poes-Pao and V, which is equivalent to calculating the integral:-
eqn 2.1.1 
and divided into inspiratory and expiratory components (WOBres,insp and WOBres,exp 
respectively) by a line joining the points of zero flow. These measurements were summed 
over the breaths for one minute and divided by minute ventilation to give results as J.L-1• 
Data were excluded for breaths corrupted by swallowing artefacts and each result was the 
average from the breaths over one minute. 
Forced Oscillometry 
This technique is described in Chapter 1.2. The Res and Xrs values were averaged over the 
inspiratory and expiratory phases of each breath to give separate values for the two phases of 
the respiratory cycle (Rrs,insp, Res,exp) (see Figure 2.1.1). The values from a one-minute 
recording were then averaged. Following the reasoning laid out in Chapter 1.2 for estimating 
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WOBres from oscillometry variables, integrals were calculated which combined V and the 
oscillometry variables Rrs, Xrs and IZrsI (where the latter is the magnitude of the complex 
variable representing impedance) as follows:-
S·2 WOB FOT.R = V Rrsdt eqn 2.1.2 
eqn2.1.3 
eqn 2.1.4 
Again these were calculated for each breath, separated into inspiratory and expiratory 
components (e.g. WOBFOT,Rinsp, WOBFoT,Rexp, etc.), summed over the breaths of one minute 
and normalised by minute ventilation. 
Figure 2.1.1. Within-breath Rrs and Xrs values are shown for one respiratory cycle from 
one of the asthmatic subjects at the midpoint of the histamine challenge test. 
Rrs,insp and Xrs,insp were calculated for each breath by averaging the inspiratory values for these 
variables. Rrs,exp and Xrs,exp were similarly obtained from the expiratory values. 
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Sample Size 
An estimate of sample size was obtained by requiring the 95% confidence intervals of the bias 
to be ±0.025 J.L-1• Assuming a typical value for WOBres of 0.5 J.L-1 and a pessimistic value 
for coefficient of variation of 18% (which was twice that for Rrs found in a pilot study), then 
the number required to give this precision on the bias was 52225• This leads automatically to 
the precision of the limits of agreement which was ±0.043 J.L-1• 
Statistical Analysis 
Statistical analyses were performed with StatView v 5.0.1 (SAS Institute Inc., Cary, NC, 
USA). Correlation was assessed using Pearson's r correlation coefficients. Prediction 
equations were generated by least squares linear regression. Agreement of the prediction 
models with the absolute values was assessed using an analysis similar to that proposed by 
Bland and Altman225 (indicated as "Bland-Altman"). The repeatability of measurements was 
calculated as a coefficient of variation by expressing the standard deviation of repeated 
measurements as a percentage of the mean. Median and range were used for baseline 
pulmonary function data. 
Results 
First Set of Asthmatic Subjects 
Bronchoprovocation tests on the first five asthmatics produced 96 measurements. Rrs,insp 
progressively underestimated RL,insp as airway obstruction increased (Figure 2.1.2(a)) leading 
to a divergence of the curve on the scatter plot from a straight line. The size of the error due 
to upper airway wall shunt was variable causing the scatter plot to fan out at high values. A 
similar relationship was seen between WOBFOT,Rinsp and WOBres,insp (Figure 2.1.2(b)). The 
oscillometry parameter most strongly correlated with RL,insp was Xrs,insp and with WOBres,insp 
was WOBFoT,Xinsp (Table 2.1.2). The strength of these associations was particularly striking, 
illustrated in Figure 2.1.3. A tight linear relationship was preserved until the highest observed 
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values of Xrs,insp' Prediction equations for RL,insp and WOBres,insp were therefore derived from 
Xrs,insp values. 
Second Set of Asthmatic Subjects 
Bronchoprovocation testing on the second set of asthmatics lead to a further 123 data points. 
RL values in this group ranged from 0.0005 to 4.57 kPa.s.L-1 with a median value of 0.21 
kPa.s.L- l . The values were skewed towards the normal range because the airways of the six 
subjects were unconstricted except for a few points towards the end of each histamine 
challenge test. The lower limit of the range measured is physically unrealistic and a 
consequence of the significant error involved in measuring normal values of RL by 
oesophageal manometry. 
The accuracy of the equation for predicting RL,insp from Xrs,insp was tested on these data and the 
results are shown in Figure 2.1.4(a). The equivalent results using absolute Rrs,insp values are 
shown for comparison. The prediction model using Xrs,insp is clearly more accurate at 
predicting RL,insp. In particular agreement is maintained until a relatively high value of RL,insp 
(approximately 2.5 kPa.s.L-1). The same analysis is repeated comparing WOBFOT,Xinsp and 
WOBFOT,Rinsp with WOBres,insp and is shown in Figure 2.1.4(b). 
Non-asthmatic Subjects 
Measurements were then performed on subjects with respiratory conditions other than asthma. 
A pair of duplicate readings was obtained for each of these subjects and the relationship 
between RL,insp and Xrs,insp and WOBres,insp and WOBFOT,Xinsp compared as before (see Figure 
2.1.5). Although scatter was greater, the results can be seen to follow largely the same linear 
relationship seen in the pure asthmatics. In the non-asthmatic subjects the mean (±SD) 
difference between the actual RL,insp values and that predicted from Xrs,insp was 0.033 (±0.36) 
kPa.s.L- l . Similarly the mean (±SD) difference between the actual WOBres,insp values and that 
predicted from WOBFOT,Xinsp was 0.038 (±0.16) J.L-1 
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Figure 2.1.2. Data from the first fIVe asthmatic subjects showing (a) Rrs,insp plotted 
against RL,insp and (b) WOBFOT,Rinsp plotted against WOBres,insp • 
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Table 2.1.2. Pearson correlation coefficients (.-2) relating oscillometry variables to those 
calculated from oesophageal manometry for the first five asthmatic subjects. 
a) Resistance 
RL,insp 
RL,exp 
b) Work of breathing 
Note:-
WOBres,insp 
WOBres,exp 
WOBres 
0.79 
0.59 
0.79 
0.56 
0.77 
Oscillometry Parameters 
Xrs 
0.94 
0.92 
Oscillometry Parameters 
Zrs 
0.88 
0.83 
WOBFOT,x WOBFOTX 
0.96 
0.92 
0.96 
0.90 
0.83 
0.90 
1. The appropriate inspiratory, expiratory or total component was used for correlating the 
oscillometry variables with the within-breath components ofRL and WOBres• 
2. All p-values < 0.0001 
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Figure 2.1.3. Data from the fIrst five asthmatic subjects showing (a) Xrs,insp plotted 
against RL,insp and (b) WOBFOT,xinsp plotted against WOBres,insp. 
The lines of best fit to the data are shown with their equations and Pearson correlation 
coefficients . 
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Figure 2.1.4. Data from the second set of six asthmatic subjects showing the accuracy of 
the prediction model derived from (a) Xrs,insp for predicting RL,insp and (b) WOBFOT,xinsp 
for predicting WOBres,insp. 
These are scatter plots of the difference between the predicted values of RL,insp and WOBres,insp 
(using the equations from Figure 2.1.3 derived from the first five asthmatics) and the actual 
values against the actual values. For comparison, the same plot using Rrs,insp values is also 
shown. Mean (SD) difference values are shown for the values predicted from Xrs,insp only. 
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Figure 2.1.5. Data from all the subjects showing (a) Xrs,insp plotted against RL,insp and (b) 
WOBFOT,xinsp plotted against WOBres,insp' 
<> Asthma 
~ ILD 
+ Myopathy 
/\ 0 
._. -0.25 
~ 
B 
~ 
(f) 
ro 
a... 
~ 
--
-0.5 
g- -0.75 
.=-
-1 
-1.25 
0 
.- -0.1 
:..... 
-0.2 
-, 
.~ -0.3 
x_ 
is -0.4 
LL 
III 
-0.5 0 
S 
-0.6 
-0.7 
0 
0 
;;: 
~ 
.COPD 
• Chest mil disease 
• Normal 
1 2 3 4 5 
<> 
0.5 1 1.5 2 
<><> 
98 
Repeatability 
The repeatability values obtained for oesophageal manometry and oscillometry variables for 
the asthmatic and non-asthmatic subjects are shown in Table 2.1.3. The figures for the 
asthmatic subjects represent the worst case scenario as they are repeated measurements taken 
after each step of the histamine challenge test. In the period between doses of histamine, 
there is some variability of bronchoconstriction with time which will therefore inflate the 
quoted repeatability values. By contrast the non-asthmatic subjects were stable between 
measurements. These values for RL,insp and Rrs,insp are similar to those quoted elsewhere for RL 
and Rrs4,217. 
Table 2.1.3. Repeatability of key variables. 
Coefficient of Variation (%) 
Asthmatic subjects 
Non-asthmatic subjects 
Discussion 
Oesophageal Manometry 
RL,insp 
30 
22 
WOBres,insp 
20 
15 
Oscillometry 
Rrs,insp Xrs,insp WOBFOT,xinsp 
11 
8 
17 
12 
20 
13 
In this study an unconventional but carefully thought out approach has been taken to the use 
of oscillometry data. Rrs and Xrs were calculated as a function of time, separated into 
inspiratory and expiratory values for each breath and analysed in two ways. Firstly, the 
average inspiratory and expiratory values were compared with those from oesophageal 
manometry, RL,insp and RL,exp. Secondly, the continuous values were combined with ,,2 and 
integrated over time to give a quantity with the units of work and again these were separated 
into inspiratory and expiratory values. Attention was focussed on the inspiratory integral as 
this reflects active resistive work. The use of expiratory values is complicated by the 
phenomenon of expiratory flow limitation which dissociates the relationship between pressure 
and flow. Despite this, when expiratory values were assessed, a similar pattern of results to 
inspiratory values were seen although the correlation coefficients dropped in magnitude 
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(Table 2.1.2). A single forcing frequency of 5 Hz was used as a compromise between limiting 
the errors attributable to breathing frequency and reducing the impact of upper airway wall 
shunt. Finally we analysed the usefulness of variables other than Rrs (i.e. Xrs and Zrs) at 
estimating resistive properties. 
Two interesting and perhaps surprising results have emerged from this study. Firstly the 
strongest predictor of RL,insp (and consequently WOBres,insp) was not Rrs,insp but a linear model 
using Xrs,insp. Secondly this relationship between RL,insp and Xrs,insp appeared to be independent 
of the underlying disease process. 
The fIrst result is clearly supported by Figure 2.1.4. It would have been possible to use a 
fItted model for Rrs,insp values instead of absolute values which would have improved its 
ability to predict RL,insp but this would not have performed as well as Xrs,insp. This fact is 
reflected in their relative correlation coefficients (Table 2.1.2) and can be seen from Figure 
2.1.2. Here it is clear that the relationship between RL,insp and Rrs,insp is curvilinear (and hence 
any fItted model would have to be nonlinear) and secondly the Rrs,insp values would fan out 
from a fItted curve at higher values of RL,insp leading to poorer prediction of RL,insp at these 
values. For the asthmatic subjects, the "Bland-Altman" analysis for the Xrs,insp values had a 
bias of -0.066 and standard deviation of±0.25 kPa.s.L-I . The usefulness of this model can be 
assessed roughly by comparing the magnitude of the limits of agreement (±0.5 kPa.s.L-1) with 
the range of values seen (0-5 kPa.s.L-1) which gives a ratio of ~10%. Similarly it was found 
that WOBres,insp was better predicted by a linear regression model using WOBFoT,Xinsp than by 
absolute values of WOBFoT,Rinsp which is also clearly shown in Figure 2.1.4 and a similar 
discussion to the above is appropriate. In this case the "Bland-Altman" analysis for the 
asthmatic subjects yielded a bias of -0.029 and a standard deviation of±O.l J.L-1• Compared 
with the range of values seen of 0-1.6 J.L-1, this gives a ratio between the limits of agreement 
and the range of ~ 12.5%. One factor limiting the accuracy of Xrs,insp as a predictor of RL,insp 
and WOBres,insp is its repeatability which is poorer than that of Rrs,insp (Table 2.1.3). It is 
possible that this could be improved by attention to the technique of measurement, for 
example by increasing the amplitude of the forcing signal. 
What is the mechanism underlying the strong linear relationship between Xrs,insp and RL,insp? 
It is not an isolated fInding in this study as Xrs is known to become more negative with 
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increasing airways obstruction. This has been shown in both the settings of COPD226 and 
asthma227 and lead to its proposal as an alternative measure during bronchial challenge 
testini28. The relationship between Xrs and Raw or FEV 1 has been found to be stronger than 
for Rrs 219-221. 
Xrs is composed of a contribution from both inertance and dynamic elastance (Ers,dyn); Ers,dyn is 
the dominant term at a forcing frequency of 5 Hz. Ers,dyn is larger than static elastance (Ers,st), 
the latter being measured under steady state conditions. The difference between Ers,dyn and 
Ers,st is accentuated by increasing flow rates or airway obstruction39 and is attributable to 
several phenomena, viscoelasticity12, time constant inhomogeneity (Otis effect)14 and 
shunting by either the upper1l8 or central229 airway walls (Mead effect). The contribution 
from viscoelasticity occurs even in normal subjects and represents the time dependent 
resistive and elastic behaviour of the lung and chest wall tissues. Time constant 
inhomogeneity describes heterogeneity in mechanical properties in different areas of the 
lungs, usually as a consequence of underlying pathology, which leads to regional variations in 
rates of emptying of the lungs and the potential for air recirculation. Central and upper airway 
wall shunting occurs when the impedance of the lung periphery becomes comparable to the 
tissue impedance of the central and upper airway walls usually as a consequence of increasing 
distal airways obstruction or airway closure. Here upper airway refers to supraglottal and 
central to immediate subglottal structures. 
Simulation studies have been performed to evaluate the relative influence of viscoelasticity, 
airway wall shunting and time constant inhomogeneity on Ers,dyn. A sophisticated approach 
was taken by Lutchen et aL 171,230 who looked at Ers,dyn from breathing frequency to 5 Hz using 
a morphometric model of the lung. He predicted that increased bronchoconstriction could 
increase Ers,dyn in several ways. Firstly, homogeneous bronchoconstriction could produce a 
large increase in Ers,dyn by central airway wall shunting23o. Secondly, severe inhomogeneous 
bronchoconstriction (with a greater than 80% reduction in calibre in a small number of 
airways) could produce a similarly large increase in Ers,dyn by the mechanism of time constant 
inhomogeneity171. The effect of viscoelasticity was detectable but more modesr3o. Support 
for the significance of heterogeneous bronchoconstriction is also present in a second model 
generated by Anafi et aL231 which simulated the physical behaviour of a single peripheral 
airway taking into account airway flow and parenchyma and smooth muscle properties. This 
predicted that a constricted airway had two stable states, open and nearly closed, and lead 
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automatically to a two-compartment lung model and the situation of heterogeneous airways 
obstruction. The relationship between peripheral airway resistance and Ers,dyn predicted by 
this model when the proportion of closed airways was increased from zero to nearly complete 
is shown in Figure 2.1.6. 
Figure 2.1.6. Relationship between peripheral airway resistance (Rp) and Ers,dyn using 
the two-compartment model proposed by Anafi et al.231 when the proportion of open 
airways, cp, is decreased from 1 to 0.1 in steps of 0.1. 
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Less complex lumped element models representing time constant inhomogeneity and airway 
wall shunting have been used extensively in previous oscillometry studies to interpret Rrs and 
Xrs data usually presented as a function of frequency. The common conclusion of most of 
these studiesI18,128,232-235 is that a model incorporating central airway wall compliance (Mead 
effect) fits the data better than one proposing parallel pathways (Otis effect) both qualitatively 
and as regards generating realistic physical values for the model coefficients. Further support 
for the significance of the Mead effect comes from data on expiratory flow limitation. This is 
the extreme case of the Mead model as the oscillometry forcing signal is unable to pass the 
flow-limited airway segments and instead is dissipated in the parallel impedances represented 
by the central and upper airway walls. In the recent study by Dellaca et al.2I8, Xrs dropped 
dramatically in the presence of expiratory flow limitation (confirmed by oesophageal 
102 
pressure-flow loops). They were again able to simulate this effect using a lumped element 
model which allowed an airway wall shunt in parallel with airway and tissue compartments. 
The effect of expiratory flow limitation was reproduced when the resistance of the airways 
was increased from 0.05 to 25 kPa.s.L- l . 
Bronchoconstriction could also increase Ers,dyn by a direct effect on static tissue elastance due 
to changes in tissue properties236 or airway closure but the magnitude of this component is 
uncertain and difficult to unravel from airway effects23o. Studies attempting to partition 
airway and tissue properties conclude that the effect exists but is probably a lesser component 
of the increase in Ers,dyn seen during bronchoconstriction235,237. 
To determine the relative contributions of the different mechanisms to the decrease in Xrs with 
increasing RL, the scenario was simulated here using a lumped element model at a single 
frequency of 5Hz which incorporated time constant inhomogeneity and both central and upper 
airway wall shunting. This model is described in detail in the Appendix 5. Representative 
values from the literature were chosen for the model parameter values and the only variable 
was the peripheral resistance, Rp, which was allowed to range over the values seen for RL. 
The simulation results are shown compared with the experimental data from the first five 
asthmatic subjects in Figure 2.1.7. It can be seen that the model reproduces the qualitative 
behaviour of the data with the parameter values chosen and is also a reasonably accurate 
quantitative fit. 
The simulation was then repeated incorporating one mechanism at a time and the results are 
shown in Figure 2.1.8(a). Heterogeneous parallel pathways on their own did not reproduce 
the Xrs behaviour, even when the time constants between the two pathways differed by several 
orders of magnitude. By contrast, introducing either upper or central airway wall shunt 
produced marked effects on Xrs, causing it to decrease as respiratory resistance increased. 
Initially both effects were of the same order of magnitude but at high levels of respiratory 
resistance the central airway wall shunt became relatively more important. The conclusion 
from these simulations was that both central and upper airway wall shunting were the major 
mechanisms dictating the linear relationship between Xrs and RL at 5 Hz and time constant 
inhomogeneity had little effect. This conclusion should be viewed with a note of caution as, 
although it is in keeping with the previous lumped element modelling results1l8,128,232-235, it is 
at variance with approaches using different forms of modell7l,230,231. It is possible that the 
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Otis effect does in fact have more impact on Xrs than shown in these simulations but that the 
lumped element model as implemented does not accurately reflect the in vivo phenomenon. 
Why do all the subjects regardless of the nature of the respiratory pathology lie on the same 
curve? This result was not predicted beforehand as it was anticipated that lung diseases such 
as ILD and chest wall disease would have elevated Ers,st values and therefore the Xrs - RL curve 
would shift significantly downwards. One suggestion to account for the observed behaviour 
is that the influence of RL on Xrs is much larger than that due to Ers,st even when the latter is 
increased several fold. This explanation was supported by a further simulation (Figure 
2.1.8(b)). Firstly lung elastance was decreased by a factor of five to simulate COPD 
(compliant lungs) which resulted in a small absolute increase in Xrs' Then elastance values 
were increased by a factor of five firstly for the lungs (stiff lungs) and then for the chest wall 
(stiff chest wall) to simulate ILD and chest wall disease respectively. The increased Ers,st 
values did shift the Xrs curve downwards but not greatly. The largest effect was at small 
resistance values where the change was of the order of -0.25 kPa.s.L- l whilst at larger values a 
change of only -0.1 kPas.L- l was seen. In retrospect this behaviour is also seen in the 
experimental data. Examining Figure 2.1.5, the Xrs values tended to be more negative than 
the group results in subjects with chest wall disease and ILD and less negative than the group 
in subjects with COPD. 
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Figure 2.1.7. The results of lumped element modelling compared with the experimental 
data from the first five asthmatic subjects for (a) Rrs,insp and (b) Xrs,insp' 
In the case of the simulation RL,insp is replaced by the respiratory resistance of the lumped 
element model, which was calculated from the sum of the central airway resistance (Re), the 
chest wall resistance (Rw) and peripheral airway resistance (Rp). The values of Re and Rw 
were constant and are given in Table A5.I. Rp is the real part of the sum of the impedances of 
the two peripheral pathways (Zpl and Zp2) (see Appendix 5 for further details). 
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Figure 2.1.8 (a) Relative importance of three mechanisms (heterogeneous parallel 
pathways and upper and central airway wall shunting) contributing to the relationship 
between Xrs and respiratory resistance (Rp+Rc+Rw) illustrated by repeating the 
simulations with the three effects combined and in isolation. (b) Simulation of the effect 
on the relationship between Xrs and respiratory resistance (Rp+Rc+Rw) of changes in 
static elastance of the lungs or chest wall Normal elastance is compared with a five-fold 
decrease in lung elastance (compliant lungs), a five-fold increase in lung elastance (stiff 
lungs) and a five-fold increase in chest wall elastance (stiff chest wall). 
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Conclusions 
• The measured and simulated results in this study suggested that at 5 Hz the value ofXrs,insp 
was linearly related to the airway resistance and, when used in an appropriate linear 
regression model, provided a more accurate estimate of RL,insp than absolute values of 
Rrs,insp. 
• This behaviour extended to the prediction of WOBres,insp where a model based on the 
integral WOBFoT,XillSP proved superior to absolute values of WOBFOT,Rinsp. This could 
provide the basis for using forced oscillometry as a non-invasive estimate of work of 
breathing. 
• The linear relationship between RL,insp and Xrs,insp appeared to be independent of the 
disease process. 
• Lumped element simulation suggested that this relationship between RL,insp and Xrs,insp was 
due to central and upper airway wall shunting of the forcing signal which swamped any 
change in Xrs,insp due to other physical properties such as elastance. 
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2.2 Evaluation of two non-invasive methods for measuring 
respiratory elastance in spontaneously breathing subjects 
Introduction 
Respiratory elastance (Ers) comprises serial contributions from the lung parenchyma and the 
chest wall and is elevated in conditions which increase the stiffness of either of these 
components. This effect has been demonstrated in diseases affecting the lungs alone such as 
ILD238,239, in conditions where there is a primary chest wall abnormality such as ankylosing 
spondylitis158, kyphoscoliosis240,241, thoracoplasty159 or pleural thickening242 and in situations 
where there is a restrictive defect without lung or chest wall disease such as obesity80,156,158 or 
myopathy154,243,244. Ers has clear potential as a measurement of severity and progression in 
such conditions245,246. Elastic work of breathing (WOBe1as) is closely related to Ers, its value 
for each breath being estimated from the equation 
1 2 
We/as = 2 ErsVr . eqn2.2.1 
It is therefore an alternative to Ers incorporating additional information on breathing pattern. 
Ers and WOBelas are not routinely measured in the pulmonary function laboratory because this 
process is invasive as described in Chapter 1.1. Two non-invasive methods for estimating 
these variables both based on positive pressure breathing were introduced in Chapter 1.2. The 
first148 is an old method using a constant pressure over several breaths (CPAP) first described 
in 1956 by Heafand Prime whereas the secondl72 uses more complex mathematics (LSMLR) 
to look at small differences between adjacent pressure supported breaths (NIV). Such 
approaches to determining respiratory mechanics can nowadays be easily implemented with 
the combination of electronic non-invasive ventilators, digital signal recording and 
computerised analysis of results. 
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Aim 
The aim of this study was to evaluate these two techniques for estimating Ers (and thereby 
WOBelas) in a modem setting by comparison with conventional measurements using 
appropriate method comparison methodology. 
Methods 
Study Design 
Ers was measured in two sets of subjects, the fIrst set being from the pulmonary function 
laboratory and the second set intubated patients in ICU. The measurement was performed in 
three ways in each subject, by a conventional approach and by the two non-invasive methods 
(CP AP and NIV). 
Subjects 
To give values throughout the normal and pathological range, subjects with a variety of 
respiratory problems were recruited. In all, 66 subjects were studied, 20 ventilated patients in 
the intensive care unit (ICU) and 46 in the pulmonary function laboratory. The ventilated 
patients (age range 48 to 87 years) comprised 11 patients immediately following 
cardiothoracic surgery (7 coronary artery bypass grafting, 3 valve replacement and 1 excision 
of myxoma) and 9 requiring emergency ventilation for acute respiratory failure (3 acute 
respiratory distress syndrome, 3 respiratory failure post-surgery, 2 pneumonia and 1 
cardiogenic pulmonary oedema). The laboratory subjects (Table 2.2.1) consisted of normals 
(7) and those with mild asthma (11), COPD (9), ILD (9), chest wall disease (8) and myopathy 
(2). This was the same group of subjects studied in the laboratory in Section 2.1. 
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Table 2.2.1. Subject characteristics. 
Number Age (years) FEV1 FVC FEVIIFVC 
Normal 7 (5 male) 27 (20-30) 98 (92 -108) 83 (79-88) 
Asthma 11 (all male) 34 (28-47) 109 (82-123) 70 (62-82) 
COPD 9 (8 male) 68 (53-73) 54 (31-107) 104 (70-160) 39 (25-52) 
Myopathy~ 2 (no males) 62 (60-64) 63 (46-79) 68 (43-93) 81 (72-90) 
ILD§ 9 (4 male) 61 (50-75) 84 (50-122) 105 (50-130) 77 (59-80) 
Chest wall 
disease' 
8 (3 male) 68 (49-78) 32 (27-40) 40 (31-66) 58 (39-92) 
All values are median (range) 
~Mitochondrial myopathy (1), diaphragmatic palsy (1) 
§Idiopathic pulmonary fibrosis (3), connective tissue disease (3), sarcoidosis (1), silicosis (1), 
hypersensitivity pneumonitis (1) 
'Kyphoscoliosis (4), thoracoplasty (3), pneumonectomy (1) 
CP APINIV Methods 
Ers was measured non-invasively using both CP AP and NIV methods, performed twice on 
each subject. These techniques and their application in this study were described in detail in 
Chapter 1.2. 
Conventional Methods in the ICUlPulmonarv Function Laboratory 
In the ICU, conventional measurement of Ers was performed with the subject on controlled 
ventilation. In the pulmonary function laboratory, Ers was measured using a combination of 
oesophageal manometry to measure EL and predicted values for Ecw. The theory and 
practical details of both these techniques were covered in Chapters 1.1 and 1.3. 
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Sample Size 
No pilot data had been collected prior to the main study with which to perform this 
calculation. It was therefore presumed that similar numbers to that for the forced oscillometry 
study (Chapter 2.1) would be required in order to define adequately the performance of the 
methods. 
Statistical Analysis 
Statistical analyses were performed with StatView v 5.0.1 (SAS Institute Inc.). Correlation 
was calculated using Pearson's r correlation coefficients. The baseline characteristics of 
subjects have been given as median and range. Mean results were used to summarise the 
results on each patient group. Agreement of the results of the non-invasive with the 
conventional methods was assessed using an analysis similar to that proposed by Bland and 
Altman225 and is indicated as "Bland-Altman". The repeatability of measurements was 
calculated as a coefficient of variation by expressing the standard deviation (SD) of the 
difference between repeated measurements as a percentage of the mean measurement. 
Results 
The NIV method gave results for Ers in all subjects whereas the CP AP method failed in 6 
cases (9%) because no step in volume was detected when CP AP was applied. Five of these 
were ICU patients and one was a subject in the pulmonary function laboratory with ILD. On 
average, the CP AP method produced similar results to the control method whereas the NIV 
method consistently overestimated (Figure 2.2.1). The difference in results between the new 
and control methods for the chest wall disease patients is artificial. The control value in these 
subjects was generated by assuming a normal value for Ecw which is an underestimate. 
The individual results for the NIV method are shown in Figure 2.2.2(a) (chest wall disease 
patients excluded). Correlation between NIV and control methods was significant (:r=O.72, 
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p<0.0001). The outlying subject from ICU who suffered from morbid obesity artificially 
inflated this value and, if his result were excluded, the correlation coefficient fell (r=0.59, 
p<0.0001). The mean±SD difference between the two sets of results (Figure 2.2.1(b)) was 
0.46±1.0 kPa.L-1. Figure 2.2.3 performs the same analysis for the CPAP method. Correlation 
was higher (r=0.86, p<0.0001). The CPAP method had the better agreement particularly for 
lower values. The mean±SD difference between the CP AP and control methods was -
0.007±0.69 kPa.L-1• Individual results for the chest wall disease patients are shown in Figure 
2.2.4. These were consistently above the line of identity suggesting that the non-invasive 
methods were successful at detecting elevated Ecw. 
Figure 2.2.1. Mean Ers values for each patient group using the non-invasive and control 
methods. Error bars show standard error of the mean (SEM). 
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The repeatability values obtained for elastance measured by oesophageal manometry and the 
non-invasive methods are shown in Table 2.2.2. These figures represent the worse case 
scenario as they reflect the repeatability of two measurements only. The process involved in a 
single measurement was defined in Chapter 1.2. In practice multiple measurements would be 
performed and averaged to give the fmal result for a subject. 
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Figure 2.2.2. (A) Individual Ers results from the NIV method plotted against the 
conventional (conv) values. (B) Difference between Ers value from the NIV method and 
the conventional value plotted against the conventional value. 
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Figure 2.2.3. (A) Individual Ers results from the CPAP method plotted against the 
conventional values. (B) Difference between Ers value from the CP AP method and the 
conventional value plotted against the conventional value. 
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Figure 2.2.4. Ers values for the patients with chest wall disease from the non-invasive 
and conventional methods. 
Note that the conventional values are an underestimate because they assume normal chest 
wall elastance. (+ CPAP; • NIV; --- Identity) 
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Table 2.2.2. Repeatability of Ers values. The figure given for the conventional 
measurement is from oesophageal manometry. 
Method of Measurement 
Conventional CPAP NIV 
Coefficient of Variation (%) 8 24 36 
Discussion 
This study has evaluated two simple non-invasive techniques for measuring Ers which use 
equipment widely available in all respiratory departments and procedures that require little 
cooperation, measuring only pressure and flow at the mouth during spontaneous tidal 
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breathing. The CPAP method was shown to be feasible in the 1950s-60s148 but its relevance 
to modem practice has not been re-evaluated using the convenience of modem non-invasive 
ventilation equipment. By contrast the NIV method was proposed more recently. It has been 
evaluated by comparison with oesophageal manometry on patients in ICU173 but in the 
pulmonary function laboratory it has only been validated using the forced oscillation 
technique as the control 172. Each method took five to ten minutes to perform repeated 
measurements and was successfully carried out on the majority of patients, including those 
with severe COPD, ILD or chronic respiratory failure. 
The "Bland-Altman" analysis for the CP AP method (Figure 2.2.3) showed a bias of -0.007 
kPa.L-1 and SD of 0.69 kPa.L-1. The ratio of the limits of agreement (±1.4 kPa.L-1) to the 
range (0-4.2 kPa.L-1) was 33%. The data displayed better agreement at lower e1astance 
values. For the NIV method, the "Bland-Altman" analysis gave a bias of 0.46 kPa.L-1 and SD 
of 1.0 kPa.L-1. The ratio of the limits of agreement (±2.0 kPa.L-1) to the same range as for the 
CPAP method (0-4.2 kPaL-1) approached 50%. Repeatability showed the same pattern as 
accuracy, the CPAP method having a coefficient of variation of 24% and the NIV method 
36%. In summary, the error involved with both techniques was large but despite this it was 
clear that the simpler CP AP method consistently outperformed the more complicated NIV 
method in terms of bias, limits of agreement and repeatability although it proved less reliable 
in the ICU population. 
The scatter between the results from the non-invasive and control methods came from several 
sources:-
1. Although the time points of the conventional and non-invasive measurements were close 
to each other, they were not performed simultaneously and hence there was potential for 
the measurement conditions (i.e. ventilatory flow, thoracic volume and respiratory rate) to 
have changed between the application of the methods. Dynamic e1astance is known to be 
dependent on such parameters and its value would be affected by the conditions prevailing 
at the time of measurement. 
2. All three methods relied on simplifying assumptions to give a single value of Ers. The 
conventional and CP AP methods assumed a constant Ers value over the tidal volume. The 
NIV method assumed a simple linear one-compartment two-component model for the 
respiratory system which has limited validity in the context of significant respiratory 
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pathology, although the analysis of small perturbations to linearise the problem should 
have reduced this error. 
3. Air leaks during the application of positive pressure were a further source of error. A 
constant leak would not have affected the algorithm used to calculate Ers but a variable 
leak would have introduced an error. 
4. Variations in respiratory muscle effort caused an increase in scatter. The NIV method 
assumed the same muscular effort for the first 0.5 s of breaths that were compared. In 
practice there was always involuntary variation which was compounded by voluntary 
differences when the subj ect reacted to the difference in inspiratory pressure. To 
minimise this problem the subjects were asked to put the same effort into every breath. 
The CPAP method required an absence or similar degree of expiratory effort at end-
expiration both with and without the CPAP. To achieve this the subjects were asked to 
breathe uniformly with the same effort regardless of the pressures applied at the 
mouthpiece. The validity of these assumptions was not directly assessed during the study 
but inferred from the agreement between the conventional and non-invasive methods. 
5. A factor affecting the success of the CP AP method in the ICU patients was the presence 
of intrinsic PEEP. If this were much greater than the external PEEP, then addition of 
further PEEP in the form of a CP AP pulse would have had an unpredictable effect on 
thoracic volume, in some cases not increasing it, and this might account for the clustering 
of failures of the CPAP method in the ICU group. 
6. Sedation differed between the methods in the ICU subjects. 
7. No attention was paid to the elastic behaviour of the upper airway (i.e. cheeks and 
pharynx) which are partially under voluntary control and could affect results. 
These sources of error were exaggerated at high levels of Ers where the signal to noise ratio is 
relatively poor. Changes in airway pressure with both these methods were largely 
independent of the value of Ers. By contrast, changes in thoracic volume were inversely 
proportional to Ers and hence smaller at high values. This made both methods less accurate 
with high Ers values, where the volume change threatened to disappear in the biological noise. 
Modifications could be made to improve the accuracy of these methods. In particular, 
altering the way in which positive pressure is applied could reduce variations in muscular 
effort. For example, with the NIV method, a high value of inspiratory pressure would reduce 
or even abolish muscular effort and then every 30 seconds the inspiratory pressure could be 
lowered for one breath rather than being increased. In addition, there were a number of 
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choices taken in deflning the algorithm for the NIV method which could potentially be 
improved upon with further investigation. Examples include the location of the point of 
alignment of low and high pressure breaths and the duration of the period of comparison (an 
empirical interval of 0.5 s was used here). There is scope also to optimise signal to noise 
ratios by tailoring the size of the change in inspiratory pressure or of the pulse in CP AP to the 
anticipated elastance value. Other avenues include minimising air leaks, performing more 
measurements to obtain a more accurate average value and more prolonged training of the 
subjects. 
Conclusions 
• The results of this study suggest that both of these non-invasive tests for measuring Ers 
have potential for routine use in the pulmonary function laboratory. 
• The NIV method could distinguish between subjects with normal and abnormal Ers values 
but accuracy was not sufficient to separate gradations of abnormality. 
• The CP AP method clearly showed superior performance and was the more promising 
candidate for further development. 
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Part 3: Evaluation of non-invasive techniques for 
measuring work of breathing 
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3.1 Assessment of bronchodilator reversibility 
Introduction 
Bronchodilator reversibility is usually assessed in patients with airways obstruction by 
looking at changes in FEV 1 and FVC post-bronchodilator, the aim being either to distinguish 
between patients with asthma and COPD or to predict the benefit to be expected from 
bronchodilator therapy. There is a strong body of evidence which disputes the ability of the 
acute bronchodilator response assessed by change in FEV 1 to predict the long-term 
therapeutic benefit of bronchodilation in COPD. In the absence of a significant change in 
FEVl post bronchodilator, it is possible to detect acute changes in other resting pulmonary 
function tests (such as expiratory flow-volume 100ps247, IC3,248 inspiratory muscle activiry249 
or pressure-time products250), in functional capacity assessed by exercise performance3,25l-255 
and in dyspnoea scales3,250,253,254,256-259. It is also possible to fmd evidence of long-term 
therapeutic benefit from bronchodilation measured by PEF, spirometry, exercise tolerance, 
symptoms and quality of life256260-263. 
One reason why FEV 1 is not more successful in this context is that it is not a simple surrogate 
measure of resistance but has more complex physioloW64• During a forced expiratory effort 
in a normal person, only the first fifth of the expiratory volume is effort dependent as the 
procedure is flow-limited for the remainder of expiration with the maximum flow rate defmed 
by the lung volume265. This can be understood by considering pressure in the alveolus as the 
sum of pleural pressure and pressure due to lung elastic recoil (Figure 3.1.1). Moving along 
the airways towards the mouth, pressure progressively drops from alveolar pressure to 
atmospheric for two reasons. 
• Firstly, the area of the airways diminishes and, to conserve mass, the flow of air must 
increase266. To cause the air to accelerate (termed convective acceleration), a pressure 
gradient is required. This effect is dominant at larger volumes. 
• Secondly, the airways offer resistance to air flow and a pressure gradient is required to 
overcome frictionallosses267. This effect is relatively more important at low volumes. 
Airway collapse occurs when the pleural pressure exceeds the luminal pressure in the 
intrathoracic airway by an amount sufficient to overcome the supporting tension provided by 
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the lung parenchyma. Flow is therefore limited to the maximum that does not cause airway 
collapse and any further increase in effort would not increase flow. The point at which airway 
collapse occurs is just downstream of the equal pressure point (EPP) described by Mead268 
(where luminal airway pressure equals pleural pressure) and its location (and the associated 
maximum flow) will vary with lung elastic recoil pressure, the upstream resistance and the 
mechanical properties of the airway wall. In COPD, there is increased compliance due to loss 
of elastic tissue, increased resistance due to airway narrowing and loss of parenchymal 
support for airways allowing them to collapse more easil~69. Expiratory flow limitation 
therefore occurs earlier in the forced expiration, which reduces peak expiratory flow, and, at 
any lung volume, the upstream airway characteristics of COPD cause a lower flow than that 
seen in normal lungs. This leads to the pathognomic appearance of the expiratory limb of the 
flow volume 100p27o. 
Figure 3.1.1. Schematic illustration of the concept of flow-limitation due to flow-
dependent airway collapse. 
PpI, Palv and Pree are pleural, alveolar and lung elastic recoil pressure respectively. EPP is the 
equal pressure point and Plum is the airway pressure at that point. 
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It is now recognised that bronchodilators achieve benefit not only by reducing resistance but 
also by decreasing hyperinflation and the possibility of using measurements of hyperinflation 
to assess bronchodilator response has been studied over the last two to three 
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decades3,248,255,271-278. One such variable is IC, which diminishes with increasing severity of 
COPD either due to rising functional residual capacity (FRC) or an elevated EEL V caused by 
dynamic hyperinflation. One study looked at the ability of bronchodilator induced changes in 
lung volumes to predict change in exercise capacity measured by constant workload cycle 
ergometer tests and found that change in IC or inspiratory reserve voJume (IRV) were 
significant predictors whereas change in FVC, FEV1 and peak expiratory flow rate were noe. 
Change ill IC has proved responsive to all existing forms of inhaled 
bronchodilators3,274,277,279,28o in both acute and chronic test scenarios. Some studies, however, 
suggest that it may only be of use when tidal breathing is flow-limited as it is only in this 
context that bronchodilators would increase tidal flow and allow patients to breathe at lower 
lung volumes247,281-283. 
Exercise capacity is another attractive outcome measure as it quantifies function rather than 
resting physiology and potentially has greater relevance to the patient. As a tool for assessing 
acute bronchodilator effect, it has recently been subjected to systematic revie~84 but the 
study outcomes appeared rather heterogeneous. There was a significant increase in exercise 
capacity in 11 out of 18 studies of anticholinergic agents, 7 out of 14 studies of short-acting ~2 
agonists, 1 study of formoterol, none of 3 studies of salmeterol and 1 of 8 studies of 
theophylline. This inconsistency has continued in several modem studies performed since the 
publication of the systematic revie~50,279,280,285. One explanation for this inconsistency is 
that exercise capacity in COPD is dependent not only on lung volumes which dictate 
ventilatory capaciry286-289 but also on ventilation/perfusion mismatching (i.e. wasted 
ventilationi90, skeletal muscle dysfunction286,289,291 or deconditioning (i.e. increased 
ventilatory demand for the same workloadi86,292,293, cardiac function and volition294. A more 
intriguing possibility raised in a very recent study was that the ability to convert a 
bronchodilator effect into improved exercise capacity in COPD depended on the way in which 
the chest wall muscles adapted to the changes produced by the bronchodilat0285. Subjects 
who permitted dynamic hyperinflation were more likely to experience benefit from the 
bronchodilator. 
It may be possible to improve the consistency of benefit seen with bronchodilators in exercise 
testing by using a different exercise test design such as the constant workload endurance test 
which may more closely reflect the impact of an intervention on activities of daily living. 
Most of the studies in the systematic review used either an incremental exercise test or a fixed 
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time walking tests. The former is designed to elicit maximum exercise capacity. The latter 
evokes a physiological response which lies somewhere between a constant workload 
endurance test and an incremental tesf95-298. More recently it has been demonstrated that the 
constant workload endurance test is much more sensitive to both physical (exercise training) 
and pharmacological (bronchodilator) interventions3,279,280,295,299,300. For example, in a three 
way comparison of incremental cycle ergometer test, six minute walk test and cycle 
endurance test, oxitropium produced a 19% increase in endurance time, a 1 % increase in six 
minute walk distance and no increase in V02peak295. Such tests may also have more relevance 
to subjects as they are more likely to reflect the submaximal effort involved in activities of 
daily living. The greater sensitivity of endurance tests is due to the hyperbolic relationship 
between workload and exercise time (see Figure 3.1.2). Using this approach, O'Donnell has 
systematically demonstrated positive bronchodilator effects due to ipratropium, tiotropium 
and salmeterol on endurance exercise times3,279,280. 
Figure 3.1.2. Relationship between workload and exercise time (Tlim) in an endurance 
exercise test. 
A small change in this relationship resulting from an intervention can have an amplified effect 
on~T1im. 
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Dynamic hyperinflation during exercise (due to expiratory flow limited tidal breathing) is 
thought to be one of the principal mechanisms limiting ventilatory and therefore exercise 
capacity in COPD258,301,302 and it can be measured by serial IC values during the exercise 
tesi58• This phenomenon has two consequences. Firstly, a reduction in IC limits maximum 
ventilation as VT cannot exceed IC and any further increase in minute ventilation can only be 
achieved by greater respiratory frequency. Secondly, the phenomenon of neuromechanical 
dissociation occurs. As the lungs work at higher and higher EEL V, the inspiratory muscles 
become less efficient, the respiratory system less compliant and intrinsic PEEP constitutes a 
progressively greater inspiratory workload. Despite increased respiratory muscle effort 
compared with a normal person, total ventilation is significantly lower. Bronchodilators can 
relieve this problem and increase maximum minute ventilation by enabling the subject to 
maintain the same ventilation at lower operational lung volumes. 
Dyspnoea is a further outcome measure of greater importance to subjects than their lung 
volume values. In one-stop acute testing of bronchodilator effect the most useful vehicle is a 
visual analogue scale such as the Borg score199 with dyspnoea produced by a stimulus such as 
exercise. Serial Borg scores have been taken during endurance exercise testing and changes 
in isotime Borg score post-bronchodilator can be detected even if there is no change in resting 
FEV/58. 
In Chapter 2.1 it was shown that Xrs,insp at 5Hz was strongly correlated with RL,insp, much more 
so than Rrs,insp. A similar relationship held between WOBres,insp and WOBFOT,Xinsp. Both these 
oscillometry parameters would be expected to be directly responsive to bronchodilator effect. 
In addition Xrs,exp has recently been shown to be a sensitive and specific marker of expiratory 
flow limitation during tidal breathing in COPD with the suggestion that it could be used to 
quantify the proportion of expiratory time over which flow-limitation occurs218. Again this 
quantity would be expected to diminish post-bronchodilator and be directly related to 
dynamic hyperinflation at rest. Early studies demonstrated that bronchodilator use in single 
COPD patients could be seen as changes in oscillometry parameters1l8,303. Since then a 
number of studies have reproduced this effect in larger groups of patients216,226,304-308. The 
studies are consistent in that they show a larger effect of bronchodilation on Xrs based 
parameters compared with Rrs. The consistency of these oscillometry studies ends there. 
Some used frequency ranges over which to average oscillometry parameters226,307,308 whereas 
others used values at single frequencies216,305,306. Some including the largest study did not 
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look at Xrs values216,305,308 and none perfonned within-breath analysis. Their conclusions 
regarding the usefulness of FOT at assessing bronchodilator response in COPD relative to 
spirometry and plethysmography are also heterogeneous216,308. 
Aim 
The aim of this study was to explore the ability of within breath oscillometry measurements to 
provide infonnation on acute therapeutic benefit of bronchodilators when compared with 
spirometry and with more recently evaluated tests which have a potentially greater link to 
subjective outcomes of importance to patients (such as hyperinflation, exercise tolerance and 
dyspnoea). 
Methods 
Subjects 
Target recruitment was 40 subjects to complete the protocol. Forty-four were enrolled. Three 
dropped out after the initial visit and one after the second visit (due to recurrence of an 
inguinal hernia) and these patients were not included in the results. The inclusion criteria 
were the presence of airways obstruction on routine spirometry (i.e. pre-bronchodilator 
FEV INC ratio less than 1.96 residual standard deviations below the predicted value309) and 
age ;;::: 18 years. This allowed the recruitment of subjects with airway obstruction for any 
cause. Exclusion criteria were any medical conditions or physical disability which precluded 
or limited the ability to perfonn a cycle exercise test. The study population was recruited 
from patients attending for routine pulmonary function tests at GRI between February 2002 
and February 2003. 
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Study Design 
The methodology was very similar to that described by O'Donnell et al. in a number of recent 
studies in this area3,279,280. The study had a randomised, placebo-controlled, crossover design 
and the protocol is summarised in Figure 3.1.3. There were three visits with a minimum of 
two days between each visit. The aim of visit 1 was to familiarise the subject with cycle 
exercise tests and to determine maximum work rate by an incremental cycle exercise test. 
The aim of visits 2 and 3 was to determine the effect of bronchodilator (5 mg salbutamol) 
compared with placebo (0.9% sterile sodium chloride solution) on resting pulmonary function 
tests and endurance (constant workload) cycle exercise tests. To achieve this, the pulmonary 
function tests were performed pre and 20 minutes post an intervention which was randomly 
assigned as bronchodilator on one visit and placebo on the other. The intervention drug was 
delivered over 10 to 15 minutes in a 2.5 m1 volume using a jet nebulizer (Micro-Neb 
Nebuliser, Lifecare Hospital Supplies) driven by an airflow of 8 L.min-1 (Aquilon Nebuliser 
System, AFP Medical) through a face mask (Duo Mask Adult, Lifecare Hospital Supplies). 
Randomisation was by alternate allocation of subjects to placebo or active bronchodilator as 
the fIrst intervention in order of enrolment. The pulmonary function tests were (in order of 
execution) forced oscillometry, Ers, RWV, PTT and body plethysmography. All the tests 
described in Chapter 1.2 were performed and analysed (including Ers and WOBe1as). Only 
oscillometry, RWV and PTT results are shown as these are the relevant variables in an 
obstructive setting. Dellaca's studr18 had suggested several indices for quantifying % flow 
limitation (%FL) from Xrs,exp. In this study %FL was calculated from the proportion of the 
expiratory time for which Xrs,exp < -0.7 kPa.s.L- l . In practice this meant that the percentage of 
each expiratory breath that was flow limited was determined and this percentage was 
averaged over all the breaths contained in the oscillometry recording. Not surprisingly Ers and 
WOBelas showed no change post-bronchodilator. The exercise test was performed after the 
pulmonary function tests and post-intervention only. After a period of rest and then unloaded 
cycling, the subject cycled at a workload of 80% of that achieved during their earlier 
incremental cycle exercise test. During the test, serial measurements of IC to assess dynamic 
hyperinflation and Borg score to assess dyspnoea and leg fatigue were taken each minute. All 
conventional physiological tests are described in detail in Chapter 1.3. 
Study tests were double blinded except for the operator supervising forced oscillometry, E rs, 
RWV and PTT which were single blinded to the subject. Analysis of all results was double 
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blinded. Subjects were asked to avoid major physical exertion and to omit inhaled 
bronchodilators on the day of investigation (tiotropium was not available at that time) and 
omit oral bronchodilators for 24 hours. Compliance with this request was ascertained 
verbally on the day of the visit. For each subject the tests were performed at the same time of 
day. 
Figure 3.1.3. Study protocol. 
Visit1 ~ 
Visits2&3 ~ 
Sample Size 
Demographic data 
Symptom scores 
Resting dyspnoea (MRC, BDI) 
HRQOL (SGRQ) 
Impairment of activities of daily living (LCADL) 
.... 
Incremental cycle exercise test 
Pre 
Forced oscillometry 
Ers / RWV / PTT 
Plethysmography 
.... 
Intervention 
.... 
20 minute wait 
.... 
Post 
Forced oscillometry 
Ers / RWV / PTT 
Plethysmography 
.. 
Endurance cycle exercise test 
Since little was known beforehand regarding the likely magnitude and scatter of changes in 
Xrs and work of breathing, the study was powered to detect a small (10%) change in Rrs. The 
change in Rrs expected was --0.05 kPa.s.L-1 with a standard deviation for the change of ~0.15 
kPa.s.L-1, assuming a coefficient of variation of the measurement of ~10-15%. Therefore, to 
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detect this change with 80% power and a significance level of 0.05, the sample size required 
was 35310,311. 
Statistical Analysis 
Results were summarised either as mean (SD) or median (IQR). Variables were screened for 
nonnality using the Shapiro-Wilk W Test. Comparisons were perfonned using the Student's 
paired t test except where the variable was not nonnal or not continuous when the Wilcoxon 
signed rank sum test was used31O• The level of statistical significance was taken as 0.05. No 
compensation for multiple comparisons (such as the Bonferroni method) has been explicitly 
applied and this should be taken into consideration when interpreting the significance of 
results. The effect of the crossover design on the results of the study was assessed by 
checking for period effects and treatment-period interactions310• Between day reproducibility 
of the test results was assessed by looking at the difference in pre-bronchodilator results. 
These were analysed in two ways 
• as coefficient of variation, i.e. the standard deviation of the difference between repeated 
measurements divided by the mean measurement expressed as a percentage312 
• by an intraclass correlation coefficient of reliabiliry313. R<OA indicates poor reliability, 
OA~0.75 fair to good reliability and R>0.75 excellent reliability. 
Spearman's rank correlation coefficients were calculated to identify whether any of the 
changes in the resting pulmonary function tests were associated with increased Tlim, V E,end or 
reduced Borgdysp,iso. All statistics where perfonned with Statview v 5.0.1 (SAS Institute Inc.) 
with the exception of intra class correlation where SPSS v 12.0.1 (SPSS Inc., Chicago, Illinois, 
USA) was used. 
Results 
Baseline Characteristics 
The baseline characteristics of the study population are shown in Table 3.1.1. The aim of the 
entry criteria was to select a representative population of patients with airways obstruction 
attending for pulmonary function tests at GRI who would conventionally go on to have 
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reversibility studies (similar to Sourk3I4). Thirty-six of our subjects had a clinical history and 
baseline pulmonary function tests consistent with a diagnosis of COPD3I5. A further two had 
asthma and two allergic bronchopulmonary aspergillosis. The clinical diagnosis was 
supported by the study PFT results which showed that only the two asthmatics attained 
normal FEV INC ratios with all other subjects showing a degree of irreversible airflow 
obstruction. In addition the minimum smoking history of the current or ex-smokers was 10 
pack years and the minimum age was 52. This selection of COPD patients almost certainly 
reflected the entry criteria (the presence of significant airflow obstruction on screening), the 
location of the study (the East end of Glasgow with its high prevalence of COPD) and the 
requirement of three study visits which was not favoured by younger, employed, asthmatic 
patients. 
The study population had a median FEVI of 50.7% predicted, suggesting that approximately 
half the subjects had moderate to severe airflow obstruction using the BTSINICE grading 
definition3I5. The incremental exercise test results showed a reduced peak work rate with 
ventilatory rather than cardiovascular (low BR and high HRR) limitation to be expected in 
this group. The subjects were also significantly symptomatic from the airways disease with 
measurable exacerbation rate, symptoms (symptom score), limiting dyspnoea (MRC, BDI), 
impairment of ability to perform activities of daily living (LCADL) and reduction in health 
related quality of life (SGRQ). There were equal numbers receiving either placebo or 
bronchodilator as the first intervention. 
Period Effects and Treatment-period Interactions 
No significant treatment-period interactions were revealed. Three variables were found to 
have a significant period effect, namely isotime Borg score for breathlessness (p=0.036), 
isotime Borg score for leg fatigue (p=0.025) and Rrs,exp(P=0.04). The difference in Borg 
scores arose because of lower values on average at visit 2 compared with visit 3 (average 
Borgdysp,iSO of 5.5 v 6.2 respectively) and could reflect a learning effect. There was no obvious 
explanation for the significant result for Rrs,exp. This detectable period effect was not deemed 
to require a change in the analysis method of the study results as it was small in magnitude, 
affected a few results only and had impact on both treatment and placebo arms. 
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Table 3.1.1. Baseline characteristics of study patients. 
Sex (male : female) 
Age (years) 
Clinical diagnosis (COPD: ABPA: asthma) 
Weight (kg) 
Height(m) 
BMI (kg.m-2) 
Smoking history 
- ex or current smokers : lifelong non-smokers 
- pack years 
Spirometry 
- VC (L) 
- FEVI (L) 
- FEV I (% pred) 
- FEVINC (%) 
Incremental cycle exercise test: peak exercise values 
WR (W) 
V02 (L.min-I) 
(% pred) 
HR (min-l ) 
HRR(min-1) 
RR (min-I) 
VE (L.min-1) 
(% MVV) 
BR (%MVV) 
R 
Exacerbation frequency (yr-I) 
Symptom score 
Dyspnoea 
- BDI 
- MRC 
Impairment of activities of daily living (LCADL) 
HRQOL (SGRQ) 
- Symptoms 
- Activities 
- Impacts 
- Total 
"'Median (IQR) 
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Mean (SD) 
29: 11 
64.6 (7.1) 
36: 2: 2 
74.8 (17.8) 
1.67 (0.10) 
26.3 (4.7) 
38: 2 
49 (27) 
3.35 (0.87) 
1.45 (0.54) 
54 (17) 
42 (10) 
76 (44) 
1.07 (0.47) 
65.2 (33.5) 
125 (17) 
30.4 (17.5) 
33.3 (5.4) 
45.8 (18.3) 
82.9 (20.8) 
17.1 (20.8) 
1.15 (0.14) 
2 (1-5)'" 
6.03 (2.73) 
5.13 (3.28) 
2.83 (1.01) 
31.6 (11.4) 
73.3 (23.8) 
68.9 (25.0) 
44.1 (23.4) 
56.5 (22.0) 
Reproducibility 
The availability of baseline results pre intervention for the two visits gave the opportunity to 
defme the comparative between visit reproducibility or reliability of the resting pulmonary 
function tests (Table 3.1.2). The coefficients of variation for the lung volume variables 
(FEVl, VC, IC) were similar to those quoted elsewhere255. The values for the Rrs derived 
variables were similar to the figure of 15% for Rrs6 measured by van Noord2l6. In the latter 
study they did achieve better values for Raw, sGaw, FEVl and FVC but this could perhaps be 
explained by a difference in study population, ours being more severely obstructed. The 
intraclass correlation coefficient of reliability, R, was also calculated. If this exceeded 0.75, it 
was deemed to indicate excellent reliability or reproducibiliif13. All of the 
plethysmographic, oscillometry and pulse transit time measurements satisfied this criterion 
other than WOBFOT,Xinsp which had a value of 0.744. The order of reliability was 
plethysmography > oscillometry > pulse transit time. Ern and R WV were not reliable in this 
patient group. 
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Table 3.1.2. Reproducibility analysis. Pre-bronchodilator data from visits 2 and 3. 
Mean pre- Coefficient Intraclass 
bronchodilator value of Variation R 
Visit 2 Visit 3 (%) 
Plethysmography 
VC (L) 3.336 3.333 7.2 0.945 
FEV1 (L) 1.419 1.431 9.6 0.955 
FEV1NC (0/0) 42.13 42.33 6.8 0.940 
RV (L) 3.572 3.542 9.8 0.863 
TLC (L) 6.906 6.876 4.5 0.955 
IC (L) 2.257 2.211 8.8 0.912 
Raw (kPa.s.L-1) 0.4666 0.4688 23.0 0.771 
sGaw (kP -I -I) a .s 0.5540 0.5275 22.6 0.850 
Oscillometry 
Rrs (kPa.s.L-1) 0.5393 0.5334 12.2 0.822 
Xrs (kPa.s.L -I) -0.3919 -0.3843 24.1 0.852 
Rrs,insp (kPa.s.L-1) 0.4760 0.4671 14.0 0.849 
Xrs,insp (kPa.s.L-12 -0.2085 -0.2104 17.6 0.850 
Rrs,exp (kPa.s.L- ) 0.5838 0.5799 13.2 0.778 
Xrs,exp (kPa.s.L-1) -0.5136 -0.4989 28.6 0.841 
WOBFOT,xinsp (J.L-1) 0.5283 0.5240 27.1 0.744 
%FL (%) 30.51 28.14 53.9 0.830 
Pulse transit time 
APTT max (ms) 8.811 8.584 44.3 0.802 
APTT ave (ms) 4.821 4.995 60.4 0.791 
Respiratory waveform 
variation 
RWV ditI (AU) 56.14 54.67 41.5 0.720 
RWV area (AU) 28.52 27.72 44.5 0.764 
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Treatment Effect 
Changes in variables have been given both as absolute values and percentage change, where 
the latter was calculated from the absolute change divided by the mean of the two values. The 
exceptions to this were the lung volumes where the change was expressed as a percentage of 
predicted values to avoid bias associated with those patients with lower baseline values. 
Treatment effect on resting tests was calculated in two ways, fIrstly from the between-day 
difference postbronchodilator and placebo and secondly from the within-day difference pre 
and post bronchodilator. The former gives a true indication of therapeutic effect controlling 
for the impact of maximal manoeuvres on airway calibre whilst the latter represents the 
typical clinical setting of bronchodilator reversibility testing. Only the between day results 
are shown (Table 3.1.3). All plethysmographic and oscillometry parameters showed 
signifIcant changes between placebo and bronchodilator except for TLC. Absolute change in 
PTT was also signifIcant. The within-day results were largely similar to the between-day 
changes except that change in TLC was also signifIcant and the changes in oscillometry Rrs 
values were smaller with Rrs,exp being non-signifIcant. There were no treatment effects in 
RWV in either analysis and these measurements were not analysed further. 
For the exercise data, only the between-day difference is available and the results are shown 
in Table 3.1.4. These showed signifIcant increases with bronchodilator in Tlim, VE,end and IC 
during unloaded exercise (ICunioaded). Analysis of the isotime variables showed signifIcant 
increase in VT, VE, IC, IRV, VEN02 and VENC02. The end-exercise variables showed the 
same behaviour with the addition of increases in V02 and HR. There was a drop in isotime 
Borg score which was signifIcant only as a % change. 
The largest % change following treatment was seen in resistive parameters and Tlim in the 
endurance test in the following order (from Table 3.1.3: Xrs,exp> sGaw > Xrs > Raw > Xrs,insp> 
Rrs,insp> WOBFOT,xinsp > Tlim > Rrs > Rrs,exp). By comparison changes in plethysmographic 
volumes were smaller and in the order RV > IC > FEV I > VC > FEV INC> TLC. This 
pattern of change is similar to that seen in other reversibility studies3,2I6,248,275,295,306 although 
the placement of within-breath Xrs values within the order is new. 
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Table 3.1.3. Effect of bronchodilator on resting tests: between-day analysis of 
salbutamol vs placebo. 
Absolute Change % Change 
Mean p-value Mean p-value 
Plethysmography 
VC (L) 0.216- <0.0001 6.8+- <0.0001 
FEVI (L 0.224 <0.0001 8.r <0.0001 
FEVINC (%) 3.600 <0.0001 4.8+ <0.0001 
RV (L) -0.272 0.001 -12.4+ 0.0009 
TLC (L) -0.055 NS -0.869+ NS 
IC (L) 0.277- <0.0001 10.r <0.0001 
Raw (kPa.s.L-I) -0.143 <0.0001 -33.1 <0.0001 
sGaw (kP -I -I) 0.252- <0.0001 37.7 <0.0001 a .s 
Oscillometry 
Rrs (kPa.s.L -1) -0.107 <0.0001 -20.4- <0.0001 
Xrs (kPa.s.L-I) 0.120 <0.0001 37.1 <0.0001 
Rrs,insp (kPa.s.L-1) -0.116 <0.0001 -25.4 <0.0001 
Xrs,insp (kPa.s.L-1) 0.057- <0.0001 29.0 <0.0001 
Rrs,exp (kPa.s.L-I) -0.101 <0.0001 -18.0- <0.0001 
Xrs,exp (kPa.s.L-I) 0.161 <0.0001 40.1 <0.0001 
WOBFOT,xinsp (J.L-I) -0.056" 0.0005 -22.0- 0.002 
%FL (%) -15.4" <0.0001 
Pulse transit time 
APTTmax (ms) -2 0.005 33.6- 0.03 
APTTave (ms) -2- 0.006 -74.8- 0.03 
Respiratory waveform 
variation 
RWVdiff (AU) -1 NS 0.2 NS 
RWVarea (AU) -1 NS -0.5 NS 
+ % predicted 
* Non-parametric test used (Wilcoxon signed rank for absolute changes, one sample sign test 
for % changes) 
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Table 3.1.4. Effect of bronchodilator on endurance exercise tests: salbutamol vs placebo 
- changes 
Placebo Salbutamol 
Absolute Change % Change 
Mean (SD) Mean p-value Mean p-value 
T1im (s) 303 (198) 73- 0.0004 20.5 0.001 
ICunloaded (L) 2.26 (0.73) 0.21 <0.0001 9.3 <0.0001 
Isotime variables 
V02 (ml.min-1) 1070 (450) 21' NS 2.2 NS 
VC02 (ml.min-1) 1150 (530) 10" NS 1.2 NS 
HR(min-1) 117 (22) 1 NS 1.0 NS 
RR(min-1) 32.3 (6.1) -I' NS -2.3 NS 
VT(L) 1.34 (0.56) 0.12 <0.0001 9.4 <0.0001 
V E (L.min-1) 42.0 (17.6) 2.4- 0.002 6.0 0.003 
IC (L) 1.87 (0.70) 0.16 0.02 7.4 NS 
Bor~ysp 6.13 (2.38) -0.6' NS (0.06) -13.1- 0.03 
Borgle~ 6.73 (2.63) -0.7" NS (0.06) -13.0- 0.05 
IRV (L) 0.529 (0.256) 0.09" 0.002 13.9' 0.001 
AEELV (L) -0.387 (0.317) 0.01 NS 43.4" NS 
VEN02 39.5 (6.2) 1.5 0.005 3.8 0.006 
V~C02 37.9 (6.2) 1.9 0.0001 4.8 0.0001 
End-exercise variables 
V02 (ml.min-1) 1090 (450) 40 0.045 4.0 0.02 
VC02 (ml.min-l) 1160 (520) 20 NS 2.7 NS 
HR(min-1) 122 (20) 3.7 0.02 3.1 0.01 
RR(min-1) 33.9 (6.3) 1* NS 2.5- NS 
VT(L) 1.33 (0.56) 0.09 0.0005 6.9 0.0008 
VE (L.min-1) 43.7 (17.8) 3.3' 0.006 8.1 0.0001 
IC (L) 1.83 (0.70) 0.19 <0.0001 10.7* <0.0001 
Bor~ysp 7.93 (1.85) 0.03- NS -1.6- NS 
Borgl~ 8.08 (2.16) 0.15" NS 2.7' NS 
IRV (L) 0.504 (0.278) 0.10' 0.006 10.9" 0.006 
AEELV (L) -0.428 (0.293) -0.02 NS 30.9' NS 
V~02 40.5 (7.25) 1.7 0.003 4.1 0.008 
VENC02 38.7 (6.72) 2.2 0.0001 5.4 0.0005 
* Non-parametric test used (Wilcoxon signed rank for absolute changes, one sample sign test 
for % changes) 
135 
Predicting Therapeutic Benefit 
The potential for acute bronchodilator reversibility tests to predict therapeutic benefit for 
patients was assessed by looking at the association between changes in resting pulmonary 
function tests and exercise parameters (Table 3.1.5). The exercise parameters chosen for 
comparison were Tlim as a measure of exercise capacity, Borgdysp,iso to give an indication of 
breathlessness during exercise and VE,end as a measure of ventilatory capacity. ATlim and 
ABorgdysp,iso had the same distribution of associations with exercise parameters but no 
association with resting pulmonary function test changes. By contrast A V E,end was associated 
with flow related exercise parameters and also showed significant associations with both AlC 
and changes in resistive parameters (Raw, 1/sGaw, Xrs,insp) especially when represented as % 
change. Multiple linear regression analysis showed that the linear combination of IC with a 
resistive parameter did not lead to a strengthened association. It was notable that AFEV 1 was 
not associated with A V E,end. 
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Table 3.1.5. Correlation coefficients: exercise test and resting pulmonary function tests. 
Spearman's rank correlation coefficients are given (rs). Coefficients for VC, FEVINC, RV 
and TLC were all non-significant and are not included. 
ATlim AVE,end ABorgdysp,iso 
sec % L . -I % % .mm 0 
Plethysmography 
AFEVI (L) NS NS NS NS NS NS 
MC (L) NS NS 0.392 0.367 NS NS 
ARaw (kPa.s.L-I) NS NS -0.417 -0.489 NS NS 
A(l/sGaw) (kPa.s) NS NS -0.380 -0.451 NS NS 
Oscillometry 
ARrs (kPa.s.L-I) NS NS NS NS NS NS 
AXrs (kPa.s.L-I) NS NS NS NS NS NS 
ARrs,insp (kPa.s.L-I) NS NS NS -0.315 NS NS 
AXrs,insp (kPa.s.L-I) NS NS 0.389 0.359 NS NS 
ARrs,exp (kPa.s.L-I) NS NS NS NS NS NS 
AXrs,exp (kPa.s.L-I) NS NS NS NS NS NS 
A WOBFOT,xinsp (J.rl) NS NS NS NS NS NS 
Pulse transit time 
APTTmax (ms) NS NS NS NS NS NS 
APTTave (ms) NS NS NS NS NS NS 
Endurance exercise test -
Isotime variables 
AV02 (ml.min-I) NS 0.483 NS 
AVC02 (ml.min-I) -0.332 0.531 NS 
MIR (min-I) NS NS NS 
ARR (min-I) -0.367 NS 0.485 
AVT (L) NS 0.356 NS 
AVE (L . -I) .mm -0.432 0.645 0.495 
MC (L) NS NS NS 
ABor~ysp -0.483 NS 
ABorgleg -0.522 NS 0.609 
AVFfV0 2 -0.427 NS 0.451 
AVENC02 -0.325 NS 0.362 
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Predicting Bronchodilator Response 
F or each pulmonary function variable, the definition of bronchodilator response could be 
created in two principle ways 
from reproducibility data2I6,312 
from placebo responses3I4,3I6. 
The latter has the advantage that it takes into account any effect that the physical performance 
of the test has on the post-test measurement and was the approach taken here. 
The size of the placebo effect was determined by the within-day difference pre and post 0.9% 
sodium chloride solution. There were small but significant changes in FEV INC, RV and 
sGaw but sizeable increases in all Rrs parameters and a decrease in Xrs,insp, suggesting 
measurable bronchoconstriction induced by placebo testing. A level defining a significant 
response to bronchodilator was derived for each test measurement (Table 3.1.6) based on the 
95% confidence intervals generated from the placebo results for a sample size of 40 (i.e. 2.02 
x SD)3I4. The number of responders generated by each test are shown in Table 3.1.7. FEVI 
and sGaw were the most sensitive single parameters. Since the subjects identified as having a 
bronchodilator response were not the same for each test, combining terms (e.g. absolute or % 
changes, ~IC or ~sGaw) lead to greater sensitivity as shown. 
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Table 3.1.6. Minimum values for a positive bronchodilator response dermed from the 
95% confidence intervals for the placebo response. 
Plethysmography 
VC 
FEV1 
FEV1NC 
RV 
TLC 
Ie 
Raw 
sGaw 
Oscillometry 
Rrs 
Xrs 
Rrs,insp 
Xrs,insp 
Rrs,exp 
Xrs,exp 
WOBFOT,xinsp 
%FL 
Pulse transit time 
APTTmax 
APTTave 
* % predicted 
(ml) 
(ml) 
(%) 
(ml) 
(ml) 
(ml) 
(kPa.s.L-1) 
(kPa-l.s-l) 
(kPa.s.L-1) 
(kPa.s.L-1) 
(kPa.s.L -I) 
(kPa.s.L-1) 
(kPa.s.L-1) 
(kPa.s.L-1) 
(J.L-1) 
(%) 
(ms) 
(ms) 
95% CIs for placebo response 
Absolute chan e % chan e 
+365 
+235 
+3.9 
-652 
-594 
+400 
-0.195 
+0.229 
-0.101 
+0.150 
-0.088 
+0.069 
-0.122 
+0.217 
-0.345 
-27 
-9.07 
-6.59 
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+10* 
+8* 
+5* 
-29* 
-10* 
+15* 
-34 
+35 
-16 
+39 
-19 
+31 
-17 
+44 
-71 
Table 3.1.7. Number of responders (using response defined by upper limit of placebo 
effect). 
VC 
FEVI 
FEV1NC 
RV 
TLC 
IC 
Raw 
sGaw 
R rs 
Xrs 
Rrs,insp 
Xrs,insp 
Rrs,exp 
Xrs,exp 
WOBFOT,xinsp 
%FL 
APTTmax 
APTTave 
IC orFEVl 
IC orsGaw 
IC or Xrs,insp 
IC or Xrs,insp or Xrs,exp 
FEV10rsGaw 
FEV 1 or Xrs,insp or Xrs,exp 
IC orFEVl orsGaw 
I C or FEV 1 or Xrs,insp or Xrs,exp 
Absolute 
chan e 
8 
17 
14 
9 
4 
6 
5 
17 
7 
9 
11 
6 
4 
8 
2 
6 
o 
o 
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% change 
12 
17 
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Discussion 
This study confirms that the effect of bronchodilator in COPD subjects can be demonstrated 
as a group mean change in plethysmography and forced oscillometry variables, the latter 
being larger percentage changes counterbalanced by worse reproducibility. 
The pattern of change in endurance exercise testing reported in the literature has evolved as 
experience with this test modality has increased. Initially an increase in Tlim with no change 
in V E,end and a reduction in AAso was reported3• However, more recent studies have shown 
changes identical in pattern and very similar in magnitude to our data, namely a 19-58% 
increase in Tlim, a 5-10% increase in VE,end and a pattern at isotime of increased VI, no change 
in RR and decreased Borg scores279,280,295. In this study bronchodilator generated an increase 
in exercise capacity (Tlim: 20.5%) and ventilatory capacity (VE,end: 8.1%). The increase in 
VE,end was achieved by an increase in VI,end (6.9%) in the context of an increased ICend 
(10.7%) consistent with an improvement in respiratory mechanics due to reduced 
hyperinflation. End-exercise cardiovascular stress was increased (shown by the increase in 
HR) whereas there was no change in respiratory rate. At isotime, bronchodilator reduced 
breathlessness (Borgdysp,iso: -13.1%). However, VE,iso was increased (6.0%) with no change in 
V02,iso, leading to an increase in ventilatory equivalents. This suggested that bronchodilator 
worsened ventilatory efficiency, which most commonly is due to either greater ventilation-
perfusion mismatch or hyperventilation. 
From the correlation analysis, ~Borgdysp,iso correlated significantly with ~ Tlim (rs=-0.483), a 
relationship which has been well reported elsewhere3,255,279,280. ~Borgdysp,iso was also related 
to ~RRiso and ~ V E,iso, the biggest fall in Borg scores therefore again occurring in subjects with 
the smallest increases or even decreases in V E,iso. 
~ Tlim had a significant negative correlation with ~ VC02,iso (rs=-0.332), ~RRiso (rs=-0.367), 
~ V E,iso (rs=-0.432), ~ V EN02 (rs=-0.427) and ~ V ENC02 (rs=-0.325). The relationship 
between ~Tlim and ~VE,iso is shown graphically in Figure 3.1.4. This demonstrates that 
subjects who were able to exercise for longer following bronchodilator were predominantly 
those who had no increase in VE,iso. Conversely, subjects who showed no increase in Tlim 
following bronchodilator tended to have increased V E,iso. This finding perhaps adds a further 
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explanation to the debate as to why bronchodilators do not universally enhance exercise 
perfonnance in COPD. Any improvement in ventilatory mechanics gained from 
bronchodilator may be lost due to an increase in ventilatory requirements possibly due to 
increased ventilation-perfusion mismatch. 
Figure 3.1.4. Relationship between isotime values of AVE and ATlim 
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Since bronchodilators are thought to improve exercise ability by improving respiratory 
mechanics (by reducing dynamic hyperinflation or airway resistance) and hence increasing 
ventilatory capacity198,279,280, it was surprising to find no relationship between AVE,end and 
ATlim despite an increase in both with bronchodilator therapy. There are several factors which 
could diminish the ability of this study to prove an association, namely: 
Improved ventilatory capacity due to bronchodilators may not translate into improved 
exercise perfonnance if there is a simultaneous worsening of gas exchange317 or 
suppression of peripheral muscle function318. 
Not all subjects who show a detectable change in resting pulmonary function with 
bronchodilators can convert this into an improvement in exercise capacity, the postulated 
reason being the manner in which the chest wall muscles adapt to the changes produced 
by the bronchodilato~85. More severely affected subjects who had resting hyperinflation 
and who permitted dynamic hyperinflation were more likely to experience benefit from 
bronchodilators. 
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Ventilatory capacity was not the limiting physiological component in a proportion of our 
subjects284 . 
T1im has poor reproducibility. Its coefficient of variation has been estimated as 34%, 
compared with IC (20%) and VE,end (15%i55 and, when measured as a change, the size of 
the error is compounded. 
None of the changes in resting pulmonary function variables were associated with ~Tlim (the 
measure of exercise capacity) or ~Borgdysp,iso (the measure of breathlessness), which is 
discrepant with earlier studies that were able to show a correlation, albeit weak, between ~ Tlim 
or ~Borgdysp,iso and ~IC3. However, it does fit with the finding of lack of association between 
~ V E,end and ~ Tlim and suggests again that the mechanical improvement induced by 
bronchodilators was not translated into improved exercise capacity. Alternatively, this may 
have been due to differences in study design (O'Donne1l3 had twice the number of exercise 
tests per subject in his study), severity of airways obstruction (less in our study) or subject 
heterogeneity (in our study the entry criteria allowed any cause of airways obstruction). If a 
subgroup analysis were performed including only the subjects in our study who had COPD 
(n=36), the correlation coefficient between ~Tlim and MC increased (r=0.317) but did not 
become significant. A further point is that the relationship between IC and Tlim may only 
exist for those subjects whose tidal breathing is limited by flow limitation282 and this was not 
required for entry into this studr81. 
Association of resting pulmonary function variables with V E,end have rarely been reported in 
the context of cycle endurance and bronchodilator reversibility tests280. In this study, changes 
in VE,end were significantly associated with changes in IC and resistive parameters such as 
Raw, lIsGaw and Xrs,insp' Notably, there was no association with changes in FEV 1. This 
suggests that the increase in ventilatory capacity during exercise produced by bronchodilators 
can be predicted to some extent from resting measurements of resistance or IC but not FEV I. 
In terms of a measurable change post-bronchodilator, no single variable was any more 
sensitive than FEV 1 in our cohort when significant change was defined by placebo response. 
However, each test identified a different but overlapping set of responders and combining 
parameters lead to a 50% increase in the number of responders identified. Between-study 
comparison of this outcome is difficult as there is no gold standard of reversibility with which 
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to compare and studies have used different definitions of a significant response in different 
populations3,216,314. 
Conclusions 
• Bronchodilator produced measurable changes in plethysmography, oscillometry and 
exercise test parameters. Changes in RWV and PTT were non~significant or small 
relative to the errors in the measurement. 
• Changes in resting IC and resistive parameters including Xrs,insp were significantly 
associated with changes in V E,end whereas changes in FEV 1 were not. However, neither 
changes in resting pulmonary function nor changes in V E,end were associated with changes 
in Tlim suggesting that the increased ventilatory capacity predicted by these changes in 
resting pulmonary function tests may not necessarily translate into improved exercise 
tolerance. 
• Of the oscillometry variables, LUCrs,insp was most strongly associated with 11 V E,end, 
consolidating the suggestion that it is the optimum oscillometry choice for reflecting 
resistive change. Estimation of work of breathing by combination of Xrs,insp and flow data 
conferred no advantage over the use of Xrs,insp alone. 
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3.2 Longitudinal Predictors of Progression in Interstitial 
Lung Disease 
Introduction 
The term interstitial lung disease (lLD) encompasses a range of heterogeneous conditions 
with more than 200 subtypes characterised by involvement of the pulmonary parenchyma. 
The commonest manifestations of this disease class are idiopathic pulmonary fibrosis and 
sarcoidosis319-321. The different forms oflLD broadly share a common physiological defect322 
typified by restricted lung volumes and impaired diffusing capacity. Lung compliance and 
gas exchange are also impaired. On exercise testing the characteristic rapid, shallow 
breathing pattern becomes more prominent as larger minute ventilation is achieved by 
increased respiratory frequency and there is usually arterial desaturation and a widened 
alveolar-arterial 02 gradient. 
There are differences in pathophysiological detail between the various subtypes of ILD322. A 
mixed obstructive-restrictive defect is seen in sarcoidosis, hypersensitivity pneumonitis and 
Langerhan's cell histiocytosis. There is a disproportionate reduction in diffusing capacity in 
idiopathic pulmonary fibrosis (IPF) compared with sarcoidosis and asbestosis. Residual 
volume is often elevated in asbestosis, silicosis and hypersensitivity pneumonitis but reduced 
in IPF. There is a greater degree of arterial desaturation during exercise in IPF than 
sarcoidosis or fibrosing alveolitis complicating scleroderma. These differences are 
sufficiently distinct to make it difficult to generalise the conclusions from a physiological 
study of one subtype to another whilst at the same time the considerable overlap in results 
renders the standard pulmonary function tests relatively poor at differentiating between them. 
This has been compounded by changes in pathological classification over the years323. 
The optimum approach for monitoring progression in ILD is still not clear. Interest has 
focussed on symptom questionnaires, imaging, physiological tests both resting and during 
exercise, and composite scores which include a combination of these elements. There is most 
evidence for IPF. 
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Since the 1970s many studies have demonstrated a link between baseline physiological 
impairment and increased mortality. The importance of reduced FVC324-328 and TLC0325,328-333 
values have received most support although changes in FEV1IFVC334 and TLC335,336 have also 
been studied. Resting gas exchange (in the form of Pa02 and PCA-ap2) has shown variable 
results with some studies showing an association with survival337,338 and some not336. 
Transfer coefficient (Kcoi32,336,337 did not prove useful. There are fewer studies looking at 
the prognostic significance of longitudinal trends. Studies have not in general been in favour 
of PCA_a)O/,338-340 but have confirmed the significance of changes in FVC2,333,338,340,341 and 
TLC0328,338,340,342, the timescales required to detect change being 6 months or 1 year. It has 
been of particular interest to see that, although histological differentiation between usual 
interstitial pneumonitis and non-specific interstitial pneumonitis has been important at 
baseline to predict prognosis, at later assessment time points this became irrelevant, with 
trends In pulmonary function variables being the only important prognostic 
determinants328,333. Recently in a review of the available data it was proposed that TLCO was 
the optimum measurement for quantifying impairment at baseline and fall in FVC was 
optimum for indicating progression of disease343. 
The evidence for the prognostic benefit of exercise testing in IPF is less well developed. 
Parameters such as changes in gas exchange and P CA-a)02 during exercise have been shown to 
correlate with surrogate markers of disease progression. Fulmer344 found that the change in 
P a02 during exercise correlated with the degree of fibrosis on lung biopsy and Agusti339 
showed that the change in P CA-a)02 during exercise at baseline correlated with increase in its 
resting value at 20 months. One longitudinal study was able to show an association between 
increased PCA-a)02 and decreased survivat338 but in general this variable has not been favoured 
because of poor reproducibility compared with FVC and TLC02. Data linking parameters from 
incremental cycle exercise tests to survival is contradictory. These studies have concentrated 
on gas exchange variables during exercise such as P a02 and P CA-ap2 at peak exercise and the 
ratio of change in Pa02 to change in oxygen consumption (V02)' Some337,338,345 have found 
value in these variables whereas others336,345,346 have not. Moreover, gas exchange variables 
have poorer reproducibility than VC and TLC02. Other forms of exercise test have been 
evaluated. Two studies looking at fixed time walking tests347,348 both concluded that 
desaturation during the test predicted survival with the later study also suggesting that walk 
distance was of prognostic value. Of these two outcome variables, walk distance has been 
shown to have superior reproducibility349. Data on incremental shuttle walk tests has been 
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published in IPF patients, with correlation observed between performance and TLC0350, but 
there is no information on its ability to predict survival as yet. The utility of endurance 
exercise testing in IPF has not been described. 
Cross-sectional studies of dyspnoea scales and instruments to measure HRQOL have been 
performed in IPF351-359. These have demonstrated that subjects with IPF have measurably 
worse HRQOL than controls and that the degree of deterioration in HRQOL correlates weakly 
with pulmonary function tests but more strongly with dyspnoea. One study has demonstrated 
that changes in dyspnoea measured by the CRP dyspnoea scale over 6 months and 1 year 
predict survival338 but there have been no longitudinal studies in IPF comparing HRQOL data 
with survival. Three HRQOL instruments have principally been used, namely SF-36, SGRQ 
and WHO Quality of Life 100 Item Instrument (WHOQOL_100)359. 
Two scoring systems have been developed to provide a composite outcome measure in IPF, 
the Composite Physiologic Index (CPI) and the Clinical-Radiologic-Physiologic (CRP) Score. 
The CPI was derived by creating a prediction equation for disease extent on CT scan from 
pulmonary function results (% predicted T LCO, FVC and FEV d 60 and has been shown to 
predict mortality both from baseline values and longitudinal trend328,36o. The CRP score has 
already undergone one revision and is an older and more complicated amalgam of variables, 
including in the more modem version: age, smoking history, presence of clubbing, 
radiological appearance, presence of pulmonary hypertension, TLC and P a02 on 
exercise213,337. It has also been shown to predict survival. 
There is less evidence available on the usefulness of physiological measures as prognostic 
indicators in other forms of ILD. As the various subtypes differ in pathology, baseline 
physiology (described above), natural history and responsiveness to therapy, the 
generalisation of the above data for IPF to other forms of ltD is speculative. 
The effect of ILD on lung parenchyma should be to increase its elastance and this has been 
confirmed in many cross-sectional studies238,239,245,246,344,361-366. Several forms of ILD have 
been evaluated in this way ranging from IPF344,366,367 to hypersensitivity pneumonitis362,368, 
sarcoidosis369-371, pulmonary fibrosis associated with connective tissue disease372,373 and 
asbestosis374. Studies evaluating serial changes are rare but have been performed, largely in 
children375,376 and sarcoidosis371,377-38o. There have been no systematic studies looking at the 
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link between elastance and survival, the closest being Cherniack337 who showed a weak 
association between lung mechanics and survival on univariate analysis. There are studies 
which link changes in elastance with degree of histological abnormaliry246,344,381 and some 
data which suggest elastance may be a sensitive marker of early disease245,382. Some studies 
show a change in elastance following treatmene73,383 but others especially in sarcoidosis do 
not confIrm this377-380. The major barrier preventing longitudinal elastance data on all patients 
with ILD is the invasive nature of the measurement which requires oesophageal manometry. 
There have been some attempts to evaluate non-invasive techniques to estimate elastance in 
ILD161,165 but none have progressed beyond pilot studies. 
Aim 
The rum of this study was to explore the potential of non-invasive Ers and WOBelas 
measurements (described in Chapter 1.2) to predict progression or survival in ILD compared 
with conventional pulmonary function tests, exercise tests, symptoms and HRQOL. 
Methods 
Subjects 
All patients with a diagnosis of ILD attending the respiratory clinic at GRI from November 
2001 to July 2002 were approached to take part in the study. Subjects unable to perform a 
cycle exercise test were excluded. Of 68 patients approached, 23 consented and were 
enrolled. All of these had CT scan evidence of diffuse parenchymal lung disease. 
Study Design 
This was a longitudinal observational study (Figure 3.2.1). On visit 1, forced oscillometry 
and non-invasive Ers measurements were performed as described in Chapter 1.2. The subjects 
also underwent incremental cycle exercise test to establish peak WR and familiarity with this 
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modality of exercise testing. The detailed description of all conventional physiological tests 
is given in Chapter 1.3. 
Figure 3.2.1. Study protocol. 
Visit 1 c:::::> 
Visits 2, 3 & 4 c:::::> 
Demographic data 
Forced oscillometry 
Ers measurements 
Incremental cycle exercise test 
""" 
Resting dyspnoea (BDI, MRC, CRP, OCD) 
HRQOL (SGRQ, SF-36) 
Forced oscillometry 
Ers measurements 
Spirometry, Plethysmography, Gas Transfer, 
Resting capillary earlobe blood gas analysis 
Endurance cycle exercise test 
Visit 2 occurred within one week but greater than two days following visit 1. Its aim was to 
establish baseline values for the outcome parameters. The subjects completed dyspnoea and 
HRQOL questionnaires. Forced oscillometry and Ers measurements were repeated to provide 
reproducibility data. Then spirometry (FEVl), plethysmography (VC, TLC, RV, IC, Raw, 
sGaw), gas transfer (TLco) and capillary earlobe blood gas measurements (Pa0 2, PaC02, P(A-
ap2) were performed. The fmal procedure was an endurance cycle exercise test. After a 
period of rest and then unloaded cycling, the subjects cycled at a workload of 70% of that 
achieved in their initial incremental cycle exercise test. During the test, measurements were 
taken every minute of Borg score and transcutaneous blood gases (Ptc02 and PtcC02). Visits 3 
and 4 occurred at 6 months and 1 year and were identical to visit 2. The aim of these visits 
was to determine whether the condition had progressed. 
All operators were blinded to the results of earlier tests. Subjects were asked to avoid major 
physical exertion on the day of investigation. Compliance with this request was ascertained 
verbally on the day of the visit. For each subject the tests were performed at the same time of 
day. 
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Analytical Approach 
The ideal method for assessing whether a new test is sensitive at detecting disease progression 
in ILD is to use survival as the outcome measure. When this study was initially designed, it 
was considered that survival analysis would not be possible because of low subject numbers, 
low mortality and short duration. Consequently, it was planned to use a surrogate indicator or 
progression score (Table 3.2.1) to classify the subjects into three groups, those with (1) 
"progressive", (2) "stable" or (3) "improved" disease. The inclusion of the elements making 
up this score were defmed a priori. At the time of analysis of the study it became clear that 
three to four year survival data (all cause mortality) were available for the subjects. The 
analysis planned for the progression score was therefore repeated with the subjects divided 
into survivors and non-survivors with survival status determined at the beginning of January 
2006. 
Progression Score 
Subjects were assigned a progression score derived objectively from the results of dyspnoea 
scales, HRQOL instruments, resting pulmonary function and exercise performance. A 
progression score of -2 or less was interpreted as indicating "progressive", a score of +2 or 
more "improved" and -1 to + 1 "stable" disease. A detailed description of the score is shown 
in Table 3.2.1. 
Sample Size 
No repeatability data on non-invasive Ers and WOBelas measurements were available a priori 
on which to base a power calculation. It was anticipated that recruitment figures would be 
relatively modest given the size and morbidity of the ILD population attending the clinics. It 
was therefore decided to approach the entire subject population and view the study as a pilot 
on which to base a larger or longer study if positive. 
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Table 3.2.1. Details of derivation of progression score. 
Score Component Progression Score 
1. Symptom questionnaires 
Each subject completed 4 dyspnoea scales (MRC, CRP, 
OCD, BDI) at 3 time points (0, 6, 12 months). The results for 
each questionnaire were scored by comparing values at 0 and 
12 months. If dyspnoea had increased, the score was -1, if no 
change 0 and if decreased + 1. The 4 scores were summed 
and the results converted to an overall progression score as -1 to + 1 
follows:-
D s noea Scale Score 
-2 to-4 
-1 to +1 
+2 to +4 
2. HRQOL instruments 
Pro ression Score 
-1 
o 
+1 
Each subject completed 2 HRQOL questionnaires (SGRQ, 
SF-36) at the 3 time points. Again results at 0 and 12 months 
were compared. If both questionnaires were concordant in 
showing an increase or decrease in HRQOL, a progression 
score of + 1 or -1 respectively was assigned. Otherwise the 
score was O. 
3. Vital capacity, VC 
Comparison was made between 0 and 12 month results 
:2: 10% increase + 
:2: 10% decrease + 
otherwise 
4. Gas transfer, TLco 
Comparison was made between 0 and 12 month results 
:2: 15% increase + 
:2: 15% decrease + 
otherwise 
5. Exercise performance 
Endurance exercise time was examined at all 3 time points 
and scored as follows:-
Monotonic increase over 3 time points 
Monotonic decrease over 3 time points 
Other 
Total Progression Score 
+ denominator is the average value at 0 and 12 months 
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-1 to +1 
+1 
-1 
o 
+1 
-1 
o 
+1 
-1 
o 
-5 to +5 
Statistical Methods 
Baseline results were summarised as mean (SD). Between day reproducibility of the Ers and 
WOBelas results was assessed using coefficient of variation and intraclass correlation 
coefficient as described in Chapter 3.1. Change data for the progression score analysis are 
shown as mean. Difference in mean values between the three classes of disease progression 
and evidence of linear trend was assessed using one way ANOV A. This analysis was 
repeated using a non-parametric form of the analysis, the Kruskal-Wallis Test. Change data 
for the survival analysis are shown as median (range) and difference between the two survival 
groups was assessed using the Mann Whitney V test. The relative ability of individual 
variables to predict progression score or survival was assessed by area under the curve (AVC) 
of receiver operating characteristic (ROC) curves and (for survival) by univariate and 
multivariate Cox proportional hazards regression. The ability of the progression score to 
predict survival was tested using Kaplan-Meier analysis with the logrank test. The level of 
statistical significance was taken as 0.05. No compensation for multiple comparisons (such as 
the Bonferroni method) has been explicitly applied and this should be taken into consideration 
when interpreting the significance of results. All statistics where performed with Statview v 
5.0.1 (SAS Institute Inc.) or SPSS v 12.0.1 (SPSS Inc.). 
Results 
Baseline Characteristics 
The disease characteristics of the subjects enrolled in the study are shown in Table 3.2.2. 
Follow-up was complete except for two subjects who did not attend for Visit 4. One of these 
developed leukaemia and the other was lost to follow-up. Exercise test data were obtained at 
all visits in 21 of these patients. One patient was unable to exercise at any visit because of 
lower limb arthritis and one patient could not exercise at Visit 4 because of a displaced 
femoral head. 
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Table 3.2.2. Characteristics of subjects. 
Patient Sex Age Diagnosis Biopsy Duration Smoking History 
No of Status Pack Symptoms 
(Years) years 
1 M 65 IPF1 NO 2 Current 40 
2 F 54 IPF YES 3 Ex 15 
3 M 68 IPF NO 3 Never 
4 F 58 IPF YES 5 Never 
5 M 50 IPF NO 2 Ex 45 
6 F 59 IPF NO 9 Current 50 
7 M 76 IPF NO 1 Ex 15 
8 M 65 IPF NO 21 Current 30 
9 F 71 IPF NO 1 Ex 50 
10 M 74 IPF NO 2 Ex 70 
11 F 51 IPF YES 1 Ex 10 
12 F 56 W YES 1 Never 
13 M 72 HP YES 4 Never 
14 M 70 HP YES 3 Never 
15 F 65 CTD3 associated YES 4 Never 
16 F 66 CTD associated NO 3 Never 
17 F 64 CTD associated NO 5 Ex 5 
18 F 66 Sarcoidosis YES 4 Never 
19 M 63 Sarcoidosis YES 1 Ex 0.5 
20 M 66 Drug toxicity4 NO 2 Current 24 
21 F 67 Drug toxicity5 NO 1 Ex 25 
22 M 60 Silicosis YES 18 Current 80 
23 M 52 Post-BMT6 NO 1 Never 
1 Idiopathic pulmonary fibrosis 
2 Hypersensitivity pneumonitis 
3 Connective tissue disease 
4 Bleomycin 
5 Nitrofurantoin 
6 Bone marrow transplant 
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Baseline conventional pulmonary function tests (Table 3.2.3) showed that the subjects as a 
group had the characteristics of ILD. There was evidence of a restrictive lung defect with low 
lung volumes (VC, FEV 1, RV, TLC and IC). Diffusing capacity (T Leo) was markedly 
impaired. Raw was elevated (normal <0.2) whereas sGaw was normal (>1.1) which is 
consistent with elevated resistance due to low lung volumes. Gas exchange showed a mild 
hypoxia with elevated resting PCA-a)02 (normal <2.9 kPaI95). Baseline results for Ers and 
WOBelas are also shown in Table 3.2.3. 
Incremental cycle exercise tests (Table 3.2.4) showed a reduced exercise capacity and 
V02,peak. There was a greater than predicted heart rate reserve but ventilation reached the 
predicted breathing reserve (normal VE,peak - 72% ± 15%198) suggesting a degree of 
ventilatory limitation. Breathing frequency at end exercise was higher than the COPD 
subjects in Chapter 3.1 (mean values 41 vs 33 breaths.min-1 respectively). AT, O2 pulse and 
ilV02/ilWR were all reduced suggesting an element of circulatory limitationl98. At end 
exercise Ptc02 decreased and both PCA-tcP2 and Vo/Vr increased (normal Vo/Vr <0.30198). 
This pattern of mixed circulatory, gas exchange and ventilatory impairment is consistent with 
ILDI98,322,384. 
The scores from the dyspnoea scales (Table 3.2.5) showed that the subjects had a significant 
level of symptoms as found in ILD in other studies357,385. HRQOL was also impaired. 
Compared with the values from recent studies using SF-36 and SGRQ359, the mean HRQOL 
of our subjects was markedly worse than normals (see Chapter 1.3) and slightly worse than 
other ILD cohorts. This suggested that we may have enrolled a more severely affected study 
group. 
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Table 3.2.3. Baseline characteristics of study patients: resting pulmonary function tests 
including Ers and WOBelas' 
Sex (male: female) 
Age (years) 
Weight (kg) 
Height(m) 
BMI (kg.m -2) 
Smoking history 
- ex/current smokers: non-smokers 
- pack years 
Spirometry / Plethysmography / Gas 
Transfer 
VC L 
%pred 
FEV1 L 
%pred 
FEV1NC % 
%pred 
RV L 
0/0 pred 
TLC L 
%pred 
IC L 
0/0 pred 
Raw kPa.s.L-1 
sGaw L2 kP -1 -1 . a.s 
TLco ml.min-1.kPa-1 
%pred 
Gas exchange at rest 
Pa0 2 kPa 
PaC02 kPa 
P (A-a)02 kPa 
Ers / WOBelas 
Ers,NIV 
WOBelas,NIV 
Ers,cPAP 
WOBe1as,cpAP 
kPa.L-1 
J .-1 .mm 
J.L-1 
kPa.L-1 
J .-1 .mm 
J.L-1 
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Mean (SD) 
(n=23) 
11:12 
63.4 (7.31) 
76.5 (16.2) 
1.64 (0.09) 
28.3 (5.13) 
14:9 
32.8 (24.1) 
2.68 (0.70) 
90.1 (20.8) 
1.97 (0.50) 
81.5 (17.4) 
74.0 (8.1) 
96.7 (10.8) 
1.68 (0.45) 
81.2 (22.7) 
4.36 (0.92) 
80.9 (15.9) 
1.88 (0.51) 
76.1 (21.3) 
0.23 (0.07) 
1.78 (0.60) 
3.93 (1.56) 
50.1 (17.0) 
9.91 (l.40) 
4.87 (0.60) 
4.52 (1.49) 
2.68 (1.09) 
9.27 (4.26) 
0.737 (0.262) 
1.54 (0.93) 
5.98 (4.68) 
0.444 (0.230) 
Table 3.2.4. Baseline characteristics of study patients: incremental and endurance cycle 
exercise tests. 
Mean (SD) (n=23) 
Incremental cycle exercise test 
MaximumWR W 64 (35) 
VOZ,peak L.min-I 0.93 (0.32) 
%pred 61 (23) 
HRpeak min-I 128 (19) 
HRR min-I 28 (19) 
VE,peak L.min-I 52.5 (16.0) 
%MVV 68 (16) 
RRpeak min-I 41(10) 
VT,peak L 1.29 (0.53) 
AT % pred VOZ,peak 37 (15) 
Oz pulse peak %pred 74 (25) 
AVOz/AWR ml.min-I.WI 8.33 (2.82) 
AP tcOZ,peak kPa -1.15 (1.38) 
AP tcCOZ,peak kPa -0.24 (0.54) 
P (A-tC)OZ,peak kPa 6.90 (2.25) 
VDNT,rest 0.57 (0.10) 
VDNT,peak 0.42 (0.13) 
Endurance cycle exercise test 
T lim min 8.9 (3.6) 
Isotime End-exercise 
VOz L ·-1 .mm 0.83 (0.32) 0.95 (0.33) 
HR min-I 116 (31) 125 (21) 
RR min-I 38 (9) 40 (8) 
VT L 1.23 (0.50) 1.21 (0.47) 
VE L .-1 .mm 44.2 (15.9) 46.5 (15.6) 
Bor~ysp 4.9 (2.0) 7.3 (2.3) 
Borgleg 5.9 (2.2) 7.8 (2.4) 
VENOz 55.7 (13.6) 59.1 (18.4) 
V~COz 44.7 (9.5) 46.3 (11.1) 
APtcOz, kPa -0.88 (1.29) -1.18 (1.40) 
APtcCOz kPa -0.13 (0.50) -0.23 (0.51) 
P(A-tc)OZ kPa 6.25 (2.05) 6.67 (2.42) 
VDNT 0.43 (0.13) 0.41 (0.20) 
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Table 3.2.5. Baseline characteristics of study patients: symptom and HRQOL 
instruments. 
Dyspnoea Scales 
MRC 
CRP 
OCD 
BDI 
HRQOL 
SGRQ 
Symptoms 
Activities 
Impacts 
Total Score 
SF-36 
Reproducibility 
Physical functioning 
Physical role 
Bodily pain 
General health 
Vitality 
Social functioning 
Emotional role 
Mental health 
Summary scores 
PCS 
MCS 
Mean (SD) 
(n=23) 
2.87 (0.97) 
7.48 (4.52) 
0.57 (0.25 
5.7 (3.1) 
57.0 (25.9) 
65.8 (25.2) 
37.7 (21.2) 
49.8 (21.2) 
43.0 (28.5) 
34.8 (44.4) 
66.7 (28.6) 
43.6 (22.9) 
42.6 (22.6) 
65.7 (27.8) 
43.5 (45.4) 
68.3 (15.3) 
30.0 (14.4) 
45.9 (10.3) 
Reproducibility of the Ers and WOBelas results are shown in Table 3.2.6. Results for the NIV 
method were poor and these were not analysed further. Repeatability for the CP AP method 
was more acceptable. 
Disease Progression 
The results of the algorithm for defIning disease progression are shown in Table 3.2.7. Nine 
of the eleven patients with IPF were classed as either "stable" or "progressive". Of the two 
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with IPF who appeared to improve, neither had had a biopsy to confinn the diagnosis and the 
possibility exists that they had been misclassified as IPF. Of the 7 subjects with "progressive" 
disease, 3 showed worsening pulmonary function tests (1 VC and T LCO, 2 T LCO alone), 4 had 
deteriorating exercise capacity, 4 deteriorating HRQOL and all 7 worsening dyspnoea scores. 
Table 3.2.6. Reproducibility analysis. Ers and oscillometry data from visits 1 and 2. 
Mean Coefficient Intraclass 
of Variation R 
Visit 1 Visit 2 % 
Pulse/CP AP measurements 
Ers,NIV (kPa.L-1) 2.80 2.80 29.3 0.692 
WOBe1as,NIV (J.L-1) 0.810 0.739 76.1 0.490 
(J.min-1) 10.8 8.82 116 0.434 
Ers,cPAP(kPa.L-1) 1.47 1.62 17.3 0.913 
WOBe1as,cpAP (J.L-1) 0.450 0.432 16.4 0.786 
(J.min-1) 6.21 5.38 12.8 0.792 
Table 3.2.7. Results of subdivision of stable patients into "progressive", "stable" or 
"improved" disease. 
Pro ressive Stable 1m roved 
Diagnoses IPF-4 IPF-5 IPF-2 
HP-2 Silicosis - 1 HP -1 
Sarcoidosis - 1 Drug toxicity - 1 PostBMT -1 
CTD associated - 1 Sarcoidosis - 1 
Drug toxicity - 1 
CTD associated - 2 
Total 7 8 8 
Variation of Physiological Variables with Disease Progression Status 
The analysis in Tables 3.2.8 to 3.2.10 showed whether the change in physiological variables 
over twelve months differed between the subjects when grouped by status of disease 
progression. Only the ANOV A results are shown as the non-parametric analysis produced the 
same distribution of significance of results. Since TLco, VC, Tlim, dyspnoea and HRQOL 
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were part of the algorithm used to defme the presence or absence of disease progression, it 
would be expected for them to show significant difference and linear trend. The size of the 
change in SGRQ exceeded the recognised minimum clinically important difference. 
Disease progression was associated with longitudinal trends in exercise test variables other 
than Tlim including 
rest variables: increasing PCA-ap2, RR and VE 
isotime variables: increase in RR, VE, R and ventilatory equivalents 
reduction in peak V02 but no other end-exercise variables. 
Physiologically these changes reflect worsening efficiency of ventilation and gas exchange as 
the subject's condition deteriorates. There was a strongly significant difference and linear 
trend across the patients groups for increasing Ers,cPAP and WOBelas,CPAP with "progressive" 
disease. The distribution of results for some of the significant variables is illustrated in Figure 
3.2.2. 
Finally, dividing the subjects into two groups either showing progression or non-progression, 
ROe curves were constructed and the Aue calculated (Table 3.2.11). Ers,cPAP and 
WOBelas,CPAP performed better than conventional pulmonary function and exercise testing, 
which was surprising when it was considered that this analysis was biased in favour of the 
latter variables which were used as part of the method for defming disease progression. Roe 
curves for Ers,cPAP, ve, Tlim and eRP score are shown in Figure 3.2.3. 
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Table 3.2.S. Change in physiological results over 12 months grouped by progression 
score. Results of one way ANOV A on resting pulmonary function tests. 
Significance testing was perfonned both for difference between means and linear trend. 
Change over 12 months Difference Linear 
trend 
Pro&ressed Stable Im~roved p-value p-value 
(n=7 (n=8) (n=8) 
Spirometry / Plethysmography 
/ Gas Transfer 
VC L -0.053 0.016 0.213 NS (0.10) 0.04 
%pred -2.071 2.014 7.252 NS (0.10) 0.04 
FEV1 L -0.004 0.041 0.095 NS NS 
0/0 pred 0.472 3.070 4.042 NS NS 
FEV1NC 0/0 2.143 1.250 -2.375 NS NS 
0/0 pred 3.054 1.930 2.791 NS NS 
RV L -0.080 0.114 -0.042 NS NS 
%pred -4.500 4.804 -2.914 NS NS 
TLC L -0.136 0.126 0.168 NS NS 
%pred -2.795 2.646 2.915 NS NS 
IC L -0.121 -0.060 0.212 NS NS 
%pred -5.109 -1.506 10.125 NS NS (0.10 
Raw kPa.s.L-1 0.017 -0.020 0.020 NS NS 
sGaw LZ kP -1 -1 • a.s -0.101 0.139 -0.314 NS NS 
TLco I . -1 kP -I m .mm. a -0.286 -0.500 0.850 0.007 0.01 
%pred -3.687 -6.591 12.325 0.007 0.01 
Resting Gas Exchange 
PaOZ kPa -0.556 -0.309 -0.010 NS NS 
PaCOZ kPa 0.059 -0.009 -0.087 NS NS 
P(A-a)OZ kPa 1.263 0.247 -0.086 0.049 0.02 
En / WOBeias 
Ers,cPAP kPa.L-1 0.598 -0.474 -0.203 0.006 0.01 
WOBe1as,cpAP J .-1 3.626 -1.800 -1.313 0.02 0.02 .mm 
J.L-1 0.173 -0.097 -0.071 0.007 0.007 
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Table 3.2.9. Change in physiological results over 12 months grouped by progression 
score. Results of one way ANOV A on exercise tests. 
Significance testing was perfonned both for difference between means and linear trend. 
Change over 12 months Difference Linear 
trend 
Pro2;ressed Stable Imnroved p-value p-value 
(n=7) (0=8) (0=8) 
Endurance cycle exercise test 
Tlim min -1.58 1.086 3.517 NS (0.10) 0.03 
Resting variables 
RR min-1 3.336 -1.054 -3.507 NS (0.06) 0.02 
VT L 0.051 0.044 0.036 NS NS 
VE L.min-1 2.861 0.130 -1.067 0.01 0.004 
Isotime variables 
V02 L ·-1 .mm -0.054 -0.064 -0.027 NS (0.08) 0.03 
HR min-1 -14.6 -0.667 -11.938 NS NS 
RR min-1 5.04 -4.429 -5.109 NS (0.06) 0.03 
VT L -0.005 -0.017 0.036 NS NS 
VE L.min-1 6.18 -5.954 -3.342 NS (0.07) NS 
(0.07) 
R 0.233 -0.173 -0.017 0.02 NS 
(0.07) 
Borgdysp 0.571 -0.786 -0.688 NS NS 
Borgleg 1.5 -1.786 -0.875 NS NS 
VtdV02 18.18 -4.096 -4.493 0.01 0.01 
VENC0 2 4.22 3.378 -2.46 NS NS (0.06) 
APtc0 2, kPa -0.533 -0.286 0.829 NS NS 
APtcC02 kPa 0.152 0.038 -0.152 NS NS 
P(A-tc)02 kPa 2.097 1.022 0.183 NS NS 
VnNT 0.061 0.058 -0.059 NS NS 
APtcO~AV02 kP . L-1 a.mm. -2.179 -0.717 1.581 NS NS 
End-exercise variables 
V02peak L .-1 -0.172 -0.013 0.073 NS (0.07) 0.03 .mm 
HR min-1 1.286 5.167 -23.375 NS NS 
RR min-1 1.749 -2.133 -0.569 NS NS 
VT L -0.003 0.037 0.071 NS NS 
VE L .-1 .mm 2.67 -2.356 4.24 NS NS 
R 0.029 -0.119 -0.107 NS NS 
Borgdysp -1 -2.143 -0.5 NS NS 
Borgleg 0 -1.286 -0.5 NS NS 
VEN02 15.469 -0.643 -1.763 NS NS 
VtdVC02 3.666 4.693 -0.566 NS NS 
APtc0 2, kPa -0.152 -0.229 1.2 NS NS 
APtcC02 kPa 0.210 -0.095 -0.514 NS NS 
P(A-tc)02 kPa 1.533 1.239 0.219 NS NS 
VnNT 0.029 0.080 -0.107 NS NS 
APtcO~AV02 kP . L-1 a.mm. -1.280 -0.569 1.856 NS NS 
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Table 3.2.10. Change in physiological results over 12 months grouped by progression 
score. Results of one way ANOV A on dyspnoea scales and HRQOL instruments. 
Significance testing was perfonned both for difference between means and linear trend. 
Change over 12 months Difference Linear 
trend 
Progressed Stable Imnroved p-value p-value 
(n=7 (0=8) (0=8) 
Dyspnoea scales 
MRC 0.714 0.000 -0.375 0.03 0.01 
CRP 2.857 -0.250 -2.000 0.05 0.02 
OCD -0.112 0.016 -0.065 NS NS 
BDI -1.714 0.875 1.125 NS (0.10) NS (0.05) 
HRQOL 
SGRQ 
Symptoms 2.706 -8.366 -15.258 0.35 0.15 
Activities 6.550 1.794 -14.954 <0.001 <0.001 
Impacts 5.742 -6.506 -12.545 NS (0.05) 0.02 
Total 5.186 -4.048 -13.645 0.02 0.005 
SF-36 
Physical functioning -15.000 -0.625 11.875 0.02 0.006 
Physical role -3.571 -6.250 12.500 NS NS 
Bodily pain -9.524 0.000 13.889 NS (0.08) 0.03 
General health -3.143 -10.375 16.875 0.0004 0.003 
Vitality 0.714 5.00 16.25 NS NS 
Social functioning -15.873 -2.778 6.944 NS NS (0.07) 
Emotional role 9.524 -8.333 29.167 NS NS 
Mental health -2.286 -9.5 6.00 NS (0.06) NS 
Summary scores 
PCS -6.794 -0.589 6.196 0.02 0.005 
MCS 1.44 -2.971 5.974 NS NS 
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Figure 3.2.2. Change over 12 months in physiological variables, symptoms and HRQOL 
in the patients categorised by progression score (a) TLCO (b) VC (c) VVV02 (d) Ers,CPAP 
(e) WOBe1as,cpAP (J.min-1) (1) WOBe1as.cPAP(J.L-1). 
a) 
c) 
e) 
o 
.. 
~ 
.S 
& 
1; -2 
.c 
o 
-~5 E 15 
:i 1 
Q. 
~ 
Q. 
.. 
os 
J 
o 3: -
c 
.; -1 
CD 
1; -1 
.c 
o 
Progressed Stable Improved 
Disease progression 
• 
••• 
•• 
• 
Progressed 
A 
A 
A 
'" 
Stable 
T 
T 
Improved 
Disease progression 
• 
• • 
Progressed 
'" 
.. . 
'" 
A 
Stable Improved 
Disease progression 
163 
b) 
0.6 
d: 
~ o. 
.S 0.2 
CD 
CD 
C 
III O. 
.c 
0 
-0.2 
d) 
..-
:... 
~ 1 
-
• • 
••• 
Progressed 
A 
A 
A A 
A 
A 
Stable 
T 
T 
, 
T 
T 
Improved 
Disease progression 
.-
-. 
Q. • '" ~ ~--~~--~~r---~~~-(,.) • T T 
f - T 
w -1 
c 
CD 
CD 
~ -2 
.c 
o 
1) 
-:... 
:i 
Q. 
0.50 
~ 0.2 
(,.) 
tR 
as 
~ 
CD 
0 
O. 
3: 
.5 -0.2 
CD 
CD 
C 
~ -0. 
0 
'" 
Progressed Stable Improved 
Disease progression 
-
.-
• '" T 
'" 
'T' 
'" 
T 
A 
Progressed Stable Improved 
Disease progression 
Table 3.2.11. Area under ROC curves for the progression score. 
Variable AUC 
VC 0.670 
TLco 0.665 
Tlim 0.762 
P(A-a)02 0.804 
VE,rest 0.886 
VElV0 2,iso 0.867 
CRP 0.844 
MRC 0.786 
SGRQ 0.799 
SF-36 PCS 0.772 
Ers,cPAP 0.906 
WOBe1as,CPAP (J.L-1) 0.875 
WOBe1as,CPAP (J.min-1) 0.844 
Figure 3.2.3. ROC curves showing relative performance of variables for predicting 
progression score. 
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Survival Analysis 
Eight of the 23 subjects had died (from any cause) by the beginning of January 2006. 
Difference in pulmonary function, endurance exercise test performance, symptoms, HRQOL, 
Ers and WOBelas variables between subjects who died or survived are shown in Tables 3.2.12 
to 3.2.14. Baseline values, change at 6 months and change at 12 months are given. The 
change at 12 months is further illustrated in Figure 3.2.4 by plots of the variables showing 
statistically significant change. The major differences compared with the earlier similar 
analysis for progression score were that:-
the changes in Ers,CPAP and WOBelas,CPAP had lost their significance 
there was a clearer pattern of change in exercise variables with significant differences in 
Tlim, isotime values of RR, VE, R, Borgdysp, Borgleg, VEN02, VENC02, M>tc0 2, P(A-tcP2 
and end-exercise value ofVEN02 and VENC02 
the significance of differences in dyspnoea scores weakened whereas the differences in 
HRQOL remained strong especially SGRQ. 
ROC curves were again constructed for variables with significant 12 month changes and the 
AVC values are given in Table 3.2.15. The ROC curves for VEN02,end, SGRQ (Total score), 
VC and TLco are shown in Figure 3.2.5. To corroborate the findings of the ROC curve 
analysis, the ability of longitudinal changes of each variable to predict survival was further 
assessed using Cox proportional hazards regression. The results of univariate analysis are 
shown in Table 3.2.16 again restricted to variables with significant 12 month change. 
Multivariate analysis was also performed but this lead to no significant relationships. 
According to their progression score, five of the subjects who had died were classed as having 
"progressive" disease and three "stable" disease. None of the "improved" group had died. 
Kaplan-Meier survival analysis based on these data are shown in Figure 3.2.6. The patients 
were placed into two groups depending on whether they had "progressive" or 
"stable/improved" disease on their progression score. V sing the logrank test, there was a 
clearly significant and appropriate prognostic difference between the two groups. 
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Table 3.2.12. Resting pulmonary function test results over 12 months grouped by survival. Values are median (range). Significance 
testing was performed using the Mann Whitney U test looking at differences between the groups who died and survived at each 
timepoint. 
Spirometry / 
Plethysmography / 
Gas Transfer 
VC L 
%pred 
FEVl L 
%pred 
FEVlNC % 
%pred 
RV L 
%pred 
TLC L 
%pred 
IC L 
Raw 
%pred 
kPa.s.L-l 
sGaw L2.kPa-l.s-l 
TLco ml.min-l.kPa-l 
%pred 
Resting Gas Exchange 
PaOZ kPa 
PaCOZ kPa 
P(A-apZ kPa 
E rs / WOBeias 
Ers,cPAP kPa.L- l 
WOBe1as,cpAP J.min-l 
J.L-l 
Baseline 
Survived 
n=15) 
2.45 (1.33 - 3.69) 2.62 (4.27 - 2.03) 
75 (61-106) 100 (50 - 131)t 
1.79 (1.18 - 2.35) 1.96 (1.52 - 3.18) 
70 (54 -98) 86 (51 - 123)t 
78 (53 - 89) 76 (59 - 82) 
100 (72 - 117) 99 (74 -109) 
1.44 (0.95 - 2.65) 1.70 (1.10 - 2.64) 
72 (37 -105) 83 (60 - 129)§ 
3.89 (2.75 - 5.62) 4.42 (3.34 - 6.11) 
72 (48 - 83) 86 (52 -111)t 
1.63 (0.76 - 2.55) 1.86 (1.28 -2.77) 
71 (38 - 80) 77 (39 - 113) 
0.23 (0.17 - 0.36) 0.22 (0.11 - 0.36) 
1.68 (0.91 - 2.48) 1.76 (1.09 - 3.70) 
2.7 (1.7 - 5.5) 4.0 (8.6 - 2.4)§ 
37 (22 -70) 48 (32 - 80)§ 
8.9 (8.0 - 11.6) 10.8 (7.0 - 12.1)§ 
4.9 (3.7 - 5.5) 5.2 (4.0 - 5.8) 
4.8 (2.7 -7.4) 3.9 (2.4 - 6.7) 
1.65 (0.80 - 5.31) 1.47 (0.61 -1.83) 
5.31 (3.11 - 20.22) 4.68 (1.70 - 8.44) 
0.35 (0.29 - 1.16) 0.40 (0.21 - 0.62) 
* p<O.005, t p<O.Ol, t p<O.05, § p<O.l 
Change over 6 months 
Died 
(n=8 
-0.06 (-0.21- 0.16) 
-3.03 (-6.84 - 8.02) 
-0.04 (-0.06 - 0.27) 
-1.78 (-6.20-18.34) 
1.88(-1.61- 12.42) 
2.63 (-2.67 -17.98) 
-0.04 (-0.43 - 0.16) 
-2.12 (-16.98 -6.60) 
-0.05 (-0.58 - 0.22) 
-2.55 (-8.12 - 6.14) 
-0.23 (-0.58 - 0.09) 
-9.30 (-17.39 -7.57) 
-0.02 (-0.09 - 0.08) 
0.09 (-0.78 - 0.84) 
-0.2 (-1.3 - 0.4) 
-1.25 (-19.53 -4.68) 
-0.15 (-1.40-1.19) 
0.29 (-0.95 - 0.67) 
0.72 ( -0.52 - 3.94) 
-0.06 (-1.31-0.28) 
-0.67 (-5.92 - 3.83) 
-0.01 (-0.34 - 0.12) 
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0.02 (-0.17 - 0.34)§ 
0.48 (-4.26 - 12.60) 
0.01 (-0.14 -0.21) 
-0.03 (-5.84 - 15.39) 
-0.94 (-4.22 - 4.67)§ 
-1.07 (-5.24 - 5.37) 
0.01 (-0.41 - 0.25) 
0.43 (-19.35 - 13.94) 
-0.01 (-0.28 - 0.56) 
-0.22 (-5.59 - 11.91) 
-0.03 (-0.25 - 0.09) 
-1.34 (-10.79 - 2.66) 
0.01 (-0.10-0.11) 
-0.18 (-1.33 - 0.92) 
-0.2 (-0.9 - 1.5) 
-3.14 (-10.22 - 21.84) 
0.24 (-0.97 - 1.26) 
-0.45 (-1.14 - 0.74)§ 
0.27 (-2.10 - 0.70) 
-0.03 (-0.89 - 0.66) 
-0.32 (-4.35 - 5.73) 
-0.03 (-0.27 - 0.24) 
Change over 12 months 
Died Survived 
n=7) (n=14) 
-0.15 (-0.27 - 0.05) 0.12 (-0.28 - 0.70)§ 
-1.97 (-8.64 - 0.46) 4.44 (-6.65 - 25.21)t 
-0.01 (-0.19 - 0.11) 0.04 (-0.18 - 0.47) 
0.247 (-8.23 - 9.66) 4.13 (-8.03 - 19.97) 
2.89 (-0.53 -14.22) -2.08 (-11.94 - 8.88i 
4.18 (-1.11- 20.71) -1.60 (-15.50 -12.11)t 
0.050 (-0.84 - 0.50) -0.04 (-0.37 - 0.40) 
0.60 (-33.79 - 18.12) -2.46 (-17.91-21.07) 
0.00 (-0.85 - 0.55) 0.09 (-0.53-0.78) 
-2.01 ± 6.33 1.22 (-8.97 - 15.37) 
-0.04 (-0.35 - 0.06) 0.03 (-0.48 - 0.48) 
-2.78 (-13.60 - 0.67) 0.16 (-11.88 - 21.08) 
0.01 (-0.05 - 0.13) 0.01 (-0.07 - 0.09) 
-0.09 (-1.04 - 0.10) -0.12 (-1.95 - 0.60) 
-0.1 (-1.2 - 0.4) 0.4 (-0.8 -1.7)t 
-0.76 (-18.34 - 5.07) 4.12 (-6.79 - 24.44)* 
-0.86 (-2.46 - 1.54) 0.00 (-1.26 - 1.02)§ 
0.23 ( -0.71 - 0.55) 0.00 (-1.40 - 0.97) 
0.88 ( 0.42 - 2.49) -0.11 (-2.18 - 1.92)t 
0.09 (-2.36 - 1.12) -0.14 (-0.54 - 1.00) 
-0.17 (-10.60-11.31) -0.43 (-3.37 - 6.01) 
-0.00 (-0.40 - 0.41) -0.01 (-0.28 - 0.28) 
Table 3.2.13. Endurance exercise test results over 12 months grouped by survival. Values are median (range). Significance testing was 
performed using the Mann Whitney U test looking at differences between the groups who died and survived at each timepoint. 
Baseline Change over 6 months Change over 12 months 
Survived Died Survived Died Survived 
I ( ) 
(n=15) (n=7) (n=15) (n=6) (n=13) 
Endurance cycle exercise test 
Tum min I 7.0 (2.7 - 12.6) 7.7 (4.9 - 16.6) -0.35 (-3.27 - 0.51) 1.86 (-6.38 - 9.56) -2.26 (-7.42 -1.42) 0.95 (-5.79 - 9.54)t 
Resting variables 
RR minot 23.7 (18.5 - 37.8) 21.6 (13,4 -34.5) -0.25 (-4.13 - 3.75) -0.25 (-14.00 -7.50) 1.05 (-3.75 - 13.75) -0.50 (-11.79 - 8.50) 
VT L 0,48 (0.39 - 0.68) 0.55 (0.33 - 0.76) -0.02 (-0.07 - 0.06) -0.01 (-0.17 - 0,43) 0.05 (-0.04 - 0.15) 0.06 (-0.07 - 0.19) 
VE L.min-1 12,4 (10.0 - 15.5) 10.5 (7.8 - 16.6) -0.68 (-3,44 - 2.96) -0.55 (-8.75 - 4.59) 2.91 (-0.23 - 5.55) 0.36 (-7.16 - 4.65)§ 
Isotime variables 
V02 L.min-1 0.71 (0.28 - 0.91) 0.86 (0.52 - 1.73)§ 0.01 (-0.15 -0.10) -0.02 ( -0.23 - 0.10) -0.04 (-0.08 - 0.00) -0.05 (-0.30 - 0.12) 
HR minot 115 (99 - 126) 130 (85 - 162) -5 (-19 - l3) -11 (-24 - 6) 0(-8-18) -10 (-27 - 20) 
RR minot 33.8 (17.3 -56.6) 38.3 (25.0 - 53.6) 2.1 (-2.0 - 8.0) -2.0 (-17.1 -10.6)t 6.6 (3.5 - 11.1) -7.0 (-21.5 -17.8)' 
VT L 1.10 (0.52 - 1.39) 1.18 (0.63 -2.59) -0.011 (-0.29 -0.18) -0.02 (-0.35 - 0,42) 0,01 (-0.18-0.14) 0.05 (-0.30 - 0.26) 
VE L.min-1 39.0 (23.5 - 56.2) 42.8 (25.8 -77,4) 1.7 (-2.2 -7.1) -2.7 (-20.5 -7.5)t 5.6 (1.6 - 16.1) -5.4 (-22.2 -14.0)t 
R 1.19 (0.74 - 1,40) 1.31 (1.13 -1,43) 0.02 (-0.51 - 0,44) -0.02 (-0,41-0.18) 0.16 (-0.12 - 0.63) -0.06 (-0.22 - 0.30i 
Borgdysp 3.0 (0.5 - 6.0) 5.0 (3.5 - 9.5)t 1.0 (-1.0 - 2.5) -1.0 (-4.0 -1.0)t 1.75 (-1.0 - 4.0) -2.0 (-5.0 - 3.0)t 
Borgleg 4.0 (1.5 -7.0) 7.0 (3.0 - 9.5)t 0.0 (G.O - 2.G) -1.0 (-8.0 - 2.5)§ 2.25 (0.0 - 5.5) -1.0 (-4.0 - 2.0)t 
VEN02 65.1 (40.3 -90.0) 46.0 (39.1 - 70.3) 204 (-29.5 - 15,4) -1,4 (-16,4 -10.1) 20.8 (4.6 - 47.3) -4.0 (-19.2 -17.2)" 
VENC02 51.0 (37.6 - 64.4) 39.9 (32.0 - 52.5)t 3.2 (-7.2 - 4.6) -1.0 (-6.1 -7.6) 8.6 (-9.2 -15.9) -1.6 (-9.6 - 4.2)t 
APtc0 2, kPa -0.67 (-4.27 - 0.53) -0.80 (-3.33 - 1.47) -0.13 (-2.93 - 1.20) -0.13 (-2,40 - 1.6) -1.20 (-1.60 - 0.80) 0.33 (-0.87 - 1.47)t 
P(A-tc)02 kPa 6.78 (4.76 - 10.71) 6.26 (1.72 - 8.90) 0.54 (-3.62 - 3.83) -0.10 (-1.01 - 4.l3) 3.10 (0.71 -4.74) -0.25 (-3.14 -1.68)t 
VnNT 0.60 (0.23 - 0.74) 0040 (0.22 -0.51) 0.02 (-0.08 - 0.08) -0.06 (-0.25 - 0.32) -0.03 (-0.17 - 0.25) 0.07 (-0.26 - 0.25) 
APtc0 2/AV02 kPa.min.L-1 -2.20 (-6.98 - 4.02) -1.17 (-4,44 - 3.16) -1.68 (-3.65 - 4.06) -0.58 (-4.97 - 2.97) -1.87 (-11.64 - 6.98) 0.20 (-1.75 - 5.04) 
* p<O.005, t p<O.OI, t p<O.05, § p<O.1 
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Table 3.2.13 (Continued) 
Baseline Change over 12 months 
Died Survived Died Survived 
n=7) (n=15 n=13) 
End-exercise variables 
V02peak L.min- l 0.85 (0.43 - 1.10) 0.91 (0.58 - 1. 77) -0.03 (-0.22 - 0.29) 0.01 (-0.25 - 0.11) -0.15 (-0.23 - -0.03) 0.03 (-0.36 - 0.62)§ 
DR min-! 116 (103 - 136) 132 (85 - 162) 1 (-13 - 13) -4 (-33 - 8) 5 (-10-41) -4 (-30 - 26) 
RR min- l 42.1 (35.5-63.6) 37.4 (25.4 -45.3) 1.1 (-2.6 - 9.0) -0.3 (-6.5 - 11.1) 6.5 (-3.5 - 10.5) -1.5 (-18.1-14.0)§ 
VT L 1.08 (0.56 - 1.26) 1.17 (0.56 - 2.61) 0.07 (-0.23 - 0.18) -0.01 (-0.19 - 0.19) -0.01 (-0.13 - 0.16) 0.02 (-0.34 - 0.58) 
VE L.min- l 45.2 (34.1 - 56.5) 47.1 (23.2 - 83.6) 5.0(-7.5-7.3) -0.6 (-8.0 - 16.3) 6.5 (-7.5-14.9) -0.6 (-10.7 -15.2) 
R 1.28 (0.75 - 1.75) 1.28 (1.04 - 1.42) 0.03 (-0.71-0.41) -0.00 (-0.35 - 0.21) 0.12 (-0.14 - 0.71) 0.03 (-0.20 - 0.26) 
Borgdysp 7.0 (4.0 - 10.0) 7.0 (4.0 - 10.0) 0.0 (-2.0 - 2.0) -1.0 (-8.0 - 2.0) -1.0 (-4.0 - 0.0) 0.0 (-4.0-2.0) 
Borgleg 9.0 (3.0 - 10.0) 9.0 (5.0 - 10.0) 0.0 (-3.0-4.0) 0.0 (-6.0 - 2.0) 0.5 (-5.0 - 4.0) 0.0 (-4.0 - 2.0) 
VEN02 66.1 (45.8 -107.1) 49.1 (33.3 - 68.7) 7.6 (-44.8 - 9.6) -0.4 (-12.7 -14.2) 17.5 (8.5 - 46.7) -1.4 (-22.8 -13.4)' 
VENC02 51.5 (39.9 - 77.4) 41.5 (31.8 - 53.5) t -0.1 (-14.8 - 5.3) 0.9 (-5.3 - 4.8) 10.8 (-11.5 -15.9) 1.2 (-11.6 - 3.5)+ 
APtc0 2, kPa -1.20 (-4.40 - -0.27) -1.13 (-3.73 -1.47) -0.33 (-2.53 - 1.33) -0.40 (-2.40 - 1.87) -0.40 (-1.47 - 1.73) 0.27 (-1.07 - 2.00) 
P(A-tc)02 kPa 7.13 ( 4.80 - 11.29) 6.38 (1.75 - 9.34) 0.06 (-2.71 - 3.67) 0.23 (-1.45 -4.73) 3.14 (-0.82 -4.56) -0.48 (-2.60 - 1.93)§ 
VDNT 0.58 (0.24 - 0.71) 0.41 (0.18 - 0.54) 0.02 (-0.07 - 0.14) -0.07 (-0.31 - 0.31) 0.02 (-0.21 - 0.39) 0.00 (-0.22 -0.23) 
APtc0 2/AV02 kPa.min.L-l -1.84 (-6.80 - -0.35) -1.58 (-5.26 - 2.94) -1.22 (-3.39 - 4.39) -0.50 (-4.51 - 3.91) -1.58 (-6.82 - 6.80) 0.65 (-1.69-3.73) 
* p<O.005, t p<O.Ol, t p<O.05, § p<O.1 
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Table 3.2.14. Dyspnoea scale and HRQOL results over 12 months grouped by survival. Values are median (range). Significance testing 
was performed using the Mann Whitney U test looking at differences between the groups who died and survived at each timepoint. 
Baseline Change over 6 months 
Died Survived 
( ) ( ) (0=8) (0=15 
Dyspnoea scales 
MRC 3.5 (1.0 - 4.0) 3.0 (1.0 - 4.0) 0.0 (0.0 - 1.0) 0.0 (-1.0 - 1.0) 1.0 (0.0 - 2.0) 0.0 (-1.0 -1.0)+ 
CRP 10.0 (0.0 - 16.0) 6.0 (0.0 - 16.0) 1.0 (-2.0 - 4.0) 0.0 (-6.0 - 6.0) 2.0 (0.0 - 6.0) 0.0 (-10.0 - 6.0)+ 
OCD 0.43 (0.26 - 1.0) 0.60 (0.33 - 1.0) 0.00 (-0.17 -0.00) 0.00 (-0.31 - 0.l8) -0.l0 (-0.19 - 0.l6) 0.00(-0.51-0.17) 
BDI 3.5 (0.0 - 12.0) 6.0 (2.0 - 12.0) -1.0 (-2.0 - 2.0) 0.0 (-3.0- 5.0) -1.0 (-4.0 - 2.0) 0.0 (-3.0 - 4.0) 
SGRQ 
Symptoms 78.0 (23.6 - 97.5) 47.8 (7.5 - 92.8) 0.0 (-23.5 -15.7) -5.4 (-68.1-15.8) -4.1 (-14.9 - 53.5) -14.5 (-51.5 -14.7)+ 
Activities 79.4 (12.2 - 93.4) 73.0 (23.4 - 93.9) -3.7 (-13.6 - 14.3) 0.0 (-24.6-18.1) 0.0 (-0.1- 20.2) -9.0 (-24.6 - 6.0)+ 
Impacts 41.1 (1.9 - 66.2) 40.3 (1.6 - 64.6) -5.3 (-24.0 - 4.5) -1.6 (-20.4 -20.7) 4.6 (-20.1 - 29.7) -15.1 (-32.3 - 22.0)+ 
Total 57.6 (9.2 - 79.6) 51.5(14.4-75.5) -1.1 (-18.1 - 8.8) -1.8 (-21.6 - 14.l) 5.0 (-11.4 - 30.0) -14.9 (-23.3 -12.8)t 
SF-36 
Physical functioning 25 (0-90) 40 (5 - 90) -5 (-15 -20) -5 (-25 - 25) -5 (-45 - 5) 5 (-25 - 20)§ 
Physical role 0(0-100) 0(0-100) 0(-25 - 50) 0(-50 -75) 0(-25 - 25) 0(-75 - 100) 
Bodily pain 89 (22-100) 67 (33-100) 0(-11- 44) 0(-33 - 22) 0(-33 -22) 0(-22 -44) 
General health 38 (10-72) 45 (10 - 87) -5 (-25 - 30) 2 (-10 -17) -5 (-27 -10) 11.5 (-15 - 30)+ 
Vitality 45 (20 - 80) 40 (0 - 80) -5 (-35 - 5) 10 (-15 - 35)+ -10 (-20 -15) 10 (-10 - 40)+ 
Social functioning 72 (11- 100) 67 (22 - 100) 0(-22 -56) 0(-33-44) -22 (-44 - 44) 0(-22-22) 
Emotional role 17 (0 - 100) 33 (0 - 100) 0(-33 - 67) 0(0-100) 0(-100 - 67) 17 (-100-100) 
Mental health 74 (52 -92) 60 (48 - 96) 2(-12-8) 0(-36 - 28) -4 (-20 - 4) 4 (-12 - 20)+ 
Summary scores 
PCS I 24.1 (7.3 - 50.3) 30.6 (14.3 - 53.2) 0.6 (-9.5 - 11.5) 0.0 (-11.3 - 12.0) 0.6 (-26.7 - 6.5) 3.7 (-10.2 - 13.5) 
MCS 48.2 (35.6 - 59.7) 39.0 (29.7 - 62.8) -1.6 (-4.9 - 4.6) 2.6 (-2.1-18.8)+ -3.2 (24.5 - 13.5) 2.2 (-7.6 - 19.9)+ 
* p<O.005, t p<O.01, t p<O.05, § p<O.1 
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Figure 3.2.4. Change over 12 months in physiological variables, symptoms and HRQOL 
in the patients categorised by survival status (a) TLco (b) VC (c) VEN02,end (d) 
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Table 3.2.15. Area under ROC curves for survival. 
Variable AVC 
VC abs 0.755 
%pred 0.852 
TLco abs 0.765 
%pred 0.821 
FEV1NC abs 0.776 
%pred 0.791 
P(A-a)02 0.872 
Tlim 0.776 
RRiso 0.924 
VE,iso 0.814 
V~02,iso 0.929 
Borgdysp,iso 0.840 
Borgl~,iso 0.872 
APtc0 2 0.840 
P (A-tc)02,iso 0.970 
V~02,end 0.987 
CRP 0.770 
MRC 0.770 
SGRQ (Total score) 0.878 
SF-36MCS 0.806 
Ers,cPAP 0.619 
WOBelas,CPAP (J.L-1) 0.519 
WOBe1as,CPAP (J.min-1) 0.514 
Figure 3.2.5. ROC curves showing relative performance of variables for predicting 
survival. 
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Table 3.2.16. Univariate analysis of survival using Cox proportional hazards regression. 
Twelve month changes in each variable were used (apart from age and smoking history). 
Hazard 95% Confidence Intervals 
Variable Ratio Lower -value 
Age 1.113 0.982 0.09 
Smoking status 1.011 0.241 4.237 0.99 
VC abs 0.009 0.000 0.836 0.04 
%pred 0.775 0.637 0.942 0.01 
TLco abs 0.243 0.068 0.864 0.03 
%pred 0.871 0.777 0.977 0.02 
FEVtNC abs 1.164 1.020 1.328 0.02 
%pred 1.123 1.021 1.236 0.02 
P(A-a)02 2.380 1.126 5.029 0.02 
Tlim 0.813 0.646 1.022 0.08 
RRiso 1.112 1.021 1.212 0.01 
VE,iso 1.086 0.994 1.187 0.07 
V~02,iso 1.132 1.041 1.232 0.004 
V~C02,iso 1.138 1.021 1.269 0.03 
BOrgdysp,iso 1.434 1.000 2.057 0.05 
Borgleg,iso 2.748 1.259 5.998 0.01 
APtc02 0.358 0.118 1.089 0.07 
P(A-a)02,iso 1.789 1.152 2.779 0.01 
V~02,end 1.191 1.058 1.340 0.004 
V~C02,end 1.180 1.037 1.342 0.01 
CRP 1.292 0.979 1.704 0.07 
MRC 6.064 1.579 23.291 0.009 
SGRQ 
Symptoms 1.065 1.015 1.117 0.01 
Activities 1.181 1.048 1.330 0.006 
Impacts 1.061 1.009 1.116 0.02 
Total 1.109 1.033 1.190 0.004 
SF-36 
General Health 0.920 0.860 0.983 0.02 
Vitality 0.921 0.856 0.992 0.03 
Mental Health 0.902 0.825 0.986 0.01 
MCS 0.912 0.840 0.990 0.03 
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Figure 3.2.6. Kaplan-Meier analysis grouping the subjects into those with "progressive" 
or "stable/improved" disease. 
The significance of the difference between the two groups was assvssed using the logrank test. 
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Discussion 
In subjects with ILD, TLCO and VC have the strongest evidence base as predictors of disease 
progression2,324,327,328,330-333,338,341-343, this having been demonstrated both with baseline values 
and longitudinal changes over 6 months to 1 year. However, these variables may not capture 
all instances of disease worsening as it is possible to see deterioration in a subject without 
significant changes in VC and TLC0321 • In a study ofinterferon-y1b in IPF, 44 patients died, 
with no definite change seen in VC or TLCO in 19 (43%i. 
In the original study design, it was not planned to compare changes in the measured variables 
with survival because it was thought that study numbers would be too small and study 
duration too short for this variable to be useful here. Instead a progression score was 
proposed as a surrogate marker of disease progression. This score was devised for the 
purposes of this study and has not had external validation against survival elsewhere. The 
variables included in the score were:-
VC and TLCO 
Tlim which has not previously been studied in this context 
dyspnoea, longitudinal changes being associated with survival in IPF338 
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HRQOL which is significantly impaired in IPF359• 
The Kaplan-Meier analysis shown in Figure 3.2.6 illustrates that the progression score did 
predict survival. The variables able to predict poor prognosis as indicated by this progression 
score are shown in Tables 3.2.8 to 3.2.10. Variables from resting pulmonary function, 
endurance exercise tests and dyspnoea and HRQOL scores were all useful in this regard. 
Ers,cPAP and WOBe1as,cPAP appeared to perform particularly well. 
With the availability of survival data, this analysis was repeated using this more objective 
endpoint and the relevant data are shown in Tables 3.2.12 to 3.2.14. It can be seen that there 
were only a small number of significant differences at baseline between the group who died in 
the follow-up period and those who survived. The former had a more restrictive pattern on 
pulmonary function tests (reduced VC, FEV 1 and TLC), increased ventilatory inefficiency 
during exercise (increased VENC02) but there was no baseline difference in symptoms or 
HRQOL. At six months, the changes in each group did not differ in terms of lung volumes 
and gas transfer but on endurance exercise testing the group who died showed an increase in 
V E,iso (due to increased RR) and Borgdysp,isO' suggesting greater ventilatory requirements for 
the same workload. By twelve months the two groups had begun to diverge more widely. At 
this assessment, the group who died during follow-up showed the typical pattern of worsening 
ILD, namely significantly lower VC and TLco and greater FEV1NC and P(A-ap2. On exercise 
testing, they showed a fall in Tlim and widespread differences in performance at isotime. This 
included increases in RR, VE, R, VEN02, VENC02, Borg scores, P(A-tc)02 and a greater fall in 
Ptc0 2. Differences at end-exercise were less widespread, isolated to a greater increase in 
ventilatory equivalents. Differences in changes in symptoms and HRQOL had also become 
apparent by twelve months. In particular the group who died showed significant relative 
increases in CRP, MRC and SGRQ scores. The changes in the latter exceeded the recognised 
minimum clinically important difference of 4 units. The promising performance of Ers,cPAP 
and WOBelas,CPAP seen in the progression score analysis was not replicated when looking at 
survival. 
The ability of change in each variable to act as a predictive test of subsequent death or 
survival was assessed by AVC measurements from ROC curves (Table 3.2.15). An AVC of 
0.5 indicates that the variable is no better predictor than chance and 1.0 suggests the variable 
is 100% sensitive and specific. End-exercise and isotime VEN02 proved to be the most 
discriminating tests. Other variables which performed particularly well (i.e. AVC > 0.9) were 
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isotime RR and P(A-tcP2. Figure 3.2.5 illustrates the relative perfonnance of VWV02,end, 
SGRQ Total score, VC and TLCO• Cox proportional hazards regression was then used to 
corroborate the ROC curve fmdings and a similar distribution of variables were found to be 
significant on univariate analysis. 
The results of this study suggest that longitudinal changes in endurance exercise test variables 
and HRQOL appear to be potentially more successful than conventional variables such as VC 
and T LCO at predicting survival in ILD. Two particularly encouraging strategies which 
emerged from the exercise testing were the use of V EN02 at both isotime and end-exercise 
and use of the isotime variables in general. Assessing the patients at isotime effectively 
meant that they had been exposed to the same workload for the same duration on each 
occasion. By this stage in the exercise test, the variables measured (RR, VE, V02, VC02) 
were principally dictated by the subject's physiology rather than any volitional factors which 
was not true of end-exercise variables nor of the results of maximal voluntary manoeuvres 
such as FEV 1 and FVC. As a consequence, this rendered measurement of isotime variables 
relatively objective compared with other measurements. 
The particular success of end-exercise and isotime VEN02 was surprising but perhaps can be 
explained by the exponential nature of the relationship of VWV02 with WR demonstrated 
above the AT in an incremental cardiopulmonary exercise test. This is shown schematically 
in Figure 3.2.7. Patients who deteriorate will in general demonstrate greater ventilatory 
equivalents throughout the test in combination with a lower AT. This effect is demonstrated 
as a dashed line in Figure 3.2.7. The work rate of the endurance exercise test at 70% of 
maximum work rate during an incremental test would typically be above the AT. If the 
subject deteriorates between visits, a small change in AT and VEN02 at AT will be amplified 
by the shape of the curve into a large change in VEN02 towards the end of an endurance 
exercise test. 
A limitation of this study was the small number of subjects, representing the consenting 
cohort of patients with ILD attending the respiratory outpatient clinics at GRl and, probably 
because of this, multivariate Cox proportional hazards regression did not prove helpful. The 
findings in this study therefore need to be reproduced in a larger cohort. The study population 
was also heterogeneous, approximately half having IPF, the others having ILD of mixed 
aetiology. Although there are broad similarities in physiology across subjects with ILD, there 
175 
are also discernible differences347 which could weaken the study conclusions. This criticism 
is also a strength as this study is generalisable to the subject population attending an ILD 
clinic rather than simply subjects with IPF. 
Figure 3.2.7. Schematic depiction of the relationship between VEIV02 and WR during 
an incremental cardiopulmonary exercise test for a subject with ILD who deteriorates 
between visit 1 and visit 2. 
The endurance workrate is the same at each visit and the consequent change in VEN02 
(I).VEN02) is amplified during the endurance test compared with the change seen at AT 
(MT). 
1 
I1VF!V02 at AT 
MT 
WR 
Conclusions 
Visit 2 
Endurance 
workrate 
Visit 1 
I1VF!V02 at isotime or 
end-exercise 
• For unselected subjects with ILD, endurance exercise tests and the SGRQ questionnaire 
proved superior longitudinal outcome measures for predicting survival relative to the 
conventional tests in the group of subjects studied. Variables measured at isotime during 
the endurance exercise test proved to be particularly discriminating, the most successful 
being VEN02. 
• Longitudinal changes in Ers,cPAP and WOBelas,CPAP appeared to perform well at predicting 
progression scores but this was not translated into an ability to predict survival in this 
cohort. 
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3.3 Measuring recovery from exacerbation of chronic 
obstructive pulmonary disease 
Introduction 
COPD is a disorder characterised by both long-tenn symptoms and acute exacerbations. The 
importance of exacerbations in detennining disease progression has recently been highlighted. 
Patients with frequent exacerbations show poorer HRQOL386 and possibly faster rate of 
decline ofHRQOL387,388. There is also evidence to suggest that frequent exacerbations lead to 
faster physiological decline measured by both FEVl and PEF389,39o. It has been known for 
some time that functional ability measured by activities of daily living may be pennanently 
impaired in elderly patients with COPD39l. In this study at three months after discharge, 
approximately 30% of patients had not regained their previous mobility and 65% were unable 
to do housework that they could previously manage. 
Changes in lung function, symptoms and HRQOL have previously been evaluated within 
exacerbations. Change in lung function has been demonstrated both by PEF392-395 and 
spirometrl94,396,397. The largest rates of change occurred in the first few days of the 
exacerbation and larger increases in FEV lover the first two days were predictive of superior 
clinical outcome398. Recovery was sometimes slow or incomplete with only 75% regaining 
their original PEF by 35 days after the exacerbation and 7.1 % not returning to baseline lung 
function at 3 months394. Changes in symptoms have been detennined using patient 
diaries392,394,399, with the onset of symptoms occurring before changes in lung function394. 
Improvement in disease specific HRQOL following a transient fall due to an exacerbation has 
been demonstrated using the 8t George's Respiratory Questionnaire (8GRQtOO and the 
Chronic Respiratory Disease Questionnaire (CRQ)395,40l, with a review of the subject recently 
published by Do1l402. Improvement in HRQOL following an exacerbation has been shown to 
be curtailed if a further exacerbation occurs close on the frrse87. 
The use of forced oscillometry has several potential advantages in assessing the physiological 
status of patients with an exacerbation of COPD. Firstly, it is a passive manoeuvre which 
requires only tidal breathing and therefore is easy to perfonn by breathless patients in 
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respiratory failure. Secondly, within-breath measurements of Xrs could be used to quantify 
simultaneously both airway resistance and degree of expiratory flow limitation. By contrast, 
Rrs is less likely to be helpful in subjects with significant irreversible airways obstruction such 
as in COPD because of the phenomenon of upper airway wall shunt which degrades the 
relationship between Rrs and airway resistance in this situation. To date only one study has 
reported forced oscillometry data during an exacerbation of COPD403• They confirmed the 
expectation that Rrs would not change but that Xrs would rise significantly towards more 
normal values as the exacerbation resolved. Within breath Xrs data during an exacerbation of 
COPD have not been reported. 
Aim 
The aim of this study was to assess the ability of forced oscillometry and measurements 
derived from it (work of breathing and % flow limitation) to detect longitudinal physiological 
changes during an exacerbation of COPD by comparison with spirometry, gas exchange, 
symptoms and HRQOL. 
Methods 
Subjects 
Patients with a clinical diagnosis of COPD admitted to the medical receiving ward or referred 
to the Acute Respiratory Assessment Service at GRI were approached to take part in the 
study. They were within 48 hours of the point of presentation when first assessed, age> 40 
years, smoking history > 20 pack years and had baseline spirometry which satisfied the 
British Thoracic Society defmition of COPD (i.e. FEV 1 < 80% predicted and FEV IIFVC ratio 
< 70% i 23 . They had recognised features of an exacerbation, the criteria used here being 
increased breathlessness for at least 24 hours with at least two of increased cough frequency 
.. d I urul . d h 214 or seventy, mcrease sputum vo ume or pence or mcrease w eeze . The only 
exclusion criterion was decompensated respiratory failure. A smaller group of asthmatic 
subjects were also enrolled for comparison. It was anticipated that the asthmatics would have 
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much larger physiological changes than the COPD subjects which would highlight problems 
with the experimental method if they could not be detected. 
Study Design 
This was a longitudinal observational study (design summarised in Figure 3.3.1). At the start 
of each visit the subject received 5 mg of nebulised salbutamol and measurements were 
performed after 20 minutes. The drug was delivered over 10 to 15 minutes in a 2.5 ml 
volume using a jet nebulizer (Micro-Neb Nebuliser, Lifecare Hospital Supplies) driven by an 
airflow of 8 L.min-1 (Aquilon Nebuliser System, APP Medical) through a face mask (Duo 
Mask Adult, Lifecare Hospital Supplies). Visit 2 was scheduled to occur at approximately 
one week following visit 1 and visit 3 at 6 weeks. If the patient suffered a relapse between 
visits 2 and 3 which required hospital admission or further treatment by the Hospital at Home 
team, visit 3 was postponed until the patient was in a stable condition at home and on normal 
treatment. One operator (MKJ) performed all tests and was blinded to the results of earlier 
tests. 
Figure 3.3.1. Study protocol showing order of tests. 
Visit 1 «48 hours) 
Visit 2 (1 week) 
Visit 3 (6 weeks) 
Demographic data (visit 1 only) 
Symptom scores 
Dyspnoea scales 
Activities of daily living 
HRQOL (visits 1 & 3 only) 
Forced oscillometry, RWV, PTT, Ers 
Capillary blood gases 
Spirometry 
All conventional techniques were described in detail in Chapter 1.3. Symptoms were 
assessed using visual analogue scales derived from Davies214 and a simple numerical scale 
used by Paggiar0215. Dyspnoea was measured by four scales, visual analogue scale, modified 
Borg score199, OCD21O and the BDI/TDfll. Activities of daily living were assessed using the 
LCADL Questionnaire208. HRQOL was assessed using the SGRQ200. Pulmonary function 
was assessed using spirometry, and capillary earlobe blood gases. All the tests described in 
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Chapter 1.2 were perfonned and analysed (including Ers and WOBelas). Only oscillometry, 
R WV and PTT results were shown as these were the relevant variables in an obstructive 
setting. Not surprisingly Ers and WOBelas showed little change. 
Sample Size 
The power calculation for this section was the same as for the study in Chapter 3.1. To detect 
a change in Rrs of ~0.05 kPa.s.L-1 with a standard deviation for the change of ~0.15 kPa.s.L-1 
with 80% power and a significance level of 0.05, the sample size required was 35310,311. 
Given that some attrition was expected because of the frail condition of the study subjects, it 
was decided to aim for 50 patients in total. 
Statistical Analysis 
Baseline results were summarised either as mean (SD) or median (range) and changes as 
mean ± SEM. The changes in each test parameter were analysed between visit 2 and visit 1, 
visit 3 and visit 1 and visit 3 and visit 2 using the Student paired t test for COPD subjects 
(nonnally distributed data) and Wilcoxon signed rank test for asthmatics. The level of 
statistical significance was taken as 0.05. No compensation for multiple comparisons (such as 
the Bonferroni method) was explicitly applied and this should be taken into consideration 
when interpreting the significance of results. To compare the relative utility of each variable, 
a sensitivity index4 was calculated from the size of the change divided by the coefficient of 
variation obtained from Chapter 3.1. To assess the relationship between changes in 
physiological variables and symptoms or HRQOL, Pearson correlation coefficients were 
calculated for changes in the key variables between visit 1 and visit 3. All statistics where 
perfonned with Statviewv 5.0.1 (SAS Institute Inc.) or SPSS v 12.0.1 (SPSS Inc.). 
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Results 
Subjects 
The recruitment of subjects into this study is summarised in Figure 3.3.2. Of 50 COPD 
subjects who initially consented to the study, 5 were excluded (3 by spirometry showing 
absence of airways obstruction at least once during the visits and 2 were non-smokers with 
bronchiectasis). A further 6 failed to attend after the first visit leaving evaluable data on 39 
subjects. The COPD subjects successfully completed all the study protocol at the visits they 
attended and all had airways obstruction at their fmal visit after recovery from the 
exacerbation. Of the asthmatics, attendance was complete except for 2 who missed visit 2. 
Figure 3.3.2. Flowchart showing subject recruitment. 
Total subjects 
56 
I 
I J 
Clinical COPD Asthma 
50 6 
Excluded Dropped out after visit 1 
5 r- 6 
COPD with evaluable data 
39 
I 
I L .1 
Attended all 3 visits Attended visits 1 & 2 only Attended visits 1 & 3 only 
34 3 2 
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Baseline Results 
The data in Table 3.3.1 summarise the physiological status of the subjects at visit 1 of their 
exacerbation. Mean spirometry values showed moderate airways obstruction with a reduced 
IC similar to the values given by Parker395• Approximately half the subjects were in 
respiratory failure (mainly Type 1). The oscillometry results showed increased magnitude of 
Rrs and Xrs components and the derived variables (WOBFoT,Xinsp and % flow limitation) 
compared with stable COPD (see Chapter 3.1). The patients were more symptomatic than 
normal reflected by their VAS scores for sleep, wheeze and mobility and by their values on 
the TDI scale. Activities of daily living were severely impaired and HRQOL was poor, with 
SGRQ values generally higher than those quoted by Spencer400• 
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Table 3.3.1. Baseline values from Visit 1. 
All data are mean (SD) unless otherwise indicated. 
COPD Asthma 
Number 39 6 
Sex (male: female) 16:23 3:3 
Age (years) 63.1 (6.9) 47.0 (14.5) 
Weight (kg) 61.8 (16.5) 90.7 (16.1) 
Height(m) 1.59 (0.09) 1.64 (0.07) 
BMI (kg.m-2) 24.4 (6.3) 33.6 (5.4) 
Smoking history 
- ex or current smokers: lifelong non-smokers 39:0 4:2 
- pack years 40 (10-100t 20 (3-40t 
Exacerbation frequency (yr-1) 3.9 (2.9) 3.0 (2.7) 
Time interval (days) 
- admission to visit 1 2 (0 - 3) + 2 (1 - 3) + 
- visit 1 to visit 2 7 (3 - 15) + 12(7-21)+ 
- visit 1 to visit 3 42 (35 - 102) + 42 (33 - 65) + 
Symptoms 
Increased dyspnoea (%) 100 100 
Increased cough (%) 89 83 
Increased sputum (%) 61 33 
Increased wheeze (%) 61 100 
Spirometry 
VC L 2.45 (0.90) 2.90 (0.92) 
%pred 88 (25) 80 (13) 
FEV1 L 0.96 (0.42) 1.71 (0.74) 
%pred 43 (16) 56 (16) 
FEV1NC % 40 (10) 58 (14) 
PEF L -1 .s 2.75 (1.11) 4.16 (1.36) 
%pred 43 (16) 55 (15) 
IC L 1.70 (0.65) 2.52 (0.88) 
%pred 77 (28) 95 (23) 
Capillary earlobe blood gases 
Pa0 2 kPa 8.07 (1.35) 8.28 (1.41) 
PaC02 kPa 4.74 (0.77) 4.98 (0.86) 
Breathing pattern 
Respiratory rate • -1 19.3 (5.6) 16.6 (7.1) mID 
Tidal volume L 0.737 (0.249) 0.939 (0.771) 
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Table 3.3.1 (continued) 
COPD Asthma 
Oscillometry 
R rs kPa.s.L-1 0.605 (0.194) 0.702 (0.310) 
Xrs kPa.s.L-1 -0.594 (0.269) -0.469 (0.351) 
Rrs,insp kPa.s.L-1 0.517 (0.152) 0.632 (0.285) 
Xrs,insp kPa.s.L-1 -0.298 (0.117) -0.204 (0.087) 
Rrs,exp kPa.s.L-1 0.658 (0.231) 0.743 (0.323) 
Xrs,exp kPa.s.L-1 -0.776 (0.389) -0.629 (0.494) 
WOBFOT,xinsp J ·-1 10.6 (7.9) 4.72 (2.13) .mm 
J.L-1 0.762 (0.416) 0.423 (0.214) 
%FL % 50 (29) 35 (30) 
Pulse transit time 
APTT max (ms) 12.3 (8.4) 9.0 (6.2) 
APTT ave (ms) 6.7 (5.1) 3.2 (5.0) 
Respiratory waveform variation 
RWVditT(AU) 0.103 (0.068) 0.075 (0.034) 
RWVarea (AU) 0.053 (0.036) 0.032 (0.016) 
Symptom score 
VAS 
Sleep -37.6 (42.7) -32.5 (37.9) 
Wheeze -39.4 (36.0) -30.8 (38.8) 
Mobility -65.8 (34.5) -44.2 (42.4) 
Paggiaro 9.18 (2.73) 8.83 (2.79) 
Dyspnoea 
VAS 39.7 (25.9) 52.5 (29.3) 
BDI 3.79 (2.58) 7.00 (3.79) 
TDI -5.41 (1.55) -6.40 (1.95) 
OCD 0.280 (0.088) 0.439 (0.299) 
Borg 3.62 (1.54) 3.83 (2.40) 
Impairment of activities of daily living (LCADL) 54.1 (5.8) 49.8 (7.95) 
Health related quality of life (SGRQ) 
Symptoms 83.1 (13.9) 72.1 (16.3) 
Activities 87.9 (11.9) 63.2 (27.3) 
Impacts 62.8 (16.2) 45.1 (26.9) 
Total 73.8 (12.5) 55.0 (24.3) 
+ Median (range) 
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Change during Exacerbation 
The changes in physiological variables during the exacerbation are shown in Table 3.3.2. 
Percentage change values were derived in different ways for the spirometry and oscillometry 
variables. As lung volumes and flows were typically reduced and reliable predicted values 
available, these were given as % change relative to the predicted values. Since oscillometry 
values were higher than normal during the exacerbation and predicted values less well known, 
the denominator for % change was the average of the values at the relevant visit. These 
results are also summarised in Figure 3.3.3. The changes between visits 2 and 3 are not 
shown in detail as they were smaller and generally not significant (with the exception of 
FEV 1, PEF, Xrs,insp, Paggiaro symptom score, TDI, Dyspnoea (VAS) and LCADL which were 
marginally significant). This time course of change is illustrated in Figure 3.3.4. 
To obtain a measure of the "signal to noise" content or sensitivity index of the physiological 
measurements\ the changes between visits 1 and 3 are shown in Table 3.3.3 divided by the 
reproducibility or coefficient of variation of the measurement (Chapter 3.1). FEV1, VC and 
IC were the more reliable measurements followed by the Xrs variables. 
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Table 3.3.2. Change in variables between visits for all patients. All data are mean ± SEM. 
The statistical significance of paired changes was assessed using the Student paired t test for COPD subjects and Wilcoxon signed rank test for 
asthmatics. The statistical significance of % changes was assessed using the equivalent one sample test, with the null hypothesis being a mean 
change of zero. 
COPD Asthma 
Visit 2 - Visit 1 Visit 3 - Visit 1 Visit 2 - Visit 1 Visit 3 - Visit 1 
n=37 n=36 n=4 n=6 
Spirometry 
VC L 0.297 ± 0.061§ 0.354 ± 0.071 § 0.320 ± 0.311 0.782 ± 0.125t 
%pred 10.3 ± 1.8§ 12.1 ± 2.3§ 5.24 ± 11.5 21.1 ± 2.3t 
FEV1 L 0.153 ± 0.046t 0.274 ± 0.064§ 0.535 ± 0.273 0.823 ± 0.164t 
%pred 6.37 ± 1.71t 11.4 ± 2.3§ 15.7 ± 9.8 26.9 ± 4.1 t 
FEV1NC % 0.200 ± 1.100 3.18 ± 1.47 t * 9.98 ± 3.32 t 10.3 ± 1.1 
PEF L -1 .s 0.455 ± 0.140t 0.696 ± 0.142§ 1.05 ± 0.58 1.86 ± 0.37t 
%pred 6.80± 2.18* 11.0 ± 2.2§ 13.1 ± 8.2 24.3 ± 4.5t 
IC L 0.241 ± 0.054§ 0.295 ± 0.056§ 0.259 ± 0.225 0.478 ± 0.155t 
%pred 9.87 ± 1.98§ 11.9 ± 2.3§ 8.97 ± 10.7 17.8 ± 4.9t 
Capillary earlobe blood gases 
* Pa0 2 kPa 0.85 ± 0.18§ 1.18 ± 0.21§ 1.95 ± 0.24 1.64 ± 0.45t 
PaC02 kPa 0.06 ± 0.13 0.02 ± 0.14 -0.40 ± 0.36 -0.11 ± 0.30 
Breathing pattern 
Respiratory rate min-1 -1.37 ± 0.65t -1.57 ± 0.64t 0.53 ± 0.78 -2.22 ± 1.90 
Tidal volume L -0.002 ± 0.029 0.008 ± 0.183 -0.402 ± 0.428 0.056 ± 0.144 
* p<O.1, t p<O.OS, t p<O.OOS, § p<O.OOOS. 
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Table 3.3.2 (Continued) ..... 
COPD Asthma 
Visit 2 - Visit 1 Visit 3 - Visit 1 Visit 2 - Visit 1 Visit 3 - Visit 1 
n=37 n=36 n=4 n=6 
Oscillometry 
Rrs kPa.s.L-1 -0.025 ± 0.020 -0.009 ± 0.024 -0.185 ± 0.067 
>I< 
-0.10S ± 0.037t 
0/0 -3.60 ± 3.47 -0.95 ± 3.9 -31.3 ± 9.9 -16.4 ± 7.2 
Xrs kPa.s.L-1 0.132 ± 0.034§ 0.143 ± 0.039t 0.165 ± 0.066 
>I< 
0.298 ± 0.108t 
% 27.9± 7.0§ 3S.2 ± 8.9§ 45.2 ± 4.8 82.3 ± 1S.8t 
Rrs,insp kPa.s.L-1 -0.025 ± 0.015 -0.024 ± 0.019 -0.122 ± 0.078 -0.093 ± 0.034t 
0/0 -4.97 ± 3.25 -3.91 ± 3.90 -21.8 ± 13.4 -16.1 ± 8.0 
Xrs,insp kPa.s.L-1 0.032 ± 0.011 t 0.073 ± 0.017§ -0.012 ± 0.041 0.072 ± 0.018t 
0/0 13.0 ± 4.St 27.4 ± 6.7§ 9.19 ± 14.6 47.6 ± 1S.0t 
Rrs,exp kPa.s.L-1 -0.020 ± 0.027 0.006 ± 0.030 -0.219 ± 0.064 
>I< 
-0.100 ± 0.040 
>I< 
0/0 -2.57 ± 4.09 1.25 ± 4.22 -35.7 ± 8.8 -14.8 ± 7.2 
kPa.s.L-1 0.193 ± O.OSO§ 0.180 ± 0.OS4t >I< 0.431 ± 0.1S2t Xrs,exp 0.248 ± 0.103 
0/0 31.5 ± 7.8§ 37.1 ± 10.0~ 60.8± 8.9 96.0± 14.2t 
%FL % -14.8 ± 4.St -16.9 ± 4.8t -9.76 ± 10.54 -32.S ± 11.1 t 
Pulse transit time 
APTT max (ms) -0.16 ± 0.80 -0.98 ± 1.88* 0.91 ± 4.11 1.71 ± 2.59 
APTT ave (ms) -0.45 ± 0.51 -2.31 ± 0.8St 0.92 ± 3.85 0.93 ± 2.05 
Respiratory waveform variation 
-0.0304 ± 0.0094t RWV(AU) 0.0028 ± 0.0069 -0.021 ± 0.014 -0.038 ± 0.016 
RWVarea (AU) 0.0014 ± 0.0036 -0.0174 ± 0.0046§ -0.013 ± 0.009 -0.014 ± 0.008* 
* p<O.l, t p<O.05, t p<O.005, § p<O.0005. 
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Table 3.3.2 (Continued) ..... 
COPD Asthma 
Visit 2 - Visit 1 Visit 3 - Visit 1 Visit 2 - Visit 1 Visit 3 - Visit 1 
n=37 n=36 n=4 n=6 
Symptom score 
VAS 
Sleep 30.5 ± 8.1~ 23.5 ± 9.3t 30.0 ± 24.2 * 45.8 ± 18.7 
Wheeze 17.7 ± 6.5t 22.6 ± 8.4t 27.0 ± 18.8 27.5 ± 17.4 
Mobility 31.8 ± 6.5§ 37.1 ± 7.6§ * 45.8 ± 18.8t 50.0 ± 17.7 
Paggiaro -1.70 ± 0.54~ -3.14 ± 0.62§ -4.60 ± 0.75 -5.80 ± 1.20 t 
Dyspnoea 
VAS 16.9 ± 4.3§ 27.0 ± 5.7§ 31.0 ± 9.27 * 36.6 ± 14.6 
TDI 1.92 ± 0.33§ 3.39 ± 0.405§ 5.00 ± 2.12 * 6.00 ± 1.87 * 
OCD 0.068 ± 0.018~ 0.101 ± 0.027~ 0.192 ± 0.126 0.318± 0.151 
Borg -0.973 ± 0.205§ -1.15 ± 0.281 ~ -2.80 ± 1.20 * -2.92 ± 1.24 * 
Impairment of activities of daily living (LCADL) -7.24 ± 0.90§ -1l.6± 1.3§ -14.5 ± 7.2 * -23.4 ± 5.2t 
SGRQ 
Symptoms 0.121 ± 2.41 -3.80 ± 3.86 
-4.76 ± 2.26t * Activities -25.0± 10.5 
Impacts -9.88 ± 2.92~ -22.4 ± 7.7t 
Total -6.67 ± 1.96~ -20.1 ± 7.0t 
* t t § p<O.I, p<O.05, p<O.005, p<O.0005. 
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Figure 3.3.3. Comparison of the magnitude of the percentage changes in spirometry and 
oscillometry parameters between visit 1 and visit 3 for the COPD subjects. 
Spirometry values are given as change in % predicted. % changes in oscillometry parameters 
were calculated by averaging the results from the fIrst and last visits and using this as the 
denominator. Error bars show SEM. 
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Table 3.3.3. Sensitivity index of spirometry and oscillometry measurements in COPD 
subjects. 
This analysis uses % change rather than % predicted values for spirometry in order to be 
comparable with the coeffIcient of variation. 
Spirometry 
VC 
FEV. 
IC 
Oscillometry 
R rs 
Xrs 
Rrs,insp 
Xrs,insp 
Rrs,exp 
Xrs,exp 
WOBFOT,xinsp 
%FL 
% change 
% change 
% change 
% change 
% change 
% change 
% change 
% change 
0/0 change 
% change 
change 
Change Coefficient of 
(Visit 3 - Visit 1) variation 
15.5 
24.8 
16.7 
-0.95 
35.2 
-3.91 
27.4 
1.25 
37.1 
-40.5 
-16.9 
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% 
7.2 
9.6 
8.8 
12.2 
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14.0 
17.6 
13.2 
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Index 
2.15 
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0.09 
1.30 
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Figure 3.3.4. Time course of recovery of physiological variables for COPD subjects. 
(A) Volumes and flows (B) Xrs and WOBFOT,xinsp. 
Values are change relative to visit 1. Error bars show SEM. 
A) 
~0.8 
I 
tJ) 
-I 
-3: o 0.6 
-LL 
~ 
0 
::r 0.4 
-CI) 
E ~ 0.2 
0 
> 
0.0 
1 2 
Visit 
B) 
_ 0.3 
~ 
~ 
...., 0.2 
-~ o 0.1 
3 
-vc 
-e-FEV1 
~IC 
-e-PEF 
-Xrs 
-e- Xrs,insp 
~Xrs,exp 
-e- WOBFOT,Xinsp 
~ ~ ~.Ol~~~~----------------------~----­
o 
-or; ~.1 
-I 
. 
tJ) 
ai ~.2 
D.. 
:.. ~.3 
I!! 
>< ~.4 
2 3 
Visit 
190 
Correlation Between Physiological Variables and Symptoms 
The correlation coefficients between changes in physiological variables and changes in 
symptoms or HRQOL were calculated for hypothesis generation purposes and are shown in 
Table 3.3.4. 
Table 3.3.4. Pearson correlation coefficients showing association between changes (visit 
3 -visit 1) in physiological variables and symptom and HRQOL scores 
FEV! VC IC PEF Pa0 2 Xrs,insp Xrs,exp %FL WOBFOT,xinsp 
OCD 0.500 NS NS NS 0.594 0.430 NS NS -0.406 
Borg NS NS NS NS NS NS NS NS NS 
TDI 0.372 0.321 NS NS 0.552 0.458 0.396 -0.402 -0.341 
LCADL -0.499 NS NS NS -0.495 -0.408 NS NS 0.481 
Mobility NS 0.428 0.329 NS 0.438 0.493 0.449 -0.410 -0.338 
SGRQ 
Activities NS NS NS NS NS NS -0.333 NS NS 
Impacts NS NS NS NS NS -0.420 -0.374 0.444 0.408 
Total NS NS NS NS NS -0.442 -0.442 0.443 0.384 
Discussion 
This study has demonstrated that improvement following an exacerbation of COPD can be 
detected either physiologically by spirometry, oscillometry or gas exchange or by following 
symptom scores or HRQOL (Table 3.3.2 and Figure 3.3.3). The majority of the improvement 
in all variables occurred within the first week of monitoring (Table 3.3.2 and Figure 3.3.4). 
All the spirometric variables (i.e. FEV!, PEF, VC, IC) increased significantly with the sole 
exception of FEV1NC which agrees with fmdings elsewhere392-397. One difference found 
here was that the size of the change was very consistent in terms of % predicted ranging from 
11.0% for PEF to 12.1 % for V C. This is at odds with the fmdings in the recent similar study 
by Stevenson et al. where the change in IC was found to be larger (19% predicted)403. The 
size of the change was much larger in the asthmatic subjects ranging from 17.8% predicted 
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for IC to 26.9% predicted for FEV1• Significant changes of similar magnitude were seen in 
Pa0 2 for both COPD and asthmatic subjects (1.18 kPa vs. 1.64 kPa increase). 
In the COPD subjects there were sizeable and significant increases in Xrs,insp and Xrs,exp (27.4% 
and 37.1%) and decreases in WOBFOT,xinsp and %FL (-37.9% and -16.9%). As explained 
earlier, this can be interpreted physically as a decrease in both transpulmonary resistance and 
expiratory flow limitation during the study period. By comparison there was no change in 
Rrs,insp and Rrs,exp (% change -3.91 % vs. 1.25%). The study by Stevenson et al. is the only 
previous report of longitudinal changes of forced oscillometry variables during an 
exacerbation of COPD or asthma403 and this showed a strikingly similar pattern of change to 
that seen here. One difference was that the lack of change in Rrs was interpreted as implying 
that resistance does not improve during an exacerbation of COPD403 but this inference can be 
contested. Firstly, in subjects with COPD, airway obstruction is present both during the 
exacerbation and after recovery. This may render changes in Rrs difficult to detect primarily 
because upper airway wall shunt weakens the relationship between transpulmonary resistance 
and Rrs when airway obstruction is present404• Secondly the fact that resistance does fall 
during recovery from an exacerbation is shown by the fact that there is a significant rise in 
FEV 1. According to the "equal pressure point" model described by Mead268, flow at any lung 
volume increases if elastic recoil pressure rises or upstream resistance falls. The likeliest 
change in this scenario to produce the increased FEV 1 is a fall in airway resistance. 
In the asthmatic subjects the largest changes were again seen in Xrs,insp and Xrs,exp (% change 
47.6% vs. 96.0%). Absolute changes in Rrs,insp and Rrs,exp were also significant and much 
larger than those seen in COPD subjects. Rrs based variables may be relatively more useful in 
asthmatics because values of resistance approach normal after recovery and the masking 
effect of upper airway wall shunt would be reduced. 
Changes in PTT only reached significance at visit 3 and changes in RWV were not consistent 
over the recovery period, increasing between visits 1 and 2 and decreasing between visits 1 
and 3. In the COPD subjects there was a uniformly significant improvement in symptoms, 
ADLs and improvement in SGRQ (with the exception of the Symptoms score) confirming 
subjective recovery from the exacerbation. Significance of changes was more patchy in the 
asthmatic cohort reflecting the smaller sample size. 
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To compare the relative ability of spirometry and oscillometry to detect improvement during 
an exacerbation of COPD, the sensitivity index of each variable was calculated by dividing 
the change in the variable by its coefficient of variation (Table 3.3.3). This effectively 
estimated the variable's signal to noise ratio. It can be seen that spirometry was the superior 
measurement when reproducibility was taken into account. The coefficient of variation of the 
Xrs results could be improved by increasing the amplitude of the 5 Hz forcing signal, the 
duration of data collection or the number of times the measurement was repeated. 
To assess the ability of changes in physiological variables to predict changes in symptoms or 
HRQOL, the correlation coefficients between changes in these variables from visit 1 to visit 3 
were calculated (Table 3.3.4). The broadest association with symptomatic improvement was 
found for changes in FEV 1, P a02, Xrs,insp and WOBFOT,xinsp. Only changes in the oscillometry 
variables (Xrs,insp, Xrs,exp, WOBFoT,Xinsp and %FL) were associated with changes in HRQOL. 
Changes in PEF were not associated with symptom or HRQOL changes. Conversely, the 
symptom scales most broadly associated with physiological improvement appeared to be the 
TDI score and the V AS for mobility. Changes in Borg score were not correlated with 
physiological improvement. 
A surprising aspect of the correlation analysis was the relatively weak association of change 
in IC with symptomatic improvement. Recently it was shown that, of resting pulmonary 
function tests following bronchodilator, change in IC was the strongest predictor of 
improvement in exercise capacity405. Also Stevenson et aL403 found that patients reporting 
less breathlessness at the time of discharge were the ones in whom IC improved most during 
recovery. One factor contributing to this difference is that the patients in this study showed a 
slightly different pattern of physiological abnormality at baseline and change during recovery 
than seen in either of the two studies above. The patients here showed more of an obstructive 
picture (mean baseline FEV1: 0.96 L [43% predicted] compared with 1.03 L [47% predicted] 
403; mean change in FEV1: 0.274 L [11.4% predicted] compared with 0.20 L 403) and less 
hyperinflation (mean baseline IC: 1.70 L [77% predicted] compared with 1.37 L [62% 
predicted]403; change in IC: 0.295L compared with 0.42 L [19% predictedt03). When 
combined with the inferior reproducibility (in absolute terms) of IC measurements, the 
biological noise in the measurements may have masked the association between change in IC 
and change in symptoms or HRQOL in this study. 
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Several difficulties were encountered in perfonning this study. Firstly, unless pre-
exacerbation data are available there are no precise objective criteria for establishing when a 
patient has reached a stable state post-exacerbation. This was defined pragmatically here as a 
time point at least 6 weeks after visit 1 with the patient at home in what they deemed a stable 
condition and on nonnal medication. Secondly, it was difficult to achieve complete follow up 
with the type of subjects in this study due to chronic severe symptoms and the tendency to 
relapse. For clinical reasons, there was some variability in the exact time point at which the 
patients were assessed but the principle of assessing them at the beginning, early in recovery 
and then when largely back to stable state was achieved with reasonable success. 
Conclusions 
• Changes in parameters derived from Xrs (including WOBFoT,Xinsp and %FL) were easily 
detected during an exacerbation in both COPD and asthmatic subjects, were more widely 
associated with changes in symptom and HRQOL scores and could represent useful 
objective measurements for documenting recovery from an exacerbation. By contrast 
changes in Rrs,insp and Rrs,exp were small in COPD subjects and not useful in this context. 
• Forced oscillometry is potentially an attractive and simple test to perfonn in these 
breathless patients because it is a passive manoeuvre requiring only tidal breathing. 
Spirometry does have superior signal to noise behaviour but by comparison with 
oscillometry is a maximal test which can be unpleasant to perfonn. 
• The physiological changes seen during recovery from an exacerbation of COPD 
comprised both an improvement in operating lung volumes and a reduction in resistance 
(assessed by FEV 1 and Xrs). 
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4. Major Findings and Conclusion 
The aim of this thesis was to develop and evaluate techniques for the non-invasive 
measurement of resistance, elastance and work of breathing. 
The ability of forced oscillometry to predict RL and Wres was investigated through histamine 
challenge tests in asthmatic subjects. The most important findings were:-
• Xrs measurements had a strong linear relationship with RL and could predict its value more 
closely (using an appropriate linear regression model) than could oscillometry resistance 
(Rrs) values. 
• As a consequence, a non-invasive method for measuring Wres was generated by combining 
inspiratory Xrs,insp and V . 
• The linear relationship between RL,insp and Xrs,insp appeared to be independent of the 
disease process. 
• Lumped element modelling was able to explain this effect using a model which allowed 
central and upper airway wall shunting. 
Two non-invasive techniques using positive pressure breathing delivered by modem CP AP 
and NIV technology were assessed as methods of measuring Ers and WOBelas• 
• The CP AP method (initially proposed by Heaf and Prime in 1956) clearly showed 
superior performance and was the more promising candidate for further development. 
• The NIV method could distinguish between subjects with normal and abnormal Ers values 
but accuracy was not sufficient to separate gradations of abnormality. 
Work validating the non-invasive measurement of intrinsic PEEP was not presented because 
limited data were ultimately available for this validation. 
The new techniques were then evaluated in three clinical contexts. Firstly, changes in resting 
pulmonary function variables including forced oscillometry and derived work of breathing 
were compared with improvements in endurance exercise test performance during 
bronchodilator reversibility testing:-
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• Bronchodilator produced measurable changes in plethysmography, oscillometry and 
exercise test parameters. Changes in R WV and PTT were non-significant or small 
relative to the errors in the measurement. 
• Changes in resting IC and resistive parameters including Xrs,insp were significantly 
associated with changes in V E,end but changes in these and V E,end were not associated with 
changes in Tlim. This suggested that the increased ventilatory capacity predicted by these 
changes in resting pulmonary function tests may not necessarily translate into improved 
exercise tolerance. 
• Of the oscillometry variables, ~rs,insp was most strongly associated with 1:1 V E,end, 
consolidating the suggestion that it is the optimum oscillometry choice for reflecting 
resistive change. Estimation of work of breathing by combination of Xrs,insp and flow data 
conferred no advantage over the use of Xrs,insp alone. 
• There was a negative association between bronchodilator-induced increase in VE,iso and 
increase in Tlim, suggesting that reduction in ventilatory efficiency post-bronchodilator 
might be associated with poor improvement in exercise capacity. 
Secondly, the ability of non-invasive Ers and WOBelas measurements to detect longitudinal 
trends in ILD was compared with conventional pulmonary function tests, exercise tests, 
symptoms and HRQOL. The results indicated that:-
• Longitudinal changes in Ers,CPAP and WOBelas,CPAP appeared to perform well at predicting 
the empirical progression score but this was not translated into an ability to predict 
survival. 
• Endurance exercise tests (especially isotime variables and VEN02) and SGRQ scores 
proved superior longitudinal outcome measures for predicting survival relative to 
conventional tests such as VC and TLCO. 
Lastly, the ability of forced oscillometry and derived measurements (work of breathing and % 
flow limitation) to detect longitudinal physiological changes during an exacerbation of COPD 
was examined in comparison with spirometry, gas exchange, symptoms and HRQOL. 
• Changes in parameters derived from Xrs (including WOBFOT,xinsp and %FL) were easily 
detected during an exacerbation in both COPD and asthmatic subjects, were more widely 
associated with changes in symptom and HRQOL scores and could represent useful 
objective measurements for documenting recovery from an exacerbation. By contrast 
changes in Rrs,insp and Rrs,exp were small in COPD subjects and not useful in this context. 
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• The physiological changes seen during recovery from an exacerbation of COPD 
comprised both an improvement in operating lung volumes and a reduction in resistance 
(assessed by FEV 1 and Xrs). 
In conclusion, the aims of this thesis, namely to propose, validate and evaluate techniques for 
the non-invasive measurement of respiratory mechanics were largely achieved. In particular 
the non-invasive measurement of work of breathing did prove possible with the techniques 
proposed and the accuracy of these methods was established. However, in the clinical 
scenarios studied, work of breathing did not add to the information already obtained from 
resistance or elastance. 
There are several directions in which the work from this thesis could be developed. One of 
the most striking fmdings was the usefulness of inspiratory reactance to assess resistive 
properties in COPD subjects. When combined with the proven ability of expiratory reactance 
to indicate expiratory flow limitation (and thereby indirectly hyperinflation), this makes the 
forced oscillation technique a clear contender as an outcome measure in future trials of 
therapy for COPD. This would be true regardless of whether the intervention were 
pharmacological or mechanical (such as one-way valves, extra-anatomic stents, CP AP or 
NIV). 
The techniques assessed for measuring elastance showed limited promise only. The NIV 
method is a complicated technique and there may be potential to improve it if further time 
were devoted to its development. In particular, the idea of applying higher inspiratory 
pressures to relax the respiratory muscles and then reduce the pressure for one breath is 
attractive and would be easily studied. 
Finally, the use of endurance cardiopulmonary exercise tests as a longitudinal outcome 
measure in interstitial lung disease was particularly fruitful, with the ventilatory equivalent for 
oxygen standing out as the most sensitive indicator of poor survival. The use of isotime 
analysis in serial tests ensured that the subjects were compared after exactly the same 
workload in each test and provided an objective assessment of the subject's physiology at that 
time point. The findings in this group of ILD patients should be repeated in a larger cohort. 
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Appendix 1. Technical Recommendations for Forced 
Oscillometry Measurements 
The most recent statement of the technical requirements for forced oscillometry devices was 
written in 200320• The principle points are summarised below and compared with the 
performance of the device used in this study. 
1. The FOT system should impose a load against spontaneous breathing of < 0.1 
kPa.s.r l below 5 Hz. 
This was not formally addressed with the device but subjects were able to breathe 
comfortably on the mouthpiece for several minutes. 
2. The pressure transducer across the pneumotachograph should have a common mode 
rejection ratio of at least 60 dB up to the highest frequency investigated. 
This condition was satisfied135• Additionally, the phase difference between the FOT 
device flow and pressure signals was measured by looking at the system response to a 
5Hz signal across a purely resistive load of 0.2 kPa.s.L-1 (Jaeger Toennies). The phase 
difference between the two signals was calculated from the phase of the cross power 
spectrum (see Chapter l.2) and was found to be 0.1 ms (i.e. negligible). 
3. Apeak to peak size of the forcing signal (Paa) of 0.1 to 0.3 kPa is optimal. The largest 
Paa should not exceed 0.5 kPa peak to peak 
Pao amplitude depended upon the load. 
Load 0.2 kPa.s.L-1 - Pao 0.08 kPa peak to peak 
Load 0.38 kPa.s.L-1 - Pao 0.11 kPa peak to peak 
Load 2.0 kPa.s.L-1 - Pao 0.2 kPa peak to peak 
Birch demonstrated reasonable results from any load where Pao was >0.02 kPa 135 
4. The flowmeter and the pressure transducer should be linear (within 2%) up to at least 
1 L.s-1 and up to 0.5 kPa respectively. 
The transducer used to measure P ao was a piezoelectric single-ended gauge transducer 
with a range of ±2.5 kPa (Sensortechnics PXL0025DN50, Rugby, Warwickshire, UK). 
The linearity of this measurement was tested using an electronic pressure meter 
(Comark C9551, UKAS accredited calibration). The results are shown in Figure Al.l. 
Compared to the pressure meter, the absolute accuracy of the pressure transducer was 
within 24 Pa and 2%. Flow was measured using a heated Hans Rudolph screen 
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pneumotachograph with a range of ±160 L.min- l (HR3700A, Hans Rudolph Inc.). 
The pressure drop across the pneumotachograph was measured using a piezoelectric 
differential pressure transducer with a range of ±0.25 kPa (Sensortechnics 
PXL02X5DN). The linearity of the pneumotachograph was assessed using an 
electronic flow meter at flows above 0.25 L.s-l (Timeter RT200 Calibration Analyzer 
with Flow Module RT203, Allied Healthcare Products Inc., St. Louis, MO, USA) and 
standard rotameters at flows below 0.25 L.s-l (Gapmeter Laboratory Flowmeter Kit, 
Platon Flow Control Ltd, UKAS accredited calibration). The results are shown in 
Figure A1.2. Compared to the electronic meter, the absolute accuracy of the 
pneumotachograph was within 0.05 L.s- l and 4% except for two values at low flow 
rate (and hence low denominator which exaggerated measurement errors). 
Figure A1.I. Plot demonstrating linearity of the pressure transducer used to measure 
pressure at the mouth in the FOT device. 
(P -P ) 
a) shows transducer pressure, Pt, plotted against meter pressure, Pm. b) shows t m as a 
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Figure Al.2. Plot demonstrating linearity of the pneumotachograph used to measure 
flow in the FOT device. 
a) shows pneumotachograph flow, FlowPNT, plotted against meter flow, Flowm• b) shows 
(Flow PNT - Flow m) 
---=-:..:-=-----....:::..:- as a % plotted against Flowm• 
a) 
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5. A reference impedance with a magnitude of ~].5 kPa.s.rl is recommended A 
maximum error of ]0% or 0.0] kPa.s.rl is allowed 
Resistance calibration was performed using 3 resistors (0.2 kPa.s.L-I, 0.38 kPa.s.L-1 
and 2 kPa.s.L-1) shown in Figure Al.3 and the summary results from all the 
calibrations are shown in Table Al.l. 
Table ALl. Measurements of calibration resistors 
Nominal Resistor Value 
0.2 kPa.s.L-
0.38 kPa.s.L-1 
2 kPa.s.L-1 
Measured Resistance, Rrs 
Mean (kPa.s.L-1) SD (kPa.s.L-1) 
0.207 
0.387 
l.910 
0.004 
0.004 
0.004 
6. Coefficient of variation is the main index of repeatability of Zrs data. Reporting 
coherence is optional. 
Coefficient of variation was used to analyse repeatability of our results. 
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7. The volume history of the subjects should be monitored for at least 30 seconds before 
the measurement is made. 
This recommendation was followed. 
8. A total of 3 to 5 technically acceptable measurements should be performed. 
In general two measurements of 1 minute apiece were performed and repeatability 
assessed on these. 
Figure A1.3. Three calibration resistors used for the forced oscillometry device. 
These were pure resistors with Rrs values of 0.2, 0.38 and 2.0 kPa.s.L-1• Their origins (left to 
right) were Jaeger-Toennies, the Royal London Hospital Department of Clinical Physics and 
Hans Rudolph (Flow Resistance Standard R20, Hans Rudolph Inc.) respectively. 
- / 
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Appendix 2. Conversion from ATP to BTPS 
Flow was converted from ATP to BTPS using the following equation191,406:_ 
where 
. . (P B - PH 0) 310 
V -V 2 eqnA2.1 
BTPS - ATP (P
B 
- 6.3) (273 + T
amb
) 
V BTPS is the flow under BTPS conditions 
V ATP is the flow under A TP conditions 
P B is the barometric pressure 
P H
2
0 is the partial pressure of water vapour at ambient levels of humidity and 
T amb is the ambient temperature. 
PB and Tamb were logged daily. Humidity was assumed to be 50%. The conversion to BTPS 
is necessarily an approximation because the exact conditions of the inspiratory and expiratory 
air were not known. Inspiratory air was a mixture of dry compressed air from a wall supply, 
the temperature of which was modified by the equipment tubing, and rebreathed air from the 
instrument head and tubing. The expiratory air had a different gas composition, the exact 
proportion of each gas changing as expiration continued. This altered gas viscosity which in 
turn altered measured flow as the pneumotachograph was calibrated with air. It can be 
calculated, however, that the error due to this effect was low (approximately 0.2%406). In 
addition, the temperature and humidity of expired air was different from inspired air, being 
closer to that seen under BTPS conditions and altered in an unpredictable way by the 
equipment tubing, the biological filter and the heated pneumotachograph. For a further 
discussion on the difficulties of this conversion see Millel07• 
From a pragmatic viewpoint, therefore, inspiratory and expiratory flow were corrected using 
the factor shown in equation A2.1, assuming inspiratory and expiratory gases were both at 
ATP. 
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Appendix 3. Volume Drift 
The calculation of V by integrating V from a pneumotachograph introduced the problem of 
volume drift whereby V over time showed a negative or positive trend regardless of the 
zeroing accuracy of the pneumotachograph. This arose from several sources191:_406 
1. the respiratory exchange ratio, i.e. the volume of expiratory air produced by 
metabolism differed slightly from the inspiratory air consumed 
2. expiratory air was under different conditions of temperature and humidity from 
inspiratory air and therefore occupied a different volume 
3. asymmetry of the pneumotachograph 
4. zeroing error on the pneumotachograph 
5. leaks from the pressurised mouthpiece during elastance measurements 
Points 1 to 3 did not alter the points of zero flow but did alter the relative magnitude of 
inspiratory and expiratory flow whereas 4 to 5 altered the flow zero point. The preferred 
method of correction therefore depends on the relative contributions of these factors. 
Since zeroing error was removed by calibration of the equipment and leaks were clearly 
identified during the measurements, the correction used in this study was chosen so as not to 
alter the zero points but rather to apply a scaling factor to reduce mean expiratory and 
increase mean inspiratory V or vice versa depending on the direction of the volume drift, as 
follows:-
kE=l- ~V 
2J.lEt E 
eqnA3.1 
eqnA3.2 
where k 1 and k E were the inspiratory and expiratory correction factors, ~ V was the volume 
drift over the measurement period, J.l 1 and J.l E were the mean inspiratory and expiratory flow 
rates and tl and t E were the total time spent in inspiration and expiration respectively. kl 
and kE were of mean valuel.02 and 0.98. 
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Appendix 4. Technical Details of Balloon Catheter System 
The linearity of the pressure transducers used with the balloon catheters was assessed over 
their working range using an electronic pressure meter (Comark C9551, UKAS accredited 
calibration) and the results are shown in Figure A4.1. 
Figure A4.1. Plot demonstrating linearity of the pressure transducers used to measure 
P oes and P gas 
a) shows transducer pressure, Pt, plotted against meter pressure, P m. b) shows (Pt - Pm) as a 
Pm 
% plotted against Pm. 
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A key task in setting up this equipment was to determine the phase delay (i.e. the frequency 
response) between the pressure transducer in the FOT equipment and the balloon 
catheter/pressure transducer assembly. The equipment and technique used to assess frequency 
response from 0.5 to 24 Hz are illustrated in Figure A4.2. The relative amplitude and phase of 
the signals from the two transducers were determined using cross spectra (see Chapter 1.2) and 
the results shown in Figure A4.3. Using this technique, it was found that the time delay at 5 
Hz between the pressure signals from the FOT transducer and the balloon catheter was 12 ms, 
increasing to 24 ms if an extension tube was used. These time delays were corrected in 
software. Note that the FOT equipment had been designed such that there was no measurable 
time delay between the FOT flow and pressure signals, a fact that was confirmed by looking at 
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the phase difference between the two signals when a purely resistive load (calibration resistor) 
was used. The time difference between the two signals was less than 0.1 ms. 
In addition, the volume coefficient of displacement of the transducer was determined, this 
being the volume of air required to enter the transducer to generate a given pressure. 
Approximately, the ratio of coefficient of displacement to oesophageal compliance gives the 
percentage error in P oes and was estimated in this case to be <0.1 % 188 (assuming oesophageal 
compliance of 1.9 mVrnmHg408). 
Figure A4.2. Equipment used to measure frequency response. 
Sinusoidal signals of frequency 0.5 to 24 Hz were obtained sequentially from the signal 
generator and loudspeaker and were measured simultaneously by the FOT pressure transducer 
and the balloon catheter system. The differences between the two signals were analysed using 
cross-spectra to give relative amplitude and phase. 
Sensortechnics single-ended gauge 
pressure transducer (pXLO025DN) 
2.5 kPa fsd --------. 
Sealed container 
Balloon catheter 
,/ 
Array of four pressure transducers 
(DCPB) 
Sensortechnics differential pressure 
transducer (pXL02X5DN) 
0.25 kPafsd 
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Hans Rudolph 3700A 
heated screen 
pneumotachograph 
160 Lmin-1 fsd 
Intersurgical smoothbore 
corrugated tube (5018) 
Length 1.8 m Diameter 22 rom 
Loudspeaker 
, 
HP3300A Signal 
Generator 
Figure A4.3. Frequency response of the balloon catheter pressure relative to the FOT 
pressure transducer a) Amplitude b) Phase. 
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Appendix 5. Lumped Element Model used for the 
Simulation of the Relationship between Xrs and RL 
Figure AS.1 shows the lumped element model used in the simulation. Zuaw and Zbr represent 
the shunting effect of the upper and central airway walls respectively. Holding the cheeks 
was simulated by doubling the quoted value of Zuaw 118. Airway impedance was split into 
central (Zc) and peripheral components. Two peripheral airway-tissue pathways (Zpl, Zp2) 
were included to allow for heterogeneous time constants. Zw was the impedance of the chest 
wall and PB barometric pressure. Zrs was obtained from the following expression 
Z = Zuaw ·Zt 
rs Z +Z uaw t 
eqnAS.1 
eqnAS.2 
The model neglected gas compressibility as this was unlikely to be a significant effect at S Hz 
and viscoelasticity was represented as a simple compliance included in the value of the 
peripheral compliance. 
Representative values for the model components were obtained from the literature and are 
summarised in Table AS.l. In describing the model, compliance (the reciprocal of elastance) 
was used as this has been the convention in previous studies and thus values were easier to 
compare. Impedance (Z) for any component of the model was derived from resistance (R), 
inertance (I) and compliance (C) using the expression 
Z = R + (roI - _1_) . i where i = ~ and ro = 21[f . 
roC 
eqnAS.3 
fis frequency. Zbr was assumed to be a pure compliance (Cbr)' The value often used for this 
parameter is O.OS L.kPa-l , this being the estimate made by Mead from changes in the volume 
of the anatomic dead space and airway transmural pressures229. In our model this value 
appeared to be too large as its original derivation included the entire dead space, it was greater 
than the measured compliance of the supraglottal airway wall (0.014 L.kPa- l ) and it produced 
simulation results which did not have the correct qualitative behaviour in either Rrs or Xrs. 
Several studies in which parameters were fitted to a similar model have estimated a smaller 
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value for Cbr in the range 0.002 to 0.02 L.kPa-1 234,409,410 and hence a value in this range (0.005 
L.kPa-1) was used in the simulation. 
Figure AS.I. The lumped element model used in the simulation. 
Zuaw and Zbr represent the shunts of the upper and central airway walls respectively. Airway 
impedance is split into central (Zc) and parallel peripheral (Zpb Zp2) components. Zw is the 
impedance of the chest wall. P ao is mouth pressure and PB is barometric pressure. 
Table AS.1. Parameter values used in the lumped element simulations. 
Resistance Inertance Compliance Source 
(R) (I) (C) 
(kPa.s.L-1) (kPa.s2.L -1) (L.kPa-1) 
Zuaw 0.8 0.0034 0.014 Peslin 1985 411 
Zc 0.07 0.002 -
Zp1 - Hantos 1986 170 
see text 1.7 
Zp2 -
Zbr - - 0.005 see text 
Zw 0.05 - 0.5 Hantos 1986 ltV 
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To reproduce the effect of bronchoconstriction, the resistances of the peripheral airways (RpI, 
Rp2) were increased from a baseline of Rpl = Rp2 = 0.2 kPa.s.L-1 to a maximum combined 
value of 3.4 kPa.s.L- I . Heterogeneous airways obstruction was created by increasing the 
value ofRp2 whilst maintaining a fixed relationship between Rpl and Rp2 as follows:-
Rpl =5xRp2 -0.8 eqnA5.4 
where 0.2:::; Rp2:::; 4 kPa.s.L-I . The peripheral compliance of 1.7 L.kPa-1 was divided equally 
between the two pathways. Repeating the simulation without either the upper or central 
airway wall shunt was achieved by removing Zuaw and Zbr respectively. Removing the effect 
of parallel pathways was achieved by amalgamating 01 and 02 into a single pathway with a 
baseline resistance of 1 kPa.s.L-1 and compliance 1.7 L.kPa-1. To simulate decreased static 
compliance of the lungs (stiff lungs) and chest wall (stiff chest wall), the values of compliance 
used to calculate 01, 02 and Zw were decreased by a factor of 5. To simulate more compliant 
lungs, compliance in 01 and 02 was increased by a factor of 5. 
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